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S U M M A R Y
Pertussis vaccine and pertussis toxin (PT) are veil known as IgE adjuvants for a 
variety of protein antigens. However, there is very little information on w hether PT 
acts as an IgE adjuvant for the antigens of B. pertussis itself, as studied in this 
investigation.
Initial experiments with ovalbumin (Oa) showed that an anti-Oa IgE response in 
mice was produced after both one-dose and three-dose immunization schedules, with 
PT as adjuvant for the first doses only. The one-dose schedule involved injected Oa and 
bioactive PT as adjuvant on day 0, then bleeding on day 10, 21 or 28. The sera in the 
one-dose immunization were IgE-positive only when tested individually, and became 
unreactive when pooled. The mice, in this instance, thus acted as high or low 
responders for IgE production. The optimal concentration of PT in this one-dose 
sheme was I ug per mouse. This adjuvant dose of PT was kept constant in subsequent 
experiments with the three-dose immunization schedule
A persistent boosterabie IgE response was detected with a three-dose 
immunization schedule, which involved injecting antigen (Ag) and adjuvant (Adj) on 
Day 0, then boosting on days 28 and 56, with Ag alone, and bleeding on day 63 The 
sera, when pooled, contained a high IgE titre but only from mice given the 0.1 ug and 
1 ug Oa immunization doses. These titrations for anti-Oa IgE were done by passive 
cutaneous anaphylaxis (PCA) test and by ELISA.
The PCA test, with anti-Oa IgE. was optimal with a two-day sensitization interval
a
after the intracutaneous injection of the serum and w ith/challenge dose of 1 mg ol 
antigen with Evans blue. The usual 30 min heating at 56° C, which has been reported 
to destroy IgE in serum, caused 90% inactivation of the PCA titre. A high-titre 
standard anti-Oa IgE serum had to be heated for 1 h to remove all 48 h PCA activity 
The effect of injecting PT along with Oa in the challenge dose in the above PCA 
was also studied, as previous work had found that small doses of PT inhibited 
histamine release from mast cells, and therefore the PCA reaction. We found that very 
low (0.1 ug) and very high (500 ug) doses of PT had a fast-acting, inhibitory effect on 
the anti-Oa IgE PCA test when injected along with Oain the challenge dose
The anti-Oa IgE serum was also titrated m vitro by ELISA. A sandwich ELISA, 
with an initial affinity-anti body coating stage was found to be the most sensitive and 
specific method of detecting IgE In contrast, the conventional ELISA was unsuitable 
because of high backgrounds and low specificity
With filamentous haem agglutinin (FHA), as the antigen for IgE production 
there were only two mice from a total of 30 which were IgE positive in the 48 h PCA 
test after a one-dose immunization, with PT as adjuvant. In the three-dose 
immunization schedule the resulting anti-FHA IgE sera, in the 48 h PCA yielded a 
diffuse blueing over the entire skin surface. This was thought to be due to high IgGl 
levels in the serum which also bind to mast cells and thereby interfered with the test.
When the sensitization interval in the PCA was extended, to 7-days, and the mice 
challenged with an optimal (500 ug) dose of FHA, a more distinct, localised blueing 
reaction was obtained with the sera from the three-dose protocol. Anti-FHA IgE 
responses were detected over a large immunizing dose range (0 05 - 20 ug), with 1 ug 
bioactive PT as adjuvant. The sera were also titrated by ELISA, for IgE and IgGl, and 
there was a correlation between high IgE levels and high IgGl levels in these sera.
IgE responses to PT were investigated with purified and toxoided PT as antigen 
and bioactive PT as adjuvant. Anti-PT IgE was also detected in the 7-day PCA, when the 
mice were challenged with an optimal (500 ug) dose of bioactive PT. The anti-PT IgE 
response was only detected over a restricted PT toxoid immunizing dose range (0.05 - 
1 ug) This was independent of animal strain (Ham/ICR and Balb/c), and toxoiding 
(glutaraldehyde or carbodiimide) procedure. There was a correlation between high 
IgE levels and low IgGl levels in the sera
In animals infected intranasally and sublethally with B. pertussis strain 
number 18323. neither an anti-FHA nor PT IgE or IgGl response could be detected by 
PCA or ELISA, up to 35 days after initial infection.
The possible implications of the above responses are difficult to relate to the 
disease, whooping cough, or to pertussis vaccination. A possible host-beneficial effect 
of IgE production during the disease may result from mast cell degranulation near 
the site of B. pertussis attachment in the respiratory tract, with consequent release 
of vasoactive amines in the local area thereby helping to recruit immune cells to that 
area and aiding in removal of the bacteria.
This study has shown that IgE can be produced in mice against two of the major 
vaccine components of acellular pertussis vaccines, namely FHA and PT. These 
responses were detected by the PCA test and the ELISA
I N T R O D U C T I O N
INTRODUCTION
The introduction is divided into two main sections The first, entitled Bordetella 
pertussis includes general background information on the organism, the disease and 
vaccination. Two of the antigens of B. pertussis namely the filamentous 
haem agglutinin (FHA) and pertussis toxin (PT) are then reviewed in detail, with 
particular emphasis on the role of PT as an IgE adjuvant. This conveniently leads into 
the second section, Immunoglobulin E. This section includes the historical 
benchmarks in our understanding of IgE, how it is produced and detected and what 
factors influence the response. The introduction will be concluded with a discussion 
of IgE responses as a result of parasitic and microbial infections and after 
immunization.
Bordet ell* pertussis
Yhoopmg cough - the disease
The first mention of this unusual type of coughing disease was noted in Moulton's 
The M irror of Health1' in 1540 (Lapin, 1943) However Bordetella pertussis the 
bacterium responsible for the whooping cough was first isolated in 1906 by Bordet 
and Gengou.
Initially, B pertussis was placed in the genus Haemophilus until 1952 when 
Moreno-Lopez created the new genus Bordetella Today there are 4 species in this 
genus: B. pertussis. B parapertussis. B. bronchiseptica and B. avium, which cause 
respiratory infections in man and animals. B. parapertussis was also initially 
classified as a member of the Haemophilus (Johnson and Sneath, 1973) and causes a 
milder form of whooping cough in humans. B bronchiseptica was placed in the 
genera Bacillus. Alcaligenes. Brucella then Haemophilus and causes respiratory 
infections in animals, such as kennel cough in dogs and atrophic rh in itis  in swine: 
only rarely does it affect humans (Pittman and Wardlaw, 1981). B. avium once 
belonged to the Alcaligenes and is a pathogen of poultry and other birds and is best 
known as the causative agent of turkey coryza.
The major human pathogen, B. pertussis localizes on the mucosal cilia of the 
respiratory epithelial cells during pertussis infection. Pertussis is a highly 
transmissible disease and is usually spread via droplet infection and mainly affects 
infants and young children. There are three stages during typical infection: 
incubation; catarrhal and paroxysmal. The initial, incubation, stage is asymptomatic 
and usually lasts ten to fourteen days. The catarrhal stage is indistinguishable from 
non-specific respiratory tract infections and is characterized by low-grade fever and
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mild coughing. The paroxysmal stage is characterized by spasms of coughing and the 
"whooping" being caused by a long inspiration of air after the breathlessness of a 
bout of coughing (Preston, 1988). Vomiting may also follow these paroxysms. The 
violent coughing may last for 4-6 weeks and sometimes persist for several months. 
Complications can arise due to the increase in venous pressure during these 
characteristic paroxysms, resulting in nose bleeds and bloodshot eyes. 
Bronchopneumonia may occur as a result of spread of Bordetella to the alveoli but 
more commonly it is due to secondary bacterial infections by Streptococcus 
pneumoniae. Staphylococcus aureus or occasionally Haemophilus influenzae.
The laboratory verification of whooping cough has encountered many 
problems in the past because of the fastidious nature of B. pertussis. Therefore 
attempts have been made to devise serological tests for its detection. The 
enzyme-linked immunosorbent assay (ELISA) has been used, but results with whole 
bacteria and crude extracts showed low sensitivity and specificity (Bradstreet et al, 
1972). A more specific test, using a purified antigen namely FHA, showed the assay to 
be specific for B. pertussis, except that it also measured antibody responses to B. 
parapertussis probably because of structural similarities of homologous components
CU'tcL k J t i S l
(Granstrom etal, 1982). Onorata (1987) and Friedman (1988) reviewed a number 
of methods for laboratory diagnosis of pertussis. These included fluorescent antibody 
tests, agglutination reactions and the ELISA. There were difficulties with all the 
above, and at present there seems to be no single serological test, which is both 
sensitive and specific enough to detect infection in all individuals.
Between 1946 and 1949, whooping cough was the most common of the acute 
communicable diseases to affect children below the age of 1 year. The World Health 
Organisation estimated that the total number of cases of pertussis is 60 million 
annually, and that the disease is responsible for half a million deaths per annum 
mainly in underdeveloped countries (Muller et al, 1986). Vaccination has been 
available since the 1940's, as a preventative measure in controlling the disease. The 
whole-cell (WC) pertussis vaccines used for this purpose have been produced by 
empirical approaches which involved the bacteria being killed and detoxified by 
treatment with formaldehyde, thiomersal, heating to 56* C or by a combination of 
heat and chemicals (Lapin, 1943) Today, pertussis vaccine is defined as a saline 
suspension of killed Bordetella pertussis consisting of a mixture of strains, so as to 
incorporate the three agglutinogens 1, 2 and 3 (Cherry etal, 1988) and is usually 
given as part of the triple vaccine, with diphtheria and tetanus toxoids adsorbed to 
aluminium hydroxide or calcium phosphate as adjuvants (Wardlaw and Parton, 1983) 
The vaccination schedule currently in use in the UK involves a series of three DPT 
injections, given to children in the first few months of life, starting at two months of 
age (Department of Health, 1990)
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More recently research has been focused on the development of acellular (AC) 
vaccines, because of local or systemic side effects produced by the VC vaccine. The 
first AC vaccine was used in Japan and consisted of PT and FHA co-purified from the 
culture supernate of the Tohama strain grown in static culture (Sato etai . 1984). The 
potency of VC pertussis vaccine is tested by the intracerebral mouse protection test 
(ICMPT) which was developed by Kendrick et ai, (1947). This involves mice being 
injected with vaccine, and then challenged 14 days later intracerebrally, with live B. 
pertussis The efficacy of the vaccine is related to the survival rate of the challenged 
animals. This test is regarded as the criterion for a protective pertussis vaccine 
However, the new AC vaccines are found to be active in this system only when the 
mice are challenged 21 days after immunization, which is distinct from the 14-day 
ICMPT for the VC vaccine. PT is the only known virulence determinant of B. pertussis 
which confers protection in the ICMPT. An AC vaccine has also been developed at the 
Centre for Applied Microbiology and Research, Porton, UK which consists of 
separately purified PT, FHA and AGG's toxoided with formaldehyde and adsorbed to an 
aluminium hydroxide adjuvant (Robinson etai., 1986). This vaccine has low potency 
in the ICMPT but is protective against pulmonary infection with B. pertussis. A new 
range of AC vaccines are now being developed and tested, and are at different stages 
in clinical trials, but they mostly consist of PT and mixtures of FHA, agglutinogens 
and the 69 kDa surface antigen which have been purified and detoxified where 
necessary, either chemically or genetically (Parton, 1991)
Growth and nutrition
Bordet and Gengou (1906) used a solid blood-based potato glycerol agar (BG agar) to 
isolate the Gram-negative coccobacillus of B pertussis Later Hornibrook (1939) grew 
the bacterium in a liquid medium. This consisted of casein hydrolysate to which was 
added various salts, growth factors, and starch, to remove inhibitors produced during 
growth.
Stainer and Scholte, (1971) introduced a chemically-defined medium for growth 
of 3. pertussis This consisted of the two essential amino acids, glutamate and proline 
together with nicotinic acid and cysteine, and is suitable for large-scale vaccine 
production of phase I B. pertussis Imaizumi et al. (1983) then modified this medium 
with heptakis (2,6-O-dimethyl) B-cyclodextrin as a novel growth stimulant. This 
so-called cydodextrin medium (SS-C) is used for growth of virulent B. pertussis 
which can be passaged a number of times without serological changes taking place.
In culture, alteration of expression of the virulence factors of 3. pertussis 
known as antigenic modulation, can be induced by an increase in MgSO^  or nicotinic 
acid in the growth medium or by a decrease in incubation temperature. There are
1 O
three modes produced under different growth conditions: xanthic (X-mode) which is 
the normal virulent form; and cyanic (C-mode) which is avirulent and an 
intermediate (I-mode) has also been described (Lacey, 1951: I960). The X-mode occurs 
after growth in the presence of NaCl, whereas the C-mode occurs after growth in
medium containing high levels of MgSO .^ Thus B. pertussis grown in medium
containing MgSO^  hah a decreased adenylate cyclase activity, histamine-sensitizing
activity and had reduced quantities of two cell-envelope polypeptides (Parton and 
Wardlaw, 1975; Brownlie et al, 1985). Nowadays, modulation of B. pertussis is 
understood to be caused by an alteration in gene transcription of a range of 
virulence determinants in response to a variety of environmental factors and is 
controlled by a virulence regulatory locus bvg (Scarlal° etai, 1990).
B. pertussis can alternate between virulent and avirulent forms either by 
phenotypic change (antigenic modulation) or by a genotypic change (phase 
variation). The biological activities of B. pertussis are dependent on the phase of 
growth of the organism which is distinct from antigenic modulation described above. 
Bordet and Sleeswyck (1910) considered there to be two serological states of the 
pertussis bacillus depending on the growth medium. Later Leslie and Gardner (1931), 
analysed strains of B. pertussis by agglutination and postulated that there were four 
phases. Phase I appears after initial isolation on BG medium and possesses the major 
virulence determinants required for host infection and WC vaccine production. At 
the other extreme, Phase IV is completely degraded antigenically, is avirulent and 
usually results from repeated passage. Phases II and III are both intermediate. Weiss 
and Falkow, (1984), from avirulent phase IV variants, isolated haemolysin-positive 
revertants, which also expressed FHA and PT Stibitz etai, (1988) reported cloning of 
the vir (bvg) gene and that phase variation, could partly be explained by a 
frame-shift mutation at an unstable stretch of guanines in the vir (bvg) gene. 
Mutational events involving insertions and deletions of genetic material can also 
result in phase variation
Biologically-active components
The components of interest in this work are PT and FHA which are described later 
The other virulence factors possess a range of biological activities which combine to 
make B. pertussis a complex microorganism from the standpoint of pathogenicity. A 
summary of the virulence components and their biological activities is presented in 
Table 1
Filamentous haemagglutinin
The haemagglutination (HA) activity of B pertussis was first demonstrated by Keogh
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Table 1 : B iologically active components of Bordetellm pertussis
Component Biological
properties
Location 
in the cell
Reference
Adenylate 
cyclase toxin
Increases cAMP 
levels
Extracytoplasmic Wolff etai, (1980)
Rogel etal, (1989)
Heat labile 
toxin
Dermonecrotic; 
Causes spleen 
atrophy 
Vasoconstrictive
Cytoplasmic Nakase andEndoch. 
(1984)
N akase and 
Endoh (1988)
Tracheal 
cyto toxin
Ciliostatic Extracellular Goldman etai., (1982) 
Gentry-weeks etolX 1988)
Agglutinogens Adhesion Cell surface Cowell etai., (1987)
Lipopoly-
saccharide
Endotoxic,
Adj u van ti city
Cell surface Peppier, (1984) 
Ibsen etai, (1988)
Filamentous
haemagglutinin
Adhesion Cell surface
and extracellular
Ashworth etal.KYWD
Pertussis
toxin
Multiple Extracellular Wardlaw 6c Parton (1983)b 
Burns (1988)
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Table 2: History of developm ents in knowledge of FHA
Date Event Investigators
1947 Discovery of HA activity 
of Bpertussis
Keogh etai,
1952 HA not a protective antigen Masry
1974 Tvo distinct components involved 
in HA: LPF-HA and FHA
Sato etai,
1982 Anti-FHA responses detected after 
vaccination and infection
Granstrom etal.,(xlb
1984 FHA regarded as a protective 
antigen
Oda etai,
1985 Mutant FHA minus and PT 
minus strains exhibited 
loss of adherence to
ciliated epithelia Tuomanen 6c Weiss.
1988 Gene sequence of FHA Stibitz etai.,
1989 Nucleotide sequence Reiman etai..
1990 Amino acid sequence of FHA Domenighini etai.,
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etai., (1947), who observed that whole cells of B. pertussis agglutinated or clumped 
washed red blood cells. Later, Sato eta i, (1974) isolated and purified the two disinct 
components responsible for HA : FHA and LPF-HA now known as pertussis toxin (PT). 
The two could be distinguished by different HA inhibitors: cholesterol for FHA and 
haptoglobin for PT. FHA is the more potent in that it has five to seven times greater 
HA activity per mg of protein than PT. (Sato etai, 1983). Table 2 summarises some of 
the im portant events in FHA literature.
FHA has a rod-shaped filamentous structure, 40-100nm long, and with subunits 
of Mr 220,000 and a MW of 200,000 (Sato et at, 1983). FHA was widely thought to be 
related to pili and was previously known as fimbriai haemagglutinin, until 
experiments by Ashworth et at’ (1982) indicated that the electron
microscopically-visible pili did not label with anti-FHA, but instead with antibody to 
one of the agglutinogens.
FHA is an adhesin and is involved in attachm ent of B. pertussis to respiratory 
cilia. Mutant strains, deficient in one or several bacterial virulence factors have 
been tested for the ir ability to adhere to single, human ciliated respiratory epithelial 
cells in vitro. Loss of adherence was associated with lack of secretion of either of two 
surface antigens; FHA or PT. The strains regained adherence if both components were 
later added back into the assay system (Tuomanen 6c Weiss, 1985). Exogenous addition 
of FHA to the FHA-minus strains and PT to the PT-minus strains also caused a 
significant increase in adherence. There was also a requirem ent for the two 
virulence determinants to be present for maximum adherence.
An anti-FHA reponse can be elicited in humans after vaccination with WC or AC 
vaccines and after infection. IgG, IgM and IgA responses have all been reported after 
vaccination and infection (Granstrom eta i, 1982) When mice are immunized with 
various doses of FHA, they were protected from aerosol infection after challenge with 
live B. pertussis However intraperitoneai (i.p) injection of FHA did not protect mice 
from intracerebrai (i.c) challenge (Oda etai., 1984). Therefore FHA, unlike PT, is not 
protective in the ICMPT, but there is a requirem ent for FHA in the vaccine, because 
FHA reduces the amount of PT toxoid needed for the vaccine to pass both the i.c and 
aerosol challenge tests. In the Swedish acellular vaccine field trials, vaccination with 
PT toxoid alone was shown to protect against typical whooping cough with laboratory 
confirmation, but did not protect against infection and colonisation. However, there 
was evidence that the addition of FHA to the PT toxoid provides some protection 
against infection (Storsaeter etai, 1990)
Pertussis toxin
The molecular weight of PT is around 105,000. It is a subunit toxin consisting of two 
components: the A protomer (SI), with ADP-ribosyl transferase activity and the B
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oligomer (S2-S5) which is thought to be involved in binding to receptor molecules 
(Tamura etai, 1982). The SI subunit is an ADP-ribosyltransf erase, and so PT belongs 
to a family of ADP-ribosylating toxins which includes cholera toxin (CD. However, 
the target proteins of PT and CT, the regulatory G proteins in eukaryotic cells are 
different. Whereas CT, ADP-ribosylates Gs. PT attacks Gi, Go and Gt. The result is that PT 
inhibits the ability of the G proteins to mediate signals from cell surface receptors to 
effector w ithin the cell and thus alters the responsiveness of cells to regulatory 
molecules and other exogenous stimuli. Not all of the activities of PT depend on the 
enzymatic activities of SI. Unlike cholera toxin, the B subunit of PT consists of four 
dissimiliar subunits, S2, S3, S4 and S3 (Tamura etai, 1982). The B oligomer consists of 
two dimers (S2-S4 and S3-S4) connected by S3. This B oligomer alone acts as T cell 
mitogen and enhances glucose oxidation in adipocytes. These effects are due to 
cross-linking of cell surface receptors by divalent attachm ent of the B oligomer via 
the two dimers, which in tu rn  triggers a cascade of intracellular signal events. On the 
basis of indirect evidence, leukocytosis promotion, adjuvanticity and 
histamine-sensitizing activity were also attributed to cross-linking (Burns, 1988). 
However, recently, it has been shown that specific mutations in the toxin gene, that 
reduce enzymatic activity also reduce these particular activities of PT (Black eta i, 
1988)
Pertussis toxin was cloned and sequenced by Locht and Keith in 1986, and has a 
diverse range of biological activities w hich is reflected in the different names that 
have been assigned to it in the past such as pertussigen, HSF, LPF and IAP (Pittman, 
1984). A list of some of the biological activities is provided in Table 3
Lymphocytosis and Leukocytosis promotion
Lymphocytosis was first observed by Frolich in 1897 (Wardlaw and Parton, 1983). In 
patients with pertussis, the peripheral leucocyte count may be greater than 
175,000/mm^. It has also been shown that the active disease is not a prerequisite since 
lymphocytosis occurs following injection of WC vaccine (Sauer, 1933) or purified LPF 
(PT) (Morse, 1965, Morse and Morse, 1976). In these early studies it was suggested that 
lymphocytosis was caused by lymphocytes usually found in the lymphoid tissue 
entering the blood stream, ra th e r than by increases in lymphocyte production. 
Lymphocytosis in whooping cough was best observed in patients over 6 months of 
age and less frequently in younger patients (Lagergren, 1963)
LPF (PT) is a T-cell mitogen for spleen and lymph node cells. It has also been 
suggested that LPF enhances production of IgE through the agency of lymphocytosis 
which prevents suppressor cells from exerting the ir effects on the production of this 
reaginic antibody (Tada etai, 1972)
13
Table 3. B iological activ ities of pertussis toxin in the mouse
Biological activity Previously designated 
name of substance
Minimum active dose 
(ng/m l)
Adjuvant for IgE - 0.1
Sensitization to 
histamine and serotonin
Histamine senstizing factor (HSF) 0.5
Enhancement of insulin 
secretion
Islet-activating protein (IAP) 20
Induction of leukocytosis 
and lymphocytosis
Leukocytosis/ Lymphocytosis- 
promoting factor (LPF)
8-40
Lethality - 550
Protective antigen - -
Adapted from Munoz and Bergman, (1979) with additional information from Parton,
(1989)
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Histamine sensitization
Parventjev etai, (1947) found that WC vaccine increased the susceptibility of mice to 
histamine 100-fold. Similarly, B. pertussis extracts induced hypersensitivity to 
histamine in mice as well as leukocytosis and lymphocytosis. Clausen et al., (1968) 
noticed that all these effects peaked around the 3rd day after treatm ent with B. 
pertussis, although animal species were found to differ widely in their sensitivity to 
the lethal effects of histamine. Mice and rats are naturally highly resistant to 
histamine, whereas guinea pigs and rabbits are highly susceptible. Guinea pigs and 
rabbits become if anything, more resistant to histamine after treatm ent with WC 
vaccine or PT, which is why mice are used for assay of HSF. Death is the main 
criterion of sensitization (Munoz and Bergman, 1968).
Islet activation
Tabachnick and Gulbenkian, (1969) found that after WC vaccination, there was a 
correlation between hypoglycaemia (reduction in glucose levels) and 
hyperinsulinaem ia, and suggested that these effects were linked. It is also known that 
PT acts on pancreatic B cells, blocking the inhibition of insulin release. Sumi and Ui, 
(1975) injected rats with B. pertussis ceils and found a marked increase in the blood 
concentration of insulin in response to injection of insulin secretagogues such as 
arginine. Hypoglycaemia probably occurs due to the IAP component (i.e. PT) altering 
the B ceils, resulting in increased secretion of insulin, but only after various 
insulin-releasing stimuli (Katada and Ui, 1977). Adrenaline is known to inhibit 
insulin secretion in normal pancreas cells but not in pertussis infected cells. Sidey et 
al, (1987) suggested that the observed stimulatory effects of ether on insulin 
secretion in pertussis-treated mice, could be explained by the release of adrenal 
catecholamines leading to increased insulin secretion.
Pertussis vaccin e and Pertussis toxin as im m unological adjuvants
In the 1940‘s, whole cells of Bordetellapertussis were first observed to alter certain 
biological systems in man and animals (Table 4). Greenberg and Fleming, (1947) 
demonstrated that mixtures of pertussis vaccine and diphtheria toxoid gave enhanced 
levels of antitoxin. Later, Mota, (1958) identified the mast cell-sensitizing effect of 
whole cells of B. pertussis in rats and mice This effect caused an increase in the 
homocytotropic antibodies which were found to have similar characteristics to the 
human IgE-type reaginic antibody (Levine and Vaz, 1970). In the initial studies, Mota 
used horse serum as the protein antigen, but similar effects have been found with a 
variety of antigens including Ovalbumin (Oa), bovine serum albumin (BSA), sheep 
red blood cells (RBC), dinitrophenyl keyhole limpet haemocyanin (DNP-KLH) and 
bovine gamma globulin (BGG), using whole cells of B pertussis as the adjuvant. Other
Table 4: Literature summary on PT adjuvanticity
Observation Investigator(s), Date
WC pertussis vaccine has 
adjuvant activity
Greenberg 5c Fleming,! 1947)
Mast cell sensitizing effect of WC 
of B pertussis - the production of 
homocytotropic antibody
Mota. (1958)
Alkaline saline extracts of B. pertussis had 
adjuvanting effect on IgG and IgE
Clausen etai., (1969. 1970)
Main adjuvant effect attributed to HSF Lehrer etai., (1975. 1976)
Highly purified PT (0.1 ng) stimulated IgE 
antibody production to Oa
Munoz etai, (1981)
PT causes an increased vascular permeability 
in brain tissue of mice resulting in experimental 
autoimmune encephalomyelitis (EAE)
An anti-PT IgE response could not be
Linthicum etai., (1982)
detected in mice after Oa and PT immunization Munoz and Peacock, (1990)
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adjuvants that were similarly active were aluminium hydroxide and Freund's 
complete and incomplete adjuvants.
Clausen et al., (1969, 1970) analysed alkaline, saline extracts of B. pertussis for 
adjuvant activity, with Oa as the antigen, in different strains of mice. Two types of 
homocytotropic antibodies were detected. The 2-h passive cutaneous anaphylaxis 
(PCA) antibody was a 7S immunoglobulin which did not persist in the skin of mice 
and was heat stable and resistant to reduction and alkylation. The other, 72-h PCA 
antibody was similar to the reaginic antibody of allergic persons, since it was 
inactivated by heating undiluted sera at 56° C for 30 min, and remained in the skin 
for long periods of time. B. pertussis alkaline saline extracts were found to be the 
best adjuvant for the production of the 72-h PCA, while Freund s adjuvant was 
superior in stimulating the 2-h PCA antibody The main adjuvant activity for IgE was 
later attributed to the HSF of B. pertussis (Lehrer et al., 1975. 1976) w hich is now 
known as pertussis toxin. Carswell and Oliver, (197S) found that when rats were 
sensitized i.p with DNP-Oa, with or without B. pertussis there was a definite increase 
in the serum IgE in the adjuvanted animals. There was also an increase in cutaneous 
immediate-type hypersensitivity but, surprisingly, no increase in immediate 
pulmonary reactivity to aerosol challenge. Munoz etai, (1981) found that as little as 
0.1 ng of a highly purified PT given i.v effectively stimulated the formation of IgE 
antibodies to Oa in mice.
While PT is the main adjuvant component of B. pertussis the LPS was also active 
in the guinea pig model. Guinea pigs were injected i.p with 10 ug Oa plus 5 Ug of LPS 
which had been extracted by the phenol-water method. In the same experiment, a 
crude PT extract was also tested for IgE adjuvant activity. In this guinea pig system, 
the LPS of B. pertussis was the main active material responsible for the enhancem ent 
of IgE antibody production (Mota etai, 1974).
Sekiya, (1983) investigated the effects of various B. pertussis components on the 
production of IgE and IgGl responses. The effect of the K-agglutinogens, FHA, 
dermonecrotic toxin (HLT), LPS and pertussigen (PT) were all investigated for the
stimulation of IgE and IgGl to Oa in C57BL/6 mice (known to be high responders) 
The IgE was detected by heterologous PCA in the skin of Lewis rats, while IgGl 
antibody was detected by PCA in the skin of mice. Among the B. pertussis components 
tested, pertussigen (PT) was found to be the most effective adjuvant for increasing 
both IgE and IgGl antibodies to Oa. FHA only slightly increased the IgGl titres, while 
the LPS increased both antibody levels moderately HLT and the K-agglutinogens 
showed no increase in antibody levels. When each of the above components were 
then tested for there ability to modify the adjuvant action of pertussigen, HLT was the 
only component which interfered with the adjuvant action of pertussigen when
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given on the day of immunization with Oa.
The adjuvant activity of the LPS of B. pertussis is shared by the LPS of most 
Gram-negative bacteria (Newburger et al, 1974; Morrison and Ryan, 1979). 
Danneman and Michael, (1976) have investigated the ability of Gram-ve LPS from 
Salmonella species and E coli to function as an adjuvant and as an antigen in IgE 
and IgGl immune responses in mice. LPS failed to induce LPS-specific IgE or IgGl 
under a variety of experimental conditions. However the isolated LPS and whole heat 
killed bacteria were capable of enhancing IgE and IgGl antibody formation to the 
protein antigen Oa.
Experimental autoimmune encephalomyelitis (EAE) in mice is also dependent 
upon the use of B. pertussis suspensions as adjuvant. Intravenous administration of 
B. pertussis caused an increased vascular permeability in brain tissue and an 
increased vascular sensitivity to vasoactive amines which promoted the development 
of EAE (a disease of the CNS). PT was responsible for these adjuvant activities, whereas 
purified endotoxin was inactive (Linthicum etai, 1982).
As seen in Table 3. only 0.1 ng/m l PT is required to elicit an adjuvant effect on 
anti-Oa IgE production in mice. The active component is PT since highly  purified 
fractions of B. pertussis induced the production of IgE in mice (Munoz and Bergman, 
1977). Wardlaw et al, (1979) investigated the effect of antigenic modulation on 
adjuvanticity. They showed that X-mode vaccine was highly active in the induction of 
reaginic antibodies to Oa in mice, an effect consistent with the view that the adjuvant 
activity was due to PT. In C-mode cells, the effect was less and was transien t and 
probably was due to the LPS. Mota etai, (1974) had previously concluded that the LPS 
was the main active material responsible for the enhancem ent of IgE antibody 
production in guinea pigs.
There are numerous reports demonstrating that the IgE response is dependent
on many variables including dose of antigen and adjuvant and w hether boosting was
given. IgE is only produced in certain strains of mice which were classed as high
responders (Lehrer etai., 1975). Table 5 shows a listing of known high, medium and
low responder strains. Similar systems have been optimized for the ra t (Jarrett etai., 
T a r r 'd t d n d t  Hdlly 
1980, 1981) and the guinea pig (Mota etai, 1974).
In order to produce a substantial IgE response, it is im portant to consider 
several factors, including the dose of antigen and/or adjuvant, the timing of the 
injection(s) and of the bleeding times, and as emphasised, the mouse strain 
Laboratory animals have been immunized using numerous combinations of the above 
factors to produce IgE. Table 6 details some of the investigations into IgE responses to 
Oa. The dose of adjuvant has been varied between 0 02 ug to 10,000 ug without having 
a dramatic effect on the IgE response The antigen concentration (100 ug) seems to be
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Table 5 : High and low responding mouse strains
High responders
SWR/J C57BL/6 A/HeJ 
Ham/ICR CBA/J 
Balb/C
Medium responder
A O
Lov responders
C57L SWR SJL
References 
Revoitella and Ovary. (196$) 
Lehrer et al, ( 1975, 19^ § )  
Suko etai\ (197” )
Levine and Vaz, ( 1970)
Lehrer etai., (1975)
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Table 6: Immunization procedures for the production of IgE in mice
Optimal dose ( ug) Boosting Time-course IgE titre Reference
Antigen Adjuvant interval of expt. Day No( )
(PT) (days) (days)
125 Oa 50 80 512(10-60) Clausen etai.A 1970)
100 Oa 10 56 63 640 (50) Levine and Vaz, (1970)
100 Oa 21 28 806(28) Sadowski etai., (1979)
lOODNP-Oa 10,000 21 28 970(28)
100 Oa 0 02 21 28 1470(28) Sekiya, (1983)
5
constant in the four studies Mainly, the immunization schedule involves boosting as 
prim ary immunization can sometimes result in a transient IgE response. In all cases, 
the titres were calculated by PCA and ranged between 500 and 1500
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Immunoglobulin E
General introduction
In 1921, Prausnitz and Kustner first identified reaginic activity in human serum and 
subsequently correlated this activity with skin disorder in atopic allergic disease 
Ishizaka et a/, (1966) found that this reaginic activity was antibody mediated and 
could not be precipitated with any of the antibodies specific for IgG, IgA. IgM and 
IgD. This new protein was designated IgE and responsible for most allergic diseases. 
An extensive list of the major discoveries in IgE understanding are explored in Table
7.
Identification of IgE was helped initially by the discovery of a E-myeloma 
protein (Johansson and Bennich, 1967). This discovery allowed the purification of IgE 
and established that the Fc fragm ent of IgE binds with high affinity to specific cell 
surface receptors (FceR) on basophils and mast cells (Ishizaka et &l, 1970). It was 
later observed that radiolabelled IgE binds also to human lymphocytes and 
macrophages via a low affinity receptor (Lawrence etJl. 1975)
The initial in vivo test used for detection of IgE was the passive cutaneous 
anaphylaxis (PCA) test developed by Ovary, (1958)aThe discovery of the IgE-myeloma 
also made it possible to raise antisera against human IgE, which in turn  allowed 
measurement of total and specific IgE in serum. These anti-IgE sera were utilized in 
such in vitro tests as the radioallergosorbent test (RAST) for IgE, which has now 
been superceded by a range of immunoassays.
IgE is found only in very low concentrations in human serum and comprises 
less than 0.001% of the total circulating antibodies in normal individuals. Only a small 
proportion of the plasma cells in the body synthesize this immunoglobulin. IgE does 
not cross the placenta and has the capacity to passively sensitize mast cells for 
anaphylactic release of histamine and other vasoactive components. IgE in serum is 
destroyed by heating to 56° C for 30 min and is also lost when stored at 4° C, unlike IgG 
remains unchanged by these treatments (Revoltella and Ovary, 1969)
Structure and purification
The structure of IgE is like other immunoglobulins in being based on the four chain 
model originally proposed by Porter, (1962), and which is based on two types of 
polypeptide chain, heavy and light. IgE differs from this basic model by having four 
constant regions whereas most of the other immunoglobulins apart from IgM have 
three (Knauer and Adkinson, 1984) The IgE heavy chain has a molecular weight of 
72,500 suggesting that there are approximately 550 amino acid residues in the four
Table 7: Major benchmarks in the history of IgE
Date Discovery Investigator! s)
1901 Phenomenon of anaphylaxis Portier ScRichet
1921 First description of 
immediate-type hypersensitivity
Prausnitz 5c Kustner
1958 Introduction of the PCA test for
detection of reaginic antibody Ovary b
1958 Mast cell sensitizing activity of
whole cells of B. pertussis Mota
1964 Presence of reaginic antibody 
in animals immune to helm inth
infections Ogilvie
1966 New class of immunoglobulin,
IgE
Ishizaka etai.,
1967 " E-myeloma protein" Johannson Sc Bennich
1967 RAST used for clinical diagnosis 
of IgE
Wide etai..
1970 High affinity IgE 
receptor on mast cells
Ishizaka*
1975 Low affinty IgE 
receptor on macrophages, 
lymphocytes and platelets
Lawrence etai, *
1980 IgE potentiating and suppressing Suemura etai..
factors of T-cells Hirashima etai.
1986 Sensitive ELISA for the detection
of IgE Kenemy e ta i,
1986 IL-4 involvement in IgE response Coffman Sc Carty,
1 reviewed by Speigelberg, (1984)
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Table 8 : Detection system s for mouse IgE
Assay .Reference Mechanism Sensitivity (ng/m l)
Homologous PCA 
(Ovary, 1958)
vascular leakage of Evans 
blue dye leakage after antigen-induced 
in vivo degranulation of sensitized 
mouse mast cells.
0.1 - 10
Heterologous PCA 
(Ovary etai., 1975)
vascular leakage of Evans blue 
dye following in vivo degranulation 
of sensitized rat mast cells
10
ELISA
(Lehrer etaJ., 1979, 
Kenemy etai, 1986)
quantitation of IgE bound to 
microtitre plates, followed by 
enzyme-dependent substrate colour 
development
001
RAST
(Kelly etai., 1980)
detection of antigen bound 
IgE (paper disc) with anti-Ig£ 0.1
RIA
(Liu etai., 1980)
detection of antigen (microtitre plate) 
bound IgE with radiolabelled 
anti-Ig£
0.01
LAST
(Gilles etai, 1988)
detection of IgE with latex-bound antigen 
and enzyme-labelled anti-IgE
0.1
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heavy chain constant regions (Roitt etai., 1985).
The first attempt to purify reaginic antibody from mouse serum was done by 
gel filtration on a Sephadex G-200 column (Clausen etai, 1969). A subsequent study 
demonstrated that the fraction positive in the 48-h PCA test, used routinely for 
detection of IgE, differed from the other immunoglobulin fractions (Clausen et al, 
1970). Partial purification of this reagin was later achieved by ammonium sulphate 
precipitation, gel filtration and ion-exchange chromatography (Lehrer et al, 1976) 
and contaminating immunoglobulins were, in the case of IgG. removed by Protein A. 
or by immunoabsorption with appropriate antisera. The IgE was isolated by binding 
to, and elution, from an anti-Fab immunoabsorbent.
Assay o f IgE
A list of the mechanisms of some of the in vivo and in vitro tests used to detect IgE in 
mouse serum can be seen in Table S, which will be described briefly in relation to 
sensitivity, specificity and operational difficulties. The PCA test is, at best, only 
semi-quantitative but is as sensitive as RAST (Karlsson etai, 1979). On the other hand 
RAST may be easier to perform because of the in vivo operational difficulties of the 
PCA (Kelly etai., 1980). RAST shows less intrinsic variation and is not influenced by 
serum IgE levels in the recipient animal. The latex allergosorbent test (LAST) is as 
sensitive as RAST, but does not use radioisotopes. The radio-immunosorbent assay 
(RIA) and ELISA are the most sensitive in vitro tests for IgE; as little as 0.01 ng/m l 
being detected. Moreover, there is not a requirem ent for radio labelling in the ELISA, 
which is a major advantage over other in  vitro tests.
Passive cutaneous anaphylaxis
IgE and IgGl can be detected in the mouse by the passive cutaneous anaphylaxis 
(PCA) test. Test serum is injected intraderm ally into the dorsal sides of a shaved 
laboratory mouse. After 2 h, for the detection of IgGl, and 48 h for the detection of 
IgE, the animals are challenged i.v through the tail vein with a high dose of the 
specific antigen plus Evans blue dye. The actual mechanism depends on the mast cells 
becoming sensitized with either IgGl or IgE. The degranulation of mast cells occurs 
following, in the case of IgE, cross-linking of the high affinity mast cell IgE receptor 
(Fc£RI) with specific IgE antibody and antigen (Orange et al, 1961). The cascade of
events which follows the bridging of the Fc^RI starts with the activation of a serine
esterase and is rapidly followed by activation of adenylate cyclase, calcium ion influx, 
activation of methyltransferases and many other events, the last of which is the 
release of chemotactic factors and vasoactive amines such as histamine and serotonin
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Table 9: The d ifferen t species of animal in v h ic h  the PCA test may be 
done.
Species of animal 
serum injected
Antibody
detected
Sensitization oeriod (h) in recioient soecies
Homologous Heterologous
Mouse IgGl 1.5-2
IgG2a - 3-6 (guinea pig)
IgE 48-72 24 (rat)
Rat IgGa 4
IgE 48 -
Guinea pig IgG la 4 -
IgGlb 16-48 -
IgE 48-72 -
Rabbit IgG
IgGa 4 -
IgE 48-72 -
Human IgGl 3-6 (guinea pig)
IgG3 - 3-6
IgG4 - 3-6
IgE - 48(monkey)
- no response
Data from Ovary, (1976)
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(Ishizaka. 1983). These, in turn, primarily cause increased vascular permeability of 
the surrounding capillaries, in the mouse skin during the PCA test. Thus the blue dye 
enters the area of sensitization and can be seen as a distinct blue spot on the 
undersurface of the skin (Ovary, 1964).
The animal of choice for PCA is the albino guinea pig, but other species have 
been used. Strong PCA reactions may be obtained in the mouse, with rabbit or mouse 
antibodies (Ovary. 1958). Adult female albino mice are most suitable However, the 
amounts of antibody needed for even weak reactions are about 25 to 50 times greater 
than that required in the guinea pig. The comparable test in humans is the 
Prausnitz-Kustner (PK) test which involves intradermal injection of antigen into an 
area of skin which has previously been sensitized with IgE antibody (Ovary, 1964) 
PCA has been performed in different animal species. Table 9 shows the PCA reactions 
of different animal sera in homologous and heterologous species.
In the human, the first system for detection of skin-sensitizing antibody in 
vivo was the P-K reaction. Today, especially because of the danger of hepatitis and 
HIV and with the development of sensitive in vitro techniques, human skin testing is 
undesirable and is becoming obsolete The PCA test was designed to detect 
homocytropic antibody (IgE) using a large excess of antigen. This is a limiting factor 
in the PCA test for IgE. When small amounts of antibody are injected i d, more antigen 
is needed for the challenge dose (Ovary, 1964). The molecular weight of the antigen 
also has an effect on the PCA response (Ovary, 1958, 1976, 1986; Watanabe and Ovary, 
1976). The larger the antigen, the more is required to produce a positive PCA 
response. This will be reviewed in the discussion section.
A frequent problem with 48-h PCA is that IgE sera with high concentrations of 
IgGj may cause generalized blueing, over the whole animal, which frustrates the
observation of local blueing at the dorsal injection sites (Levine and Vaz, 1970). A 
number of modifications have been made to the PCA reaction first described by Ovary, 
(1958) For example with the mouse ear. the amount of extravasated dye can be 
determined colourimetrically (Inagaki et al, 1988). PCA has also been found to be 
suppressed in rats by pretreatm ent with ether (Ovary, 1958) and by PT. The latter 
inhibits histamine release by a mechanism in which metabolism of cyclic AMP was 
not directly involved (Nakamura and Michio. 1983) Passive sensitization of mast cells 
with reaginic antibody is inhibited by simultaneous injection of a second reagin 
directed against another antigen, and also if the test animal is actively producing 
unrelated IgE (Jarrett etai, 1971)
Enzyme linked imm unosorbent assay
The conventional ELISA first described by Engvall and Perlmann. (1972) involves
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Fig 1 : F lov diagram of the conventional ELISA for specific  IgE in mouse 
serum
Coatvith specific antigen 
I
Block v ith  non specific protein 
I
Add mouse serum containing IgE 
I
Add conjugate (anti-mouse IgE-HRP or APh)
I
Substrate (OPD or PNP)
HRP - horse radish peroxidase 
APh - alkaline phosphatase 
OPD - o-phenylene diamine 
PNP - p-nitrophenylphosphate
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antigen being coated onto a microtitre plate. Any free binding sites on the plate are 
then "blocked " with an unrelated protein, such as bovine serum albumin (BSA), 
whereupon the test antisera are added. The binding of any antibodies specific for the 
antigen are, in turn, detected by anti-immunoglobulin conjugated to an enzyme such 
as horse radish peroxidase or an alkaline phosphatase. Finally, a substrate is added, 
either O-phenylene diamine or p-nitrophenyl phosphate which completes the test 
(Fig 1). The intensity of the resultant colour reaction is thus related to the amount of 
antibody in the serum.
There are very few problems in measuring serum IgG using the ELISA because 
this immunoglobulin is usually the predominant antibody and there is little chance 
of interference from other antibody types. Reading and in terpreting the absorbance 
values produced in the ELISA is more difficult. Bidwell etai, (1976) has reviewed the 
four main ways of expressing ELISA results: 1) as the extinction value, which is based 
on one serum dilution only but requires known positive and negative reference sera: 
2) as the endpoint titre at a fixed absorbance: 3) with the latter as a percentage of a 
positive reference sera and 4) as the probability percentage which applies when 
either endpoint titres or extinction values are beyond the normal range.
The main problem with identification and quantification of mouse IgE are a) 
the small quantities of IgE in relation to other antibodies present in serum b) the lack 
of suitable reagents for assay and c) the in terfering  effects of other antibodies (Zeiss 
etai, 1977, Hamilton etai, 1981). When performing the conventional ELISA to detect 
IgE such problems are still experienced and to overcome these difficulties Kenemy ei 
al.. (1985) devised a modified ELISA which involved an initial coating of the 
microtitre wells with a affinity-purified rabbit antibody directed against the chosen 
antigen. This allows a greater flexibility in the ELISA, as the antigen is bridged to the 
plate by antibody, and not just by hydrophobic interactions with the plastic, which 
could hide certain important epitopes. They found that this increased the sensitivity 
of the ELISA without significantly increasing background interference from other 
immunoglobulins. Other modifications have been made to the conventional ELISA for 
detection of IgE. Lee et al. (1988) developed an ELISA against ragweed antigen E 
(AgE). The plates were coated with a monoclonal anti-hum an IgE which was followed 
by dilutions of the test sera and finally AgE conjugated to alkaline phosphatase. This 
bound specifically to IgE and did not allow interference by ragweed-specific antibody 
of other classes
Other tests
The RAST developed by Vide etai., (1967) has been used to detect allergen-specific IgE
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in human serum. The RAST involves crude extracts of allergens being covalently 
bound to solid phase particles such as paper discs, followed by incubation with the 
patients serum. In the second step, these particles are exposed to radiolabelled 
anti-IgE. The radioactivity count is directly proportional to the quantity of IgE 
reacting with the solid-phase allergen (Gleich and Jones, 1975). The RAST, or the new 
LAST, where antigen is bound to latex beads, have been reported to detect as little 100 
pg of specific Ig£/ml of human sera (Gilles et al, 1988). RAST has also been developed 
for use in mice to quantify IgE and was found to be as sensitive as, and more accurate 
than the PCA test, for the quantitation of IgE antibody at low levels (Kelly etai.. 1980).
The original RIA procedure, by Berson and Yalow (1959), depends upon the 
competitive inhibition of binding of antibodies to specific radioactive antigen, by 
unlabelled antigen. Subsequently the RIA has been modified, incorporating new 
reagents, to detect very small amounts of IgE in serum of humans and rats (Karlsson 
etai, 1979)
The ELISA is very similar to the RAST, but requires an enzyme labelled anti-IgE 
instead of a radiolabelled anti-IgE. The ELISA and RIA are both sensitivite tests for IgE 
(Table 9). Although the RAST is a robust test, capable of working with crude allergen 
extracts, it is not as suitable as ELISA or RIA for measuring IgE antibodies to purified 
antigens, nor for detecting low levels of IgE antibodies in the order of 100 pg/m l 
(Kenemy etai., 1983)
Regulation of the IgE response  
Genetic control
There have been numerous studies of the effect of mouse strain, antigen and adjuvant 
dose, bleed time and boosting on the IgE response (Levine and Vaz, 1970, Vaz etai., 
1971; Lehrer etai, 1976). Revolte 11a and Ovary (1969), and especially Levine and Vaz 
(1970) and Vaz etai., (1971) showed that in mice, the reaginic antibody response was 
under genetic control and that under certain experimental conditions, the ability to 
produce an IgE response was associated with an MHC H-2 haplotype. Later however 
Levine and Vaz, (1972) disclosed that IgE responsiveness was not correlated with H-2 
or immunoglobulin allotype and appeared to be specific for the antigens being tested. 
Bazin, (1976) also demonstrated with 1 ug Oa-DNP and pertussis vaccine as adjuvant in 
Hooded Lister and August rats, bearing the same haplotype Ag-B5, that there was a 
marked difference in the anti-Oa-DNP IgE response, in the two strains.
In man, the genetic influence is shown by the significant incidence of atopy 
in offspring from allergic parents. This correlation has been linked to certain HL-A
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Table 10: Determinants of the IgE antibody response.
Determinant Reference
Genetic predisposition
Genetic regulation of basal serum levels Marsh etui., (1974)
MHC gene regulation of specific IgE response Marsh etai., (1980)
Environm ental factors
Intensity of antigen exposure Nagel etai, (1977)
Duration of antigen exposure Platts-Mills etai, (1981)
Host factors
Mucosal or skin permeabilty Barbee etai. (1981)
Sex, age, race Orren and Dowdle, (1975)
Cellular regulation
Macrophage processing of antigen Ishizaka etai., (1976)
T cell recognition of antigen Ishizaka etai.. (1976)
Generation of T suppressor cells Strannegard etai., (1978)
Physico-chem ical characteristics o f antigen Marsh, (1975)
Molecular weight Hayglass 6c Stefura, (1991)
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haplotypes (Marsh and Bias, 1978). It is believed that the HL-A haplotype in man is 
the counterpart of the murine H-2 MHC (Roitt et al. 1985) In atopic individuals, 
serum levels of IgE can be considerably elevated and may reach several thousand 
ng/m l (Marsh eta i, 1974, 1980) compared to normal individuals (around 100 - 200 
ng/m l). However, certain environm ental stimuli (e.g., parasite infestation) can 
induce pronounced increases in the total serum IgE levels of normal individuals 
Serum IgE levels must therefore be dependent on the interplay of both genetic and 
environm ental influences. Some of the determinants of the IgE antibody responses in 
humans are listed in Table 10. These include genetic predisposition, as allergic 
parents tend to have a h igher proportion of allergic children than those who are not 
allergic; environm ental factors such as high pollen counts in the summer months 
and cellular regulation which relates to the individual immune response.
T and B cell interactions
The regulation of IgE antibody responses is among the most sophisticated and complex 
of the immune defense mechanisms. It involves an interaction of several cell types 
and cytokines. The spleen is known to contain IgE precursor cells, giving rise to 
IgE-producing cells, as identified by Kind and Macedo-Sobrinho, (1973) using the 
heterologous adaptive cutaneous anaphylaxis reaction. This method demonstrated that 
passively-transferred splenic lymphocytes which were secreting IgE antibody could 
be detected in the skin of recipient rats by a reaction similar to the heterologous PCA. 
If these splenic lymphocytes were injected into X-irradiated (immunosuppressed) 
mice the IgE response was replenished in the recipient animals. Reaginic antibody 
forming cells were apparent in the spleen of these immunized rats 6 days after 
injection. In general, however, the spleen may play only a minor role in serum IgE 
production; the work of Barnett and Wust. (1978) revealed no significant differences 
between the circulating levels of IgE in hereditary asplenic, or in splenectomized, 
mice compared with normal controls.
It is accepted that the IgE response is under T-cell regulatory influences. The 
cellular interactions resulting in the production of IgE are similar to those involved 
in the other immunoglobulins. Hamaoka eta i, (1973) demonstrated a cooperative 
interaction between specific T and B lymphocytes as necessary for IgE production in 
mice. For most protein antigens, the antibody response of B cells also depends on 
signals received from helper T cells, which do not interact with antigen in its native 
form, but instead recognize a complex of antigen-derived oligopeptides and a major 
histocompatibility complex (MHC)-encoded molecule on the surface of another cell, 
the antigen presenting cell (Roitt etai, 1985) Okudaira and Ishizaka (1973, 1974)
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shoved that enhanced anti-hapten IgE antibody responses resulted from the 
interaction of antigen-specific memory cells v ith  helper T cells It is established that 
there exists a definite T-cell dependency for the reaginic antibody response as can be 
seen in studies v h e re  thymectomised or congenitally athymic mice v e re  used (Ito et 
al,1979: Nomoto et al. 1978). Ito et al. (1979) found that no specific IgE antibodies 
vere  induced in the serum of athymic mice, and suggested that this vas due to the 
controlling effect of a suppressor T cell population (or the ir products) v h ich  
selectively inhibited production of IgE . Chiorazzi etal. (1976) observed in mice that 
after lov dose X-irradiation or cyclophosphamide treatm ent (both 
immunosuppresive), there vas a substantial increase in the levels of IgE antibodies, 
but a reduction in the IgG response. Okumura and Tada, (1971) performed similar 
studies in rodents and shoved that after thymectomy rats also failed to produce IgE 
antibodies upon antigenic stimulation. Hovever, IgE bearing cells v ere  present in 
thymectomized animals and increased after infection v ith  Nippostrongylus 
brasiliensis. Human studies suggest that allergic individuals have veaker than 
normal T-suppressor cell function v h ich  selectively enhances the production of IgE 
(Leung etal. 1984).
There are tvo distinct v ievs on hov  IgE is regulated. One is that the IgE 
response involves immunoregulation through a mechanism of isotype svitching 
induced by the T-helper cells. In particular, T-hl cells produce gamma interferon 
(IFN) v h ich  selectively stimulate IgG2a but inhibit IgGl and IgE synthesis by B-cells. 
T-h2 cells produce IL-4 and IL-5 v h ich  stimulate IgGl, IgE and IgA but inhibit gamma 
LFN-induced IgG2a synthesis (Ishizaka, 1988; Hagen etal. 1989). In contrast, Ohmori.
(1990) shoved that IL-4 exerted an inhibitory effect on antigen-specific IgE response 
in vitro. When cultured antigen-prim ed spleen cells v ere  mixed v ith  specific 
antigen and recombinant mouse IL-4. a significant reduction in the antigen-specific 
IgE response occurred. Hovever, Finkelman et al. (1989) demonstrated in in vivo 
studies that IL-4 is required for the generation of polyclonal prim ary IgE responses 
induced by injecting mice v ith  the larvae of N. brasiliensis as ve il as a secondary 
TNP-specific IgE response in mice Treatment v ith  anti-IL-4 antibody during both 
prim ary and secondary inoculation in the above inhibited the development of the IgE 
response by greater than 99% These observations suggested that blocking v ith  
anti-IL-4 may have a beneficial effect in treating IgE-mediated disease.
The second v iev of IgE regulation vas developed after Ig£-binding factors 
v e re  isolated from T-cells, v h ic h  either potentiated or suppressed the IgE response 
Thus the IgE response may be regulated not only by antigen-specific helper and 
suppressor T cells, but also through isotype-specific mechanisms. Initial experiments
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Table 11: Comparison o f IgE-potentiating factor and IgE-suppressor 
factor
Properties IgE-potentiating factor IgE-suppressor factor
Source FcfRt W 3/25+ T cells W 3/25+ T cells
Molecular weight (kDa) 13-15 13-15
Affinity for IgE ♦
Affinity for:
Lentil lectin ♦ -
Concanavalin A - -
Peanut agglutinin - ♦
Adapted from Ishizaka e ta l, (1985)
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by Ishizaka etal, (1981) using N. brasiliensis-infected rats revealed that the T cells 
of these infected animals produced soluble factors v h ich  had affinity for IgE and 
selectively enhanced or suppressed the IgE response (IgE-potentiating factor and 
IgE-sup pressing factor respectively). Thus v h en  IgE synthesis vas enhanced, 
IgE-potentiating factor vas released by T cells and could be detected in the culture 
supernate The production of IgE-binding factors is not restricted to N. brasiliensis 
infectioft.IgE potentiating factor vas found in ra t serum 5-7 days after B.pertussis 
treatm ent and peripheral blood T ceils from treated rats spontaneously released IgE 
potentiating factors in culture (Ivata e ta l. 1983: Ishizaka etal.. 1985). Table 11 
summarizes some of the comparisons betveen the tvo factors.
Further analysis of these tvo factors suggested that IgE-potentiating factor 
contains both N-linked and 0-iinked oligosaccharide, vhereas IgE-suppressor factor 
has only the 0-linked oligosaccharide. The N-iinked oligosaccharide in the 
IgE-potentiating factor is essential for enhancem ent of the IgE response (Yodoi etal. 
1982). Another im portant finding vas that both IgE-potentiating and IgE-suppressor 
factors vere  produced by T ceils and that the nature of these binding factors is 
determined by the environm ent. When rats vere  immunized v ith  Freund's adjuvant, 
the IgE-suppressor factor vas produced. Conversely. PT stimulated T cells to release a 
soluble factor glycosylation enhancing factor (GEF), v h ich  enhanced the assembly of 
the N-linked oligosaccharide to IgE-binding factor (Ishizaka et al, 1985). GEF is a 
kallikrein-like enzyme v h ich  enhances the glycosylation of IgE-binding factors 
through an activation of a phospholipase. The production of GEF from T-cells v ith  PT 
seems to explain the PT action on increasing IgE production. It vas also found that 
GEF triggers normal mast cells to release histamine and arachidonate and could partly 
explain the role of PT in histamine-sensitization.
Interaction of IgE vith  cells
The mast ceil vas first identified by Ehrlich in 1879 (Marone, 1988) and is nov 
knovn to be the main cellular target for IgE. There are tvo basic types, mucosal and 
connective tissue mast cells. Mucosal mast cells appear to be dependent on T cells for 
proliferation, vhereas the connective tissue mast cells are T-cell independent. 
Kitamura et al, (1986) suggested that mast cells arise from common precursor cells 
that differentiate after they have reached their target sites, and that the final 
phenotype is dependent on the microenvironment. The tvo types of mast cell are 
easily distinguishable by their respective size, number of secretory granules, content 
of vasoactive amines and their staining characteristics (Lee et al , 1985) It is nov 
generally accepted that mast cells from different locations are functionally
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Table 12: Preformed and n e v ly  formed mediators in mast cells
Mediator Physiological effect
Preformed
Histamine Vasodilation (increased capillary permeability)
Heparin Anticoagulant
Chemotactic factors Chemotaxis of
Eosinophils
Neutrophils
Monocytes
Basophils
Lymphocytes
N evly  formed
SRS Bronchoconstriction
Leukotrienes Vasoactivity
Prostaglandins Bronchial muscle contraction
Platelet aggregation
Adapted from Mygind. (1986)
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heterogeneous within and between different animal species (Pearce et al. 1985) 
Lowmann et al. (1988) compared the ability of both immunological and 
non-immunological agents to stimulate histamine release from human skin, lung, 
adenoid, tonsil and colon mast cells. While they all secreted histamine in response to 
IgE and anti-IgE and a calcium ionophore. skin mast cells were also responsive to 
substance P, 48/80. poly-L-lysine and morphine This was indicative of the functional 
heterogeneity w ithin the human mast cell population. IgGl can also sensitize mast 
cells and basophils, which are very  similar to mast cells, and both release vasoactive 
amines upon degranulation. The 2 h PCA test in the mouse detects IgGl bound to mast 
cells.
It is well established that immediate-type hypersensitivity reactions are 
produced by IgE binding to mast cells. The cross-linking of the IgE molecules on the 
surface of the mast cell by antigen, triggers secretion of granule-associated 
mediators (Table 12) such as histamine (Church et al. 1982). Immunological 
stimulation by anti-IgE and antigen or by non-immunological stimulation from 
compounds such as 48/80, poly-L-lysine and morphine-like analgesics also cause 
degranulation of mast ceils and basophils. When sodium cromoglycate (an 
anti-histam ine) is administered to asthmatics before they are exposed to antigen, 
there is a reduction in histamine release from lung mast cells. Basophils, however, 
are less sensitive to sodium cromoglycate and continue to synthesise and release 
histamine.
The main vasoactive amine, histamine, was initially detected in biological 
samples by a fluorimetric assay developed by Shore et al., (1959). This method 
involved histamine being extracted with n-butanol and added to O-phthalaldehyde to 
yield a product with a strong and stable fluorescence. This method has been 
superceded by radioenzyme assay (Snyder et al, 1966) and an enzyme immunoassay 
(both reviewed by Chevrier etal., 1986).
IgE binds with high affinity to specific cell-surface receptors (Fc^R) on mast
cells and basophils. For some time it was thought that IgE interacts only with 
receptors on basophils and mast cells. However, radiolabelled IgE has been shown to 
bind to human cultured lymphoblastoid cells, mouse lymphocytes, cultured human 
macrophage and rat macrophages (reviewed by Speigelberg, 1984) All these cells 
bind IgE with relatively low affinity when compared to mast cells and basophils The 
receptors on monocytes and macrophage are thought to promote phagocytosis and 
killing of IgE-coated targets such as parasites Aggregated IgE is known to induce the 
release of mediators of inflammation from rat and human macrophages.
Bringel etal, (1982) also studied the in vitro bio logical activity of IgD
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antibodies against a fraction of Lollium perenne thought to be responsible for 
certain cases of allergic pollenosis. They used three different methods: histamine 
release, basophil degranulation and the RAST inhibition test. In all the assays the data 
indicated a possible blocking effect of the IgD antibodies upon the IgE in vitro 
mediated mechanisms. While lack of skin-sensitizing properties of IgD has been 
demonstrated (Ovary. 1969), association between IgG and IgD has been reported in 
some clinical conditions, as in hyper-IgE syndrome and in undue susceptibility to 
infections (Buckley and Fiscus, 1975). Furthermore, when immunoglobulin levels 
were studied in atopic and non-atopic people, a statistically significant increase in 
IgD was found in the atopic groups (Kohler and Farr, 1967).
In 1964, Terry and Fahey discovered that human IgG could be fu rther 
categorized into four subclasses IgGl, IgG2, IgG3 and IgG4. Analyses of responsiveness 
have suggested an association between IgGl and/or IgG3 subclasses and the T-cell 
dependent response to protein antigens whereas the T-cell independent response 
antibodies to polysaccharide antigens including bacterial capsules are usually 
comprised of the IgG2 isotype. Various food, venom, inhalant and parasitic allergens 
induce IgE and IgG4-specific antibodies in man. It has been suggested that IgG4 
represents a non-IgE antibody that can sensitize basophils for the release of 
histamine and, thus, contribute to clinical allergy (Heiner,1984).
IgE responses in parasitic in fection
Elevated IgE levels have been reported in humans infected with a variety of parasites 
including Toiocara am is (Hogarth-Scott et al, 1969) and Schistosoma man son* 
(Capron etal, 1982).
Antigen-specific IgE is thought to be protective in parasitic infections. A 
number of investigators have looked at this in experimental parasitic infections, as 
demonstrated by the reduction in parasite burden (Table 13). Most work has been 
done in the rat. Ogilvie, (1966) passively immunized rats with IgE-rich serum, or 
heated serum where the IgE had been destroyed, and showed a marked reduction in 
the number of cerceriae recovered from infected animals passively immunized with 
IgE when compared to the controls. Later, Capron e ta l (1980) found similar results 
with a h igher infective dose of the cerceriae of S mansoni than was originally used 
by Ogilvie. Gabriel and Justus (1979) demonstrated in Trichinella -infected mice a 
reduction in the recovery of larvae encysted in muscle, when IgE was passively 
administered before infection. Dessein et al (1981) examined the effect of 
suppressing the IgE response by injecting neonatal rats i.p with anti-epsilon chain 
serum or control serum (produced by injecting rabbits with FCA alone). At 7 weeks.
Table 13- Protective activ ity  of IgE in experim ental parasitic in fection s.
This was demonstrated by the reduction in parasite burden after passive 
immunization or by increase in parasite burden after IgE depletion.
Parasite Host Dose
IgE shown to be protective by: 
Passive Inversely by 
immunization IgE depletion
Control serum References
Schistosoma Rat 200 Cm ■f N.T. Heated0 Ogilvie.
mansoni (1966)
Schistosoma Rat 1000 C ♦ N.T Heated Capron etal.
mansoni (1980)
Schistc&ta Rat 1000 C N.T + Normal Damonneville
mansoni et a l, (1986)
Trichinella Mouse 500 L* ■f N.T. Heated Gabriel &
spiraJis Justus. (1979)
Trichinella Rat 1000 L N.T + Normal Dessein etal..
sp iralis (1981)
m - cerceriae 
** - larvae
c - the same serum heated to 56® C for 30 min to destroy the IgE. 
♦ - protective effect 
N.T - not tested.
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the rats v ere  infected v ith  T. spiralis larvae and injected v ith  either anti-epsiion or 
control serum every 4 days thereafter. Suppression of the IgE antibody response vas 
accompanied by marked reduction in tissue eosinophilia and very brief blood 
eosinophiiia. Moreover, IgE-suppressed rats vere  much less resistant to infection by 
the larvae than the control groups. In S. mansoni infection, Damonneville et al. 
(1986) noted that schistosomula-re lease products (SRP) induced an IgE response to the 
cerceriae. If IgE depleted anti-SRP serum vas injected into the infected animals there 
vas a significant decrease in the degree of protection. Most of these studies suggest 
that the role of IgE antibodies in certain parasitic infections is a protective one. Other 
investigators have suggested a role for IgE in helminth infections Firstly, there are 
very high human IgE serum levels in areas v h ere  these parasites are endemic 
(Johansson e ta l 1968). Secondly, v ith  in  vitro animal models, Capron e ta l (1975) 
demonstated IgE-dependent binding of macrophages and eosinophils to schistosomal 
organisms. Furthermore, others have proposed that IgE mechanisms cause mast cell 
discharge of mediators such as histamine in the gastro-intestinal mucosa and that 
these either directly or indirectly serve to expel helm inthic infections (Dineen etal, 
1973). Contrary to this is more recent evidence that mice, genetically-deficient in 
mast cells, can expel intestinal parasites as efficiently as mice v ith  normal mast cells 
(Uber etal. 1980)
IgE responses after m icrobial in fection
In contrast to the above, the possible role of IgE in microbial diseases has so far been 
largely speculative. In several investigations, antigen-specific IgE responses have 
been detected v ith  both viral and bacterial infections (Table 14)
The IgE response has been explored for tvo main reasons: as a diagnostic tool 
indicating infection, and for a possible role in the disease process This latter could be 
either detrimental or protective to the host. Detrimental effects v e re  suggested by 
Velliver e ta l (1980) regarding respiratory syncitial virus (RSV) infection. IgE vas 
found bound to exfoliated nasopharyngeal epithelial cells in most patients during the 
acute phase of infection. The continual presence of cell-bound IgE vas more common 
in patients v ith  RSV-induced bronchiolitis or asthma than patients v ith  mild upper 
respiratory tract illness or pneumonia due to RSV It vas suggested that the 
production of IgE and subsequent release of chemical mediators of bronchospasm 
may contribute to the pathogenesis of the acute illness Motala e ta l (1986) also noted 
that in Stapblycoccus «w//Tew5-induced atopic dermatitis, the anti- S aureus 
IgE-positive adults had a more severe and prolonged disease than the IgE-negative 
patients. As veil as adults, children found to be IgE-positive, had a more severe
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Table 14: Reported IgE responses in infectious diseases and their 
interpretation.
Infective
agent
Reason for assaying of IgE 
Possible diagnostic Possible role in disease 
usage of host
Protective Detrimental
Author(s)
Respiratory
syncitiai virus NT NC s We Hive r  et a l.-,
(1980)
Rubella D NC NC Salonen etal..
(1985)
Psuedomonas NT S S Shen etal..
aeruginosa (1981)
Staphylococcus NT NC s Mo tala etal.,
aureus (1986)
Bordetella D S s Finger I
pertussis (1985) ^
S- Speculative 
D - Demonstrated 
NT - Not tested 
NC - No comment
i/on
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disease, v ith  a greater prevalence of cutaneous S. aureus infections, and a greater 
prevalence of specific IgE responses to food allergens A possible protective role for 
IgE in disease has also been proposed. Shen et al, (1981) detected IgE responses to 
Pseudomonas aeurginosa in patients v ith  cystic fibrosis. They suggested that 
respiratory allergy may provide a degree of protection against pulmonary infection 
but also claimed that atopy caused a h igher incidence of infection.
Finger et al (1985) employed an IgE ELISA against vhole cells of B. pertussis 
and tested the sera from vhooping cough cases. Only a small percentage (3%) of those 
tested shoved measurable quantities of IgE to vhole cells of B. pertussis The presence 
of IgE did not seem to affect the clinical course of the disease
This single observation by Finger eta l, (1985) is the only vork  involving an 
IgE response to B. pertussis v h ich  had been published before the start of this 
investigation.
47
O B J E C T  OF  R E S E A R C H
It is ve il documented that PT is an IgE adjuvant and that only minute doses are 
needed to elicit an IgE response against protein antigens such as Oa. The possibiltiy 
that PT may serve as an IgE-adjuvant for the antigens of B pertussis, including PT 
itself, has not so far been explored.
The object of this research vas therefore to detect and quantify the IgE 
response against tvo components of B. pertussis namely FHA and PT. These vere  
chosen as the targets for IgE-adjuvanting because of their importance as components 
of present-day acellular vaccines and as virulence factors in pertussis disease.
To provide an experimental basis for this vork, Oa vas taken as a model antigen 
for IgE induction, in order to determine optimal conditions for inducing and 
detecting IgE specific for FHA and PT
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M A T E R I A L S
&
M E T H O D S
Bacterial culture
Strains
B. pertussis, BP 18334, vas obtained from the departmental culture collection. It came 
originally from Connaught Laboratories, Toronto, Canada v h ere  it had been used for 
many years as a strain for vhole-cell vaccine production. Bpertussis BP 18323 vas 
obtained from the departmental culture collection, as the standard mouse 
inlracerebrally v iru lent strain, used in potency testing of pertussis vaccine B 
pertussis BP 353 strain is a transposon mutant lacking FHA. B. pertussis BP 357 is a 
transposon mutant lacking PT. These v e re  originally gifted by Dr A. A Weiss
All strains v ere  either stored in vacuum sealed glass ampoules atR.T, or as frozen in 
a mixture of casamino acids and glycerol (Appendix 1) at 70° C.
Culture media
Bordet Gengou (BG) agar base and defibrinated horse blood vere  obtained from Oxoid 
and Gibco respectively and used to prepare BG agar plates for propagation of B 
pertussis strains. When culturing BP 353 and BP 357 the agar vas supplemented v ith  50 
Ug/ml kanamycin (Sigma)
Stainer-Scholte liquid medium (SS) vas used as described by Stainer and Scholte, 
(1971). Cyclodextrin-modified Stainer-Scholte liquid medium (SS-C) contained heptakis 
2,6-0-dimethyl-i3-cyclodextrin v h ich  vas a gift from Teijin Ltd, Chiyoda-ku Tokyo, 
Japan. The solid agar vas used for groving prim ary cultures from freeze dried or 
frozen stock cultures, and the liquid media v e re  employed in large-scale liquid culture. 
The composition of the media are listed in Appendix 1.
Grovth of organism s from frozen stock cultures
Frozen stock suspensions in casamino acids and glycerol vere  thaved at R.T for 30 min. 
One loopful of the suspension vas streaked on to each of tvo to three plates BG plates 
v h ich  v e re  incubated in a moistened box in a 37° C incubator (Laboratory Thermal 
Equipment) for 2-3 days, and checked daily for grovth. The resultant grovth vas 
checked by Gram stain to confirm the presence of Gram-negative coccobacilli and 
absence of contaminants.
Grovth of large scale liquid cultures
The grovth  vas scraped from the BG plates and transferred into 2 L dimpled flasks 
(Rasotherm. Germany) containing 1 L of liquid culture either SS or SS-C medium 
(formulae in Appendix 1). The flasks vere  incubated at 37° C v ithout shaking for 48 h 
For aerated cultures they v ere  placed on an orbital shaker (L.H Engineering), on
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medium speed setting, at 37° C for 48 h. The cells were pelleted by centrifugation 
(Sorvall RC-5B) at 13,700 g for 30 min at 4° C and the supernate decanted and saved for 
extraction of FHA and PT.
Extraction o f FHA and PT from Culture Fluids
FHA and PT v e re  extracted from membrane filtered supernates by exactly the same 
procedure but v ith  BP 357 and BP 353 suspensions respectively as starting cultures. The 
bacteria vas grovn in SS-C at 37° C for 48 h v ith  shaking, and either PT or FHA vas 
extracted from the supernate by a dye-ligand affinity chromatography method 
modified from Sekura et al., (1983) This method involved absorption at lov ionic 
strength and elution at high salt ionic strength.
To culture supernate of BP 357 (10 L), 100 ml of Blue Sepharose CL-6B (Pharmacia 
LKB) vas added and adjusted to pH 6.0 atR.T by the addition of about 100 ml of 2.5N HC1. 
The mixture vas stirred overnight at 4° C in the presence of 1 mM PMSF (Sigma) as a 
protease inhibitor. The gel supernate vas filtered through a G1 sintered glass funnel 
(Gailenkamp) and packed into an LKB 2137 chromatography column (2.6 x 35 cm, 
Pharmacia LKB) and vashed v ith  0.05M Tris-HCl pH 8.0 using a peristaltic pump. The 
FHA vas eluted v ith  0 05M Tris-HCl pH 8.0 containing 1.0M NaCl, and 10 ml fractions 
collected v ith  an Ultrotrac fraction collector connected to a uvicord II-UV 
absorptiometer (Pharmacia LKB) to monitor the elution peak. The exact same method 
vas used for extraction of PT but the culture supernate came from BP 353 The 
preparations vere  dialysed overnight against physiological saline (9% v /v  NaCl) and 
membrane filter sterilised before injection into mice. The packed gel vas regenerated 
v ith  0.1M Tris-HCl, pH 8.0 containing 0.5M NaCl and 6M urea, to remove any strongly 
bound material, folloved by alternate vashing v ith  high and lov pH buffers. The gel 
vas vashed alternately v ith  0.1M Tris-HCl pH 8 5 containing 0 5M NaCl and 0.1M sodium 
acetate pH 4.5 containing 0.5M NaCl. The gel vas then finally vashed v ith  0.05M 
Tris-HCl pH 8.0 and stored at 4° C v ith  thiomersal at a final concentration of 0 01% 
(v /v ). Formulae for all the buffers can be found in Appendix 2.
Toxoiding of PT
a) v ith  Glutaraldehyde
The method of Munoz e ta l. (1981) vas folloved. Briefly, a solution of 100 ml of PT 100 
Ug/ml vas suspended in 20mM sodium phosphate v ith  0 5M NaCl, pH 5 0 Glutaraldehyde 
0 2% (v/v) vas  added to bring the final concentration of glutaraldehyde to 0 05% (v/v) 
The mixture vas incubated at room temperature (RT) for 2 h and then enough 0.2M 
L-Lysine vas added to dilute the mixture by 1 in 10 and the final concentration of 
L-lysine to 0.02M. The mixture vas incubated for 2 h at RT and then dialysed for 2 days
against 20mM sodium phosphate buffer pH 50 containing 0.5M NaCl and 0.02M 
L-Lysine
b) v ith  Carbodiimide
PT (3 ml of 2 mg/ml) vas dialysed overnight at 4° C against 0.5M NaCl in 20mM sodium 
phosohate buffer pH 5 0. The toxoiding reagent l-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide. HC1 (EDAC. Sigma) at a concentration of 4 mg/ml vas prepared in 117 ml 
of phosphate buffer, pH 5 0. The PT and EDAC vere  mixed so that the resultant mixture 
contained 50 ug/m l of PT and 4 mg/ml of EDAC. This vas incubated at 37° C for 24 h 
without shaking then dialysed at 4° C for 3 days against daily changes of the buffer, 
20mM sodium phosphate v ith  0.5M NaCl pH 7.6 containing 0.01% (v/v) thiomersal daily.
Pertussis Vaccine Preparation
B pertussis BP 18334 was grown in 1 L of SS-C at 37* C for 48 h and cells were harvested 
by centrifugation at 13.700 g in a Sorvall RC-5B centrifuge (6 x 500 ml rotor head) for 
30 min. The pellet was resupended and washed twice in physiological saline. The 
opacity of the resultant solution was compared to the international opacity standard 
(WHO 5th International reference preparation, 1975, NIBSC, Holly Hill, Hampstead, 
London) to which B. pertussis suspensions are matched. The number of opacity units 
(ou) was determined on the ceil suspension before converting it into vaccine. The 
whole cells were then heated to 56* C for 30 min in a stirred water bath. Care was 
taken to ensure efficient heat transfer by making the level of water in the bath h igher 
than that in the bottle, and also by swirling the bottle. The bottle was cooled and 
thiomersal (BDH) at a final concentration (0.01% v /v ) added as a preservative. The final 
preparation was stored at 4* C.
Animals and Animal procedures 
Mouse strains
Stocks of Ham/ICR and Balb/c mice were obtained from Charles River UK Ltd (Manston 
Rd, Margate, Kent) and bred in house in temperature and light controlled rooms They 
were fed ad libitum.
Raising antisera
Groups ranging between 5 to 25 Ham/ICR and Balb/c mice were injected 
intraperitoneally i.p with 0.5 ml of the immunization mixture. After a time interval 
indicated by the immunization protocol the mice were killed and the blood collected as 
below
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Table 13 : Immunization schedules used for raising IgE antisera
Scheme No Injection mixture Bleed day
i Ag * Adj (1 )a 10
Ag + Adj (1) 21
Ag + Adj {1) 2S
3 Ag * Adj (1)
Ag (2S)
Ag (56) 63
* - In lection day 
Ag-Anugen: Adj-Adjuvant
Raising IgE antisera
A variety of different immunization protocols vas used to raise IgE antisera to Oa, FHA 
and PT in mice of the tvo strains. Both sexes v ere  used, as available. The general 
procedure vas to take groups of either the same age or ranging from 3 - 6  veeks and 
house them in cages of 15 - 20 animals. Antigen and adjuvant vere  administered i.p in 
dose of 0.5 ml per animal (Table 15). In the early experiments, a single immunization 
dose (Scheme 1) vas used and groups of mice vere  bled on different days. In later 
experiments, the mice received a total of three antigen (Ag) doses of vh ich  only the 
first contained adjuvant (Adj) as in (Scheme 2). The exact concentrations of Ag and Adj 
are outlined in the results section.
Preparation of sera
The mice vere  asphyxiated v ith  carbon dioxide. Blood vas collected by cardiac 
puncture and kept on ice. The vhole blood vas then incubated at 37° C for 30 min to 
accelerate clotting. The blood vas then centrifuged at 2,000 g for 20 min at 4° C. The 
serum vas extracted from the clot using a glass pasteur and stored at -20° C.
Histamine sensitizing  activ ity  (HSA)
The PT sample vas diluted in PBS and 0.5 ml vere  injected i.p into 6-8 veek old Ham/ICR 
mice. After 5 days the mice v ere  challenged i.p v ith  3 mg of histamine dihydrochloride 
(Sigma) contained in 0.5 ml of sterile saline. Survivors vere  counted 2-3 h after 
challenge. The approximate LB for each batch of PT vas calculated (Appendix 5)
Mouse v e ig h t gain
Groups of 5. 3 veek old Ham/ICR mice vere  injected i.p v ith  graded doses of the test 
sample. The veigh t of each group vas recorded using a flat pan balance (Sartorius) on 
Day 0 and recorded each day thereafter and the ve igh t loss or gain vas noted. The 
number of deaths if any v e re  recorded over the 7 day period of the experiment.
Intranasal in fection
A group of 23 mice, 3 veek old female Ham/ICR mice, vere  infected intranasally (i n) 
v ith  live B. pertussis BP 18323 A concentration of 2 x 10s cfu/ml vas prepared in 1% 
(v /v )  casamino acids and 25 Ul amounts vere dropped onto the anterior nares of an 
ether anaesthetised animal using a giison automatic pipette. This meant that each 
animal vas infected v ith  5 x 106 cfu A control group of 13 vere  instilled i n v ith  1% 
(v /v )  casamino acids alone. The veights and deaths in each group vere  recorded over a 
32-day period. At approximately 5-day intervals some of the animals from the infected 
and control group vere  sacrificed and the extent of the lung infection scored.
Passive Cutaneous Anaphylaxis
PCA tests were done in 6 to 8-week old Ham/ICR mice, of either sex and body weight 
more than 40 g, by a method based on that of Ovary (1958), One significant difference 
was the use of four intradermal (i d) injection sites per mouse so as to have a positive 
control site (anti-Oa serum) and three experimental sites for B. pertussis sera. Ten 
mice were used in a typical set of PCA tests. With each mouse, hair was clipped from the 
dorsal surface and 50 ul doses of the test sera were injected i.d into each animal under 
Hypnorm (Janssen Animal Health) analgesia. The injection site of the positive control 
serum was varied systematically between mice. Each experimental serum was usually 
tested in quadruplicate, each replication being in a different animal. To elicit the PCA 
reactions, the sensitized mice were challenged i.v at intervals ranging from 2 to 7 days 
with a mixture of either FHA or PT mixed with Oaand Evans Blue (Sigma) . The challenge 
mixture was made in PBS so that each 0 2 ml contained 0.5 mg FHA or PT plus 1 mg each 
of Oa and the dye. At 30 min after challenge, the animals were killed and the skins 
removed so that the diameter of blueing, where the dye had entered, could be measured 
on the inner surface. The diameter of each blue zone was measured in two directions at 
rig h t angles and the average taken. The averages of zones from different mice were 
summarized as arithmetic means with 95% confidence limits. On the rare occasions 
when the anti-Oa site gave an unexplained negative result, all the observations from 
that animal were discarded.
Enzyme Linked Immunosorbent Assay 
Reagents
Oa was obtained from Sigma and the PT and FHA were prepared as described earlier by 
the method of Sekura et al., (1983) Three conjugates were used a goat anti-mouse IgE, 
ICN Immunobiologicals, P.O. Box 1200, Lisle, IL 60532; sheep anti-mouse IgE conjugated 
to a horse-radish peroxidase, The Binding Site, 97 Vincent Drive, Edgbaston, 
Birmingham B15 2SQ, England; and a rabbit anti-goat IgG conjugated to horse-radish 
peroxidase (HRP), Sigma. Hydrogen peroxide and sulphuric acid were obtained from 
May Baker. O-phenylene diamine was purchased from Sigma.
ELISA for IgE
The % wells of a flat bottomed microtitre plate (Nunc Maxisorp F) were coaled with 100 
Ug/ml of Oa in coating buffer pH 9.5. All the solutions are described fully in Appendix 3 
This was incubated overnight at 4° C. The plate was then washed 3 times in 
w ashing/incubation buffer pH 7 4 and blocked with 2% (w/v) BSA in incubation buffer
o4
pH 7.4 for 1 h at 37° C. The plates were then washed three times in wash buffer. Ten-fold 
dilutions of mouse anti-Oa IgE serum were added and incubated at 37° C for 1 h. The 
plates were washed with wash buffer containing 1% BSA. Goat anti-mouse IgE (1 in 100 
dilution prepared in incubation buffer pH 7.4) was added and incubated at 37° C for 1 h. 
Plates were washed three times, then rabbit anti-goat HRP (1 in 1000) (Sigma.Lot No. 
77F-8866) in incubation buffer pH 7.4. was added and incubated for 1 h at 37° C. The 
developing substrate consisted of 200 jj.1 of a 34 mg/ml soln of O-phenylene diamine 
(OPD) in 100 ml of citrate-phosphate buffer pH 5 0. Hydrogen peroxide (20 ill) was added 
just before use. The plates were left in the dark for 30 min, and terminated by adding 50 
111 of 12% (v/v) H2SO4 . Modifications to this ELISA system are discussed in the Results 
section.
The above ELISA method was also used for measuring IgGl and total IgG. However 
HRP-sheep anti-mouse IgGl and IgG were the conjugates in the IgGl and IgG ELISA's 
respectively.
Modified IgE ELISA 
Preparation of a ffin ity  columns.
Protein antigens Oa, FHA or PT were coupled via their amino groups to cyanogen 
bromide activated Sepharose 4B (Sigma). The Sepharose 5 g was suspended in ImM HC1 
and the gel was washed with 1 L of ImM HC1 on a sintered glass funnel to wash away 
additives used in the freeze drying process. A 25 mg amount of protein antigen/ligand 
was dissolved in coupling buffer (0.1M NaHCOj, pH 8.3 containing 0.5M NaCl) and added
to the washed Sepharose. The mixture was rotated overnight at 4° C in an angled rotator 
to allow all the ligand to bind to the gel. The excess ligand was then washed away with 
coupling buffer using a sintered glass funnel attached to a vacuum pump. The 
absorbance at A2S0 of the filtrate was checked to ensure that most of the ligand had 
bound to the gel. Any active groups of the gel remaining were blocked with 2 L of 0 1M 
Tris-HCl pH 8.0 which washed through the gel column for 2 h at RT. The gel ligand 
matrix was finally washed with three cycles of alternating pH. Each cycle consisted of a 
wash of 0.1M acetate buffer pH 4.0 containing 0.5M NaCl followed by aw ash with 0.1M 
Tris-HCl pH 8 0 containing 0.5M NaCl. The gel was then poured slowly into a Biorad 
column (In ternal diameter 1.5 cm x length 15 cm) allowed to settle and stored at 4° C.
Preparation of a ffin ity -p u rified  antibody
Rabbit anti-Oa serum (25 ml) was dialysed in visking tubing against 1 L of 0 1M Tris-HCl 
pH 3 0. overnight at 4° C. The serum was pumped through the Oa affinity column using 
a peristaltic pump (LKB) with a flow rate of 1 ml/min and fractions were collected with
an Ultrotrac fraction collector connected to auvicord II-UV absorptiometer (Pharmacia 
LKB) to monitor the elution peaks. After the serum, 0 1M Tris pH 8 0 vas pumped 
through the column for 3 h to elute unadsorbed protein. The column was vashed again 
for 1 h with 0.1M Tris-HCl pH 8.0 containing 0.5M NaCl to elute any bound non-adsorbed 
protein. To elute the affinity-purified antibodies, 0.1M glycine-HCl pH 3.0 vas pumped 
through the column and 2 ml fractions were collected. The peak fractions were then 
dialysed immediately against PBS (8 g NaCl, 0.2g KH2P04, 1.15g Na^HPO ,^ 0.2g KC1 all
prepared in one litre of distilled water) pH 7.4. The column was washed with 500 ml of 
PBS containing 0.1% sodium azide and stored at 4° C. A similar procedure was also used to 
prepare affinity purified anti-FHA
ELISA for IgE
The % wells of a flat bottomed microtitre plate (Nunc F maxisorp) were coated with 200 
Ul affinity-purified anti-Oa in coating buffer pH 9.6. This was incubated overnight at 4°
C. The plate was then washed 3 times in washing buffer pH 7 4. A 100ul of Oa (100 
Ug/ml) was prepared in incubation buffer pH 7.4, and added to each well. Then the plate 
was incubated at 4° C for 1 h and washed 3 times, 5 min each, in wash buffer containing 
1% (w/v) BSA. The test sera containing anti-Oa IgE was diluted in tenfold steps from 1 in 
10 to 1 in 10,000 and 100 ul was added to appropriate wells and incubated at 4° C for 1 h. 
The plate was washed and the sheep anti-mouse IgE HRP conjugate was added and 
incubated for 1 h at 4° C. The developing substrate consisted of 200 ul of a 34 mg/ml soln 
of O-phenylene diamine (OPD) in 100 ml of citrate-phosphate buffer pH 5 0. Hydrogen 
peroxide (20 ul) vas added just before use. The substrate was added and incubated at 37° 
C for 30 min and terminated by adding 50 ul of 12% H2S04. A similar procedure was also
used for measuring anti-FHA IgE. However, in the PT ELISA instead of a AP anti-PT, 
fetuin was used to coat the PT to the plate. All subsequent incubations were as above. 
Modifications of this ELISA system are discussed in the Results section.
M iscellaneous 
Assay of FHA
The assay was performed in plastic round bottomed microtitre plates (Sterilin) with 
Titertek micro droppers (Flow). Horse erythrocytes were washed 4 times in sterile 
saline and the packed cell suspension diluted to give a 0.5% (v/v) suspension which was 
stored at 4° C. Test samples were serially diluted in saline (50 ul) in the microtitre wells 
and two drops (50 ul) of the horse erythrocyte suspension vas added to each well. 
Controls consisted of sterile saline alone and the horse red blood cells. The plates vere  
kept atR.T for 4-6 h or at 4° C overnight. The HA titre was the reciprocal of the highest
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dilution showing complete agglutination of the erythrocytes.
Protein estimation (Lowry)
The method of Lowry et al, (1951) was used. Standard protein samples of BSA (Sigma) 
were prepared in distilled water, so that the final concentration of protein in the tubes 
ranged from 50 - 500 ug/ml. Test dilutions of samples (0.5 mi) were prepared, and to 
both the standards and the unknown, 0.5 mi of 0.1N NaOH (BDH) was added. The tubes 
were then placed in a boiling water bath for 5 min and allowed to cool. A reagent was 
prepared by adding 1 ml of 1% (w/v) CuSO^  and 1 ml of Sodium potassium tartarate to 50
ml of 5% (w/y) Na^CO ,^ of which 2.5 ml was added to each tube, mixed and left at RT for
10 min. Then 0.5 ml of IN Foiin-Ciocaiteaus phenol reagent was added and the colour 
reaction was allowed to develop for 30 min. The reaction was measured 
spectrophotometricaily at 750nm against a reagent blank.
Protein A extraction
A Staphylococcus aureus formalin-killed ceil suspension (Sigma) of 200 ul was added to 
600 ul of 0.05M potassium phosphate, pH 7.5. To this 200 ul of serum was mixed by 
inversion in a 1 mi eppendorf tube. The mixture was incubated at 37° C for 30 min and 
the ceils pelleted by centrifugation at 4000 rpm in a fixed angled head for 15 min. An 
aliquot of 600 ul of once-absorbed serum was used in the IgE and IgG ELISA, and the 
rem aining 200 ul vas absorbed again following the same cycle as above. The serum was, 
in all. absorbed a total of 3 times. This meant at each absorption, the serum was diluted 1 
in 5. This was taken into account in the final results.
Immunodiffusion
1% purified agar (BDH) was dissolved in 0.3M phosphate buffer pH 8 0 containing 0.01 % 
(w/v) sodium azide. Gel bond (FMC Corp., Rockland, Maine) cut to size was placed on top 
of a microscope slide and hot agar poured on through a plastic syringe (4 ml/slide) 
Wells were punched in the agar using a 2 mm well punch and the agar plugs were 
removed using a needle. After dispensing the solutions to be tested, the slide was 
incubated overnight in a moist level box at 4° C in the cold room. The slides were 
washed in PBS for 24 h to remove any excess protein followed by 24 h in distilled water 
After drying, they were stained in coomassie brilliant blue (Gurr) to show precipitin 
lines. Generalized background blueing was destained using immunodiffusion wash 
buffer (40?* v /v  methanol, 10% v /v  acetic acid and 50% v /v  water)
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SDS-PAGE
SDS-polyacryiamide gel electrophoresis separates proteins on the basis of molecular 
size, as they move through a polyacrylamide gel matrix towards the anode (Ames, 1974). 
The proteins are solubilized first by boiling in buffer in the presence of SDS and 
2-mercaptoethanol (ie solubilizing buffer) and the resulting polypeptides separate into 
individual bands electrophoreticaily.
Gel moulds were prepared from two glass plates separated by 15 mm plastic spacers 
and sealed with yellow tape. The separating gel was prepared as described in Appendix 
4 and pipetted into the cassette to 14 cm from bottom of the plates. An overlay of 5% 
ethanol was added which removes the meniscus from the gel and leaves a perfectly flat 
surface. The gel was left for 20 min, the overlay removed, and the stacking gel was 
added whereupon a teflon comb was placed between the glass plates. The gel was 
allowed to polymerise before the comb was removed. Tris-glycine buffer pH 8.3 vas 
added to the lower electrode vessel. The sealing tape from the base of the gel plate was 
removed. The plate was inserted into the top electrode vessel using a liberal amount of 
grease around the gasket to prevent leakage. The upper electrode vessel was filled with 
Tris-glycine buffer pH 8.3 so that it covered the top of the gel and filled the wells with 
buffer (all recipes for solutions in Appendix 4) Protein samples of between 20 and 35 ul 
were pipetted into the gel lanes with a Hamilton syringe. The tank was connected to a 
power pack and the gel was run  at a constant current of 15mA/gel for 1-2 h. Once the 
dye in the samples had left the stacking gel, the cu rren t was boosted to 40mA. The 
cu rren t was switched off when the dye line reached the bottom of the gel. The gel was 
removed from the plates and stained.
Staining of SDS-PAGE gels
CooAassie blue
The gel was placed in a plastic tray and comassie blue stain (Appendix 4) was poured 
over so that the gel was completely covered and left for 1 h at RT. The gel was then 
destained, by pouring of the stain and repeatedly washing with destain (Appendix 4) at 
37° C for 1 day.
Silver
As a precautionary measure when silver staining, the gels were handled only with 
plastic gloves as this staining procedure is very sensitive to small amounts of protein. 
The gel was prefixed with 50% (v/v) ethanol containing 10% (v/v) acetic acid for 30 
min and then fixed with 10% (v/v) glutaraldehyde for 30 min. Overnight, the gel was 
rinsed in a large volume of distilled water The gel was then soaked in 5 Ug/ml
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dithiothreitoi for 30 min. The solution was poured off and. without rinsing, 0.1% (w/v) 
silver nitrate was added and left for 30 min. Developer was prepared immediately before 
use and consisted of 50 ul of 37% (v/v) formaldehyde in 100 ml 3% (w/v) sodium 
carbonate. The gel was rinsed twice quickly in developer and allowed to soak in a third 
volume of developer until the desired level of staining was reached. Whereupon 5 ml of 
2.3M citric acid was added and allowed to m il for 10 min. Finally the gel was washed in 
distilled water and preserve in 0.03% (w/v) sodium carbonate and heat sealed in 
cellophane. All the solutions that have been refered to are in 100 ml amounts, unless 
otherwise stated, the volumes of sodium carbonate and citric acid are especially critical.
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R E S U L T S
The object of this investigation was to determine w hether pertussis toxin (PT) could 
act as an IgE adjuvant for the antigens of B pertussis namely FHA and PT itself. 
Before attempting to answer this question, it was necessary to set up, with a 
well-researched antigen, appropriate experimental systems for the production and 
testing of IgE. For this purpose ovalbumin (Oa) was chosen as the model antigen and 
the mouse as the experimental animal.
IgE Responses to Ovalbumin, v i t h  IgGl M easured  in P a ra lle l
Three test systems were developed to detect and quantitate specific IgE responses to 
Oa in mice: passive cutaneous anaphylaxis (PCA), and enzyme-linked immunosorbent 
assay (ELISA) employed in both the ■conventional" and "sandwich" mode. 
Experiments were done to establish immunization protocols in mice for the 
production of IgE-containing sera. Since IgGl is also PCA-positive (with a shorter 
sensitization interval) and might therefore in terfere with the detection of IgE, it was 
necessary to assay the sera for anti-Oa IgGl as well as for anti-Oa IgE.
Measurement of IgE by PCA 
Prelim inary experim ents
The initial studies were done with two interrelated objectives: namely to develop an 
immunization protocol for the stimulation of anti-Oa IgE. and also to develop the PCA 
test for detection of these antibodies. Initially, Oa as the antigen was used at two dose 
levels of 20 and 200 ug per mouse, based on previous experience in this laboratory 
(Wardlaw eta l. 1979). Both PT and PV were used as the IgE adjuvants and were mixed 
with the Oa before i.p inoculation into groups of 5 or 10 mice. The effect of booster 
doses of antigen, without adjuvant, was also studied for its possible beneficial effect 
on IgE production. The various combinations of doses of Oa, PT and PV, and the 
num ber of mice, are set out in Table 16 which also shows the results of the 2 h PCA 
test for IgGl. and the 48 h PCA test for IgE on sera obtained at 21 days. There were 
deaths in the mice given 5 and 10 ug doses of PT In experiment 1, the serum was a 
single pool made from the blood of the surviving animals after 21 days. However, in 
experiments 2 and 3. the individual sera vere  collected and tested. The data in the 
table show that although IgGl responses were regularly elicited, IgE responses were 
detected in only 4 sera out of the 31 obtained. There was an indication in prelim inary 
experiments, that anti-Oa IgE was best produced in a) individual high responding 
mice b) with 20 ug Oa plus 5 Ug PT. c) with no booster and d) with bleeding on day 21. 
Moreover, the adjuvant dose level had to be reduced to get rid of the toxicity problem
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Table 16. Results of prelim inary experim ents to obtain IgE against Oa in 
mice. Immununization was by protocol 2 1 and the sera were tested by 48 h PCA for 
IgE and 2 h PCA for IgGl. In experiment 1 the sera from the surviving mice were 
pooled and tested in duplicate in the 2 h PCA and in triplicate in the 48 h PCA. In 
expts 2 and 3 the individual sera were tested once in the 48 h PCA.
Immunization No. of mice surviving/ No. of positive sera/
mixture on day zero 1 no. tested no. tested
Oa(ug) PT(ug) PV (ou) 2 h PCA 48 h PCA
Expt 1: with booster
20 - 10/10 2/2 0/3
20 10 - 2/10 2/2 0/3
20 2.5 10/10 2/2 0/3
200 - 10/10 2/2 0/3
200 10 - 7/10 2/2 0/3
200 2 5 10/10 2/2 0/3
Expt 2: with booster
20 - 2/2 nt 0/1
20 5 - 9/10 nt 1/9
20 10 - 7/10 nt 0/7
Expt 2: wilhout booster
20 5 8/10 nt 3/8
n t - not tested
a - Protocol 2 consisted of the shown mixtures injected on day zero followed up 
where indicated by a booster dose of 10 ug Oa without adjuvant on day 14 and bleeding 
on day 21.
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Fig 2: E ffect o f v a ry in g  the ch a llen g e  dose o f Oa in  the 48 h PCA test. Sera 
raised by the three-dose protocol and known to be IgE-positive were injected i.d 
at 1 in 10 dilution into each mice. After 48 h, pairs of mice were challenged i.v 
w ith graded doses of Oa. The bars indicate the average zone diameter (mm) and 
SEM with the num ber of replicates shown inside the bars.
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Fig 3: T itration o f  standard IgE -con tain in g antiserum  in  th e 48 h PCA 
test. The serum  had been produced by the three-dose protocol, and was a pool of 
25 mouse bloods. The points indicate the average zone diameter 
and the SEM. Scale A shows the logjo relative concentration of serum, scale B is
the log j o PCA U/ml and C the PCA U/ml.
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Plate 1: Layout o f the PCA test v i t h  2 s ites  per mouse At positions A and B, 
anti-Oa IgE r ic h  serum  was injected i.d. The anim als v e re  challenged i.v with 1 
mg of Oa and 1 mg Evans blue, 2 days after sensitization.
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Factors in flu e n c in g  the PCA test
To try  to optimize the conditions for IgE detection by PCA, it was necessary to generate 
a large pool (about 12 ml) of IgE-rich serum. This serum  was obtained from a group of 
25 mice and prepared as described below by the three-dose immunization
protocol w hich eventually proved to be satisfactory. Using this "standard" anti-Oa IgE, 
the effect of such variables as challenge dose in  the PCA, num ber of injection sites, 
effect of 56° C heating  of the serum, and incorporating  PT in the challenge injection, 
were studied.
E ffe c t o f  Oa c h a llen g e  d o se ; The standard anti-Oa IgE serum  was diluted 1 in  10, 
and two doses of 50 ul per intracutaneous injection site adm inistered to each of two 
young adult Ham/ICR mice. The anim als were used in  pairs to compensate for 
occasional injection failure. Forty-eight hours later, the anim als w ere challenged 
with doses of Oa rang ing  from 62.5 to 2000 ug, with a constant am ount of Evans blue (1 
mg). The diameter of blueing on the undersurface of the skin was measured 30 min 
later,
The results accumulated from 12 mice were presented in Fig 2. Overall, there  
was little change produced by vary ing  the challenge dose of an tigen  over a 32-fold 
range, in  tha t 62.5 Ug Oa gave the same average zone diameter as 2000 ug However 
the 1000 ug dose appeared to give significantly  h ig h e r responses than  e ither of the 
adjacent doses. This dose was therefore adopted in  all subsequent experim ents. Plate 1 
illustrates the underside of the skin of a  mouse tested by 48 h PCA with the 1 mg 
challenge dose of Oa.
E ffe c t o f  serum  d ilu tio n  on zo n e  d iam eter: To establish a dose-response curve, 
the standard serum  was tested undiluted and in  serial diltuions from  1 in 10 to 1 in 
1000, with each dilution being tested in  at least 5 skin sites on d ifferen t mice. 
Exceptionally, the 1 in  20 dilution was tested altogether about 70 times since it was 
used as a positive control in many later experiments. Fig 3 shows th a t there was an 
approximately linear relationship between zone diameter and the logl0 relative
concentration of the standard serum. The abscissa is marked off in 3 scales, the lower 
two em erging from the serum  being arb itra rily  assigned a value of 1000 PCA units 
per m illilitre (U/ml).
The slope of the line is such tha t a 10-fold increase in  serum  concentration 
gives a 6.6 mm increm ent in zone diameter. Note that the dose-response line is 
extrapolated to zone diameters greater than  20 mm in order to allow estimation of 
serum potencies above 1000 PCA U/ml. as occurred occasionally.
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Table 17. E ffect of h eatin g  anti-Oa IgE sera  on the subsequent 48 h PCA 
test. The undiluted sera were heated to 56° C for 30 min and diluted 1 in 5 w ith PBS 
before i.d injection into mice. Positive controls consisted of the same sera  unheated.
Immunization
protocol Bose
PCA activity of serum, before and 
after heating, from bleed day :
Oa(ug) PT(ng)
ua
10
Hb
21
U H
63 
U H
20 250 + c _ d nt® nt nt nt
20 1000 + - nt nt nt nt
200 250 + - nt nt nt nt
1 20 250 nt nt + - nt nt
20 2500 nt nt + - nt nt
200 2500 nt nt + - nt nt
0.1 1000 nt nt nt nt + +
3 1 1000 nt nt nt nt + -
10 1000 nt nt nt nt - -
a Unheated
b Heated 56° C for 30 min
c 48 h PCA reaction: positive i.e > 5 mm in diameter
* 48 h PCA reaction: negative
* not tested
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E ffect o f  h ee lin g  sere e l 36 9 C. An early priority in setting up the 48 h PCA test 
was to try to confirm that the positive results were due to IgE. For this purpose, the 
effect of heating a variety of anti-Oa IgE sera at 56° C for 30 min was investigated. 
These sera had been obtained by one-dose and three-dose protocols with various 
combinations of Oa and PT. Altogether 9 anti-Oa sera which had previously been 
found positive in 48 h PCA were examined before and after heating (Table 17). Each 
heated and unheated sample was tested in the same mouse to strengthen the 
comparison.
Of the 9 sera tested, only 8 were negative in 48 h PCA test after heating. One 
serum - the standard, raised with an immunizing dose of 0.1 ug Oa, was still positive 
after heating had nevertheless had its activity greatly reduced - from 13 3 mm 
average zone diameter down to 6 mm. Refering, to the above dose-response curve of 
the standard serum, the 13 5 mm reaction can be read as 80 PCA U/ml of a 1 in 10 
dilution of unheated serum and the 6 mm reaction as 8 PCA U/ml of heated serum 
diluted 1 in 10. This corresponds to 90% inactivation, and is consistent with the 56° 
C-lability of IgE.
In order to increase the inactivation, further experiments were done with 
the heating period increased from 30 min to 1 h. This completely abolished the 48 h 
PCA of the standard serum, even when undiluted, and therefore corresponds to less 
than 5 PCA U/ml. The effect of heating for 60 min was to bring about 94% 
inactivation. This result was used in the studies on IgE production to PT and FHA 
where a 1 h treatment at 56° C was routinely used to inactivate IgE in serum.
E ffect o f  PT in  th e  ch ellen ge dose The inhibitory effect of PT on histamine 
release in the PCA test was previously described by Nakamura and Michio, (1983) 
They treated mice with bioactive PT, prior to antigen challenge, and found an 
inhibitory effect on histamine release and 48 h PCA reactivity. The degree of 
inhibition was dependent on the dose (0.1 ug to 3 Ug) and injection time of PT. The 
inhibition of PCA was associated with a decrease in histamine release from peritoneal 
mast cells. Much less histamine was discharged in vitro, in response to IgE receptor 
stimulation. However, this present experiment was done to observe the effect of large 
doses of PT, mixed with the Oa (1 mg) challenge dose. Previously, the animals had 
been injected intracutaneously 48 h earlier with a 1 in 10 dilution of standard anti-Oa 
IgE-containing mouse serum.
Fig. 4 show that there was a significant depression of 48 h PCA reactivity and 
histamine release with low (0.1 and 1 ug) and high (125 and 250 ug)  doses of PT in the 
challenge mixture. The average PCA zone diameters with the 0.1 ug and 250 ug doses
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Fig 4: Possib le in h ib ito ry  e f fe c t  o f in jec tin g  PT sim u ltan eously  w ith  Oa 
in  the anti-O a IgE 48 h PCA. The challenge mixture contained a constant 
amount of Oa (1 mg) and Evans blue (1 mg) with various concentrations of PT. 
The bars indicate the average PCA zone diameter (mm) and the SEM with the 
number of replicate observations inside the bars.
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Fig 5: E ffect o f  a ran ge o f adjuvant doses o f PT, w hen  mixed w ith  a 
con stan t s in g le  dose o f Oa (20 |ig ). on the developm ent o f anti-Oa IgE 
in  m ice. Sera were obtained on days 10, 21 and 28 and tested by the 48 h PCA. 
Each bar represents the log j q PCA U/ml of a single mouse serum compared with
the standard serum which was defined as having 3 log j q U/ml.
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of PT were 8.8 and 9.4 mm respectively, while the control without PT gave a zone 
diameter of 15.4 mm. Referring to the dose-response curve (Fig. 3) when 0.1 ug PT was 
added to the challenge mixture, there was a reduction in PCA U/ml from 200 to 15 
Similarly with 125 Ug challenge dose of PT, there was a drop from 200 to 25 PCA U/ml. 
These correspond respectively to a 92.5% and 87.5% reduction in 48 h PCA reactivity. 
Surprisingly, these results suggest that PT may have a rapid pharmacological effect 
on mast cells in causing the suppression of histamine release and a significant 
reduction in 48 h PCA, over a wide challenge dose range of PT.
IgE responses to Oa after one and three dose immunizations
In order to find a satisfactory protocol for raising IgE, a number of variables had to 
be considered. These included antigen and adjuvant dose, effect of boosting, the time 
of bleeding and the effect of pooling the sera.
Anti-Oa IgE respon ses a fte r  one dose im m unization. Reference has already 
been made to preliminary experiments (Table 16), indicating that anti-Oa IgE might 
be best produced in individual high-responding mice, with no booster and bleeding 
on day 21. This was investigated further in a second experiment on a one-dose 
immunization.
Groups of mice were immunized with 20 ug Oa mixed with various adjuvant 
doses of bioactive PT. The individual sera were collected after immunization intervals 
of 10, 21 and 28 days. The results, shown in Fig. 5, are expressed in logjo PCA U/ml.
obtained by interpolating the PCA zone diameter against the standard curve (Fig. 4). 
In Day 10 sera, the IgE responses to Oa tended to be clustered around the 100 and 250 
ng PT adjuvant dose range, with doses on either side appearing to be unsuitable for 
IgE production. On bleed day 28, the anti-Oa IgE responses were scattered over the 10, 
200 and 1000 ng adjuvant doses. However, on day 21, there were substantial responses 
over a ten-fold range from 100 to 1000 ng. The maximum response occurred when an 
adjuvant dose of 1000 ng was used in the Oa immunization.
Additionally, Fig 6 shows the effect of a high Oa dose (200 ug), with varying  
PT adjuvant dose, on the subsequent IgE responses. On Day 10, only two of the four 
sera tested contained anti-Oa IgE with 200 ug Oa and 250 ng PT, while the other dose 
levels of PT were unproductive of IgE. There was a scatter of results on day 21, with 
only a small number of mice responding at the 1, 10, 100 and 1000 Mg PT levels. The 
strongest responses occurred at the 250 ng PT adjuvant concentration. The 28-day 
sera showed increasing IgE production from low to high as the PT dose increased 
from 10 to 1000 ^g.
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Fig 6: As Fig. 5 excep t that the dose o f Oa was in creased  to 200 |tg (from
20 pg) Sera were obtained on days 10, 21 and 28 and tested by PCA. Each bar 
represents the iogjo PCA U/ml of a single mouse serum compared with the
standard serum which was defined as having 3 log j q U/ml.
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Fig 7: The e ffec t of d ifferen t immunizing doses o f Oa (0.1. 1 and 10 |ig) 
in  the th ree-in jection  protocol and tested in the 48 h PCA. The mice 
had received the indicated doses of Oa on days 0, 28 and 56, the firs t dose being 
mixed w ith 1 ng PT. The serum was from a pool of 25 mouse bloods. The bars 
indicate the average zone diameter (mm) and the SEM with the num ber of 
replicates shown inside the bars.
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In summary, the low Oa (20 ug) doses seem to produce the strongest IgE 
response at 21 days w ith an immunization protocol involving 20 ug Oaand 1000 ng  PT. 
In Fig 6, the Oa dose seems to have an erratic  effect on IgE production, but the re  is a 
high response on day 28, w ith the 1000 ng  PT dose. In subsequent experim ents the 
1000 ng PT adjuvant dose was preferred . Overall, the maximum responses occurred on 
day 21 w ith 20 ug Oa as antigen and 1000 ng PT as adjuvant.
Anti-On IgE reponses nfter 3-dose immunizntions. IgE responses can be 
transien t in th e ir  duration, if  a one-dose immunization protocol is used as shown in 
Fig.3 and 6. Levine and Vaz, (1970) showed tha t by altering  a num ber of factors a 
prolonged IgE response could be elicited.
A protocol was used w hereby an tigen  and adjuvant were injected on day 0 
and the anim als then  boosted on days 28 and 56 with an tigen  alone. The final bloods 
for test (as pools) in the 48 h  PCA w ere collected on day 63 (Fig 7).
When dose of 0.1 ug Oa was used in the in tial immunization w ith 1000 ng  of 
PT, a h igh  titre  serum was produced w hich was adopted as the standard serum. The 1 
Ug dose of antigen also gave strongly  positive IgE serum. However w hen 10 ug was 
used, no IgE anti-Oa response could be detected. This suggested tha t small repeated 
doses of Oa with 1000 ng  bioactive PT (administered with the in itia l in jection) gave 
high IgE titre  serum. When the one-dose immunization protocol was used, the IgE 
response was erra tic  and could only by detected in individual sera, not in  pools. In the 
three-in jection  protocol, how ever the sera  raised against 0.1 and 1 ug Oa, w ith 1000 
ng bioactive PT in the in itia l injection, w hen pooled, produced a good IgE response as 
tested by 48 h PCA.
M easurem ent o f IgGl by conY entional ELISA 
P relim in ary  experim en ts w ith  IgG l.
To provide experience w ith ELISA methodology, it was decided to establish an anti-Oa 
IgGl ELISA system before attempts to measure ani-Oa IgE by ELISA.
Effect of On. conting concentrntions A varie ty  of coating concentrations of Oa 
were tested w ith a 2 h PCA-positive serum  in the IgGl ELISA (Fig. 8). The most 
satisfactory coating concentration was 100 ug/m l or 10 ug/w ell. The serum  endpoint 
titres a fte r coating with 100 Ug/ml and 1000 Ug/ml Oa were 78,600 and 1,400 
respectively. Thus there  was a 56-fold reduction in the antibody titre w hen the Oa 
coating concentration was raised from 100 to 1000 ug/m l. In the subsequent 
conventional IgG and IgE ELISA experiments, the coating concentration of Oa was 
kept constant at 100 ug/m l.
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Fig S: IgGl ELISA: Effect of the Oa coating concentration on the 
m easurem ent o f IgGl in a mouse serum. A 2 h PCA-positive anti-Oa IgGl 
serum  was used, w ith the sheep anti-mouse IgGl-HRP conjugate at 1 in  1000 
dilution. The Oa concentration in the coating mixture is shown on the righ t. The 
dotted line at0.D0.5 represen ts the endpoint absorbance.
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Fig 9: IgGl ELISA : Effect of d ifferen t types of ELISA plate. An IgGl-positive 
anti-Oa serum  tested by 2 h  PCA was used w ith the sheep anti-mouse 
IgGl-HRP conjugate at a 1 in  1000 dilution. The type of plate is shown on the 
righ t. The dotted line at 0.D 0.5 represen ts the endpoint absorbance.
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Type o f  p lts tic  fo r  ELISA p itie s . A variable w hich is ra re ly  reported in the 
ELISA literatu re  is the suitability of d ifferent plastics in the m icrotitre plates. Seven 
types of plates were tested in  parallel, the Oa coating concentration and anti-Oa 
serum dilutions being replicated on each. Fig. 9 shows tha t there  was very  little 
variability. However Costar El A and Nunc F maxisorp produced, slightly  h ig h e r 
endpoint titres than the o ther 5 plates. In all subsequent experim ents Nunc F 
maxisorp plates were used.
Factors in flu en c in g  the IgE ELISA
There was a requ irem en t fo r the sera  raised by the one and three-dose protocols to be 
titrated in  an In vitro  assay for IgE. To do this, a num ber of factors had to be 
considered w hen p lann ing  the IgE ELISA. These included the titration of the 
conjugates, the choice of blocking agent and the possible requ irem en t for Protein A 
extraction, of the test serum, to reduce IgG w hich m ight in te rfe re  w ith the assay.
Measurement of IgE by conventional ELISA
The conventional ELISA was explored because it offered a simple and sensitive assay 
for titra ting  large num bers of sera. Its advantages over the PCA are sensitivity, 
avoidance of use of animals, technical simplicity and convenience, and economy of 
antigen.
T iir tiio n  o f  co n ju g a tes  In in itia l studies, the secondary antibody employed was a 
goat anti-mouse IgE. Since it was not labelled w ith horseradish peroxidase (HRP), 
there was the need for a fu r th e r  antibody. This was donkey anti-goat IgG HRP 
conjugate w hich served to am plify the signal and generate a colour from the OPD and 
hydrogen peroxide substrate. Table 18 shows a chequerboard titration  w ith d ifferen t 
dilutions of both antibodies. The dilution combination of the two antibodies giving the 
most satisfactory results was 1 in 100 of goat anti-mouse IgE and 1 in  1000 dilution of 
the HRP-labelled donkey anti-goat IgG. In experim ent 1 (Table 18), it appeared that 
the 1 in 100 dilution of the firs t antibody and 1 in 1000 of the second gave satisfactory 
result. Therefore, in  experim ent 2 (Table 18), the goat anti-mouse IgE was diluted 
fu rther in order to economise on its use. This was not successful and the 1 in  100 
dilution was adopted for the subsequent titration of sera. A summary of experim ent 2 
can be seen in  Fig 10 with the 1 in 100 dilution of goat anti-mouse IgE and 1 in  1000 
donkey anti-goat IgG HRP producing a good titration curve with the standard anti-Oa 
IgE mouse serum. The endpoint titre  was taken at O.D 0.3. Since the h ig h e r dilutions 
of 1/250 and 1/500 of the goat anti-mouse IgE all had O.D's w hich w ere <0.5, they  were 
not used in the subsequent experiments.
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Table IS : Effect of d ifferen t combinations of the ELISA reagent sera for
assaying anti-Oa IgE in  standard mouse serum. The reagen t sera were goat 
anti-mouse IgE (source: ICN) and donkey anti-goat IgG HRP conjugate (source: SAPU), 
The combinations giving satisfactory results are h ighlighted in bold
Expt
No.
Reciprocal diln. of 
goat anti- mouse IgE
Range of absorbancy values (A492nm) given 
by standard IgE serum w hen tested with 
donkey anti-goat IgG HRP at reciprocal diln:
100 1000 10,000
1 10 all > 3-0 all > 3.0 1.1- >30
100 0.5- >3 0 0.2 - 0.7 0.03-0.1
2 100 n.t 0.2 - O S n .t
250 n.t 0.2 -0.3 n.t
oo\rs n .t 0.18-0.2 n.t
Footnote : The standard IgE serum  was raised against Oa in mice by the three injection 
protocol.
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Fig 10: IgE ELISA: Effect of goat anti-m ouse IgE (1CN) concentration on 
the m easurem ent of IgE. A 48 h PCA-positive anti-Oa IgE serum  was used 
w ith the donkey anti-goat IgE HRP conjugate at a I in  1000 dilution. The dilution 
of the goat anti-mouse IgE are shown on the r ig h t of the graph.
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Fig 11: IgE ELISA: Effect of sheep anti-mo use IgE (The Binding Site) 
concentration on the measurement of IgE. A 48 h PCA-positive anti-Oa 
IgE serum  was used. The dilution of sheep anti-mouse IgE HRP conjugate is 
shown on the righ t.
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Table 19 (A): E ffect o f d iffe re n t b lock ing agents on IgE ELISA. The tests 
v e re  done on an IgE-positive serum, before and after heating at 56° C, and a norm al 
serum, all at 1/100 dilution. The ELISA reagents (goat anti-mouse IgE and donkey 
anti-goat IgG HRP) were also used at fixed dilutions of 1/100 and 1/1000 respectively.
Mouse O.D with blocking agent (2%)
serum Horse Gelatin Foetal calf Bovine serum Skim milk
serum - serum albumin
IgE-positive 0.432 0.350 0.550 0.572 0.417
IgE-positive(56°C) 0.420 0.312 0.560 0.369 0.455
Normal 0.121 0.122 0.180 0.101 0.094
Table 19 (B) : Control resu lts  re la tin g  to the data in  Table 19(A). and in  
w hich th ere  was stepw ise om ission o f one or more reagen ts in  the ELISA 
on the IgE -positive serum . The desired results are shown for comparison, and the 
troublesome observations are h ighlighted in bold.
a i s A O.D with blocking agent (2% )
step /reagent Desired H.S G FCS BSA SM
omitted result
A nil >0 5 0.432 0.350 0.550 0.572 0.417
B coating <0.1 n .t n .t n.t 0.124 n .t
C blocking >0.5 0.530 0.475 0.701 0.548 0.582
D IgE-positive <0.1 0.217 0.185 0.227 0.096 0.083
mouse serum
B + C <0.1 0.111 0.134 0.255 0.137 0.067
B + D <0.1 0.053 0.072 0.170 0.083 0.035
b * c * d <0.1 0.072 0.409 0.257 0.075 0.193
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Latterly, an anti-mouse IgE conjugate raised in sheep and already labelled 
with horseradish peroxidase (The Binding Site) was tried in the conventional ELISA. 
This avoided the need for a fu r th e r  antibody. As seen in Fig, 11, the best dilution of 
the sheep anti-mouse IgE-HRP conjugate in  the ELISA was 1 in 100. Therefore in 
subsequent experim ents the p referred  conjugate (sheep anti-mouse IgE-HRP) was 
used at 1 in 100 dilution.
E ffe c t o f  d iffe r e n t b lo c k in g  e g e n ts  A major problem found in this study, in 
conventional IgE ELISA was the h igh  background O.D. This was thought to be due 
partly to incomplete blocking, thereby allowing binding of non-specific serum 
proteins, w hich augm ent the final O.D readings. In an in itia l experim ent, the O.D 
readings at test serum  dilution lin  100 was recorded with a) an IgE-positive serum, b) 
the same serum  heated to 56° C for 1 h  and c) norm al mouse serum. Five d ifferen t 
blocking agents were used all at 2%. The results in Table 19a showed that heating 
serum at 56° C, w hich inactivates IgE had little effect on the final O.D readings, w hen 
compared with unheated IgE-positive serum, with any of the blocking agents 
However w ith norm al serum, there was generally  a th ree to four-fold decrease in O.D 
throughout
In Table 19b, control wells, w ere set up w here one or more of the steps or 
reagents in  the ELISA had been omitted. The desired results are tabulated with 
h igh ligh ting  of the troublesome observations. When no steps w ere omitted, and 
where a h igh  0,D was expected with the IgE-positive serum, only FCS and BSA gave 
readings > 0.5 i.e around the endpoint value. Omission of blocking, in the ELISA, had 
no sign ifican t effect on the resu ltan t O.D readings. An im portant control, the 
no-serum well, w hich should always be < 0.1, for assay validity, yielded h ig h e r than 
expected O.D's w ith horse serum, gelatin and foetal calf serum. When blocking and 
coating w ere omitted altogether the O.D still rem ained high. When no coat or serum 
was added, only FCS gave h ig h e r than  the minimum desired resu lt and, in the one of 
the wells w ithout coat, block and serum, there was an unusually h igh  background 
reading of 0,409, w hich may rep resn t the conjugate sticking to the plastic.
The blocking agent chosen was 2% BSA, since background levels w ith this 
blocking agen t w ere usually low, while still allowing h igh  O.D readings in 
experimental wells w ith IgE-positive serum.
E ffe c t o f  a b so rb in g  seru m  w ith  Staphylococcus aureus (Co wen s tr a in )
Protein A on the surface of S. aureus binds to the Fc receptor of IgG and removes it 
from serum. This m ight have been advantageous, since IgG has been reported
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Fig 12: IgG and IgE ELISA: E ffect o f absorbing the standard mouse serum  
v i t h  P rotein  A (Sigm a). The serum was tested before absorption and after 3 
successive absorptions and the IgE and IgG content of the serum was measured 
by the conventional ELISA. The d ifferent scales on the abscissa re fe r  to the 
absorption steps w hich resulted in dilution of the serum
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Fig 13: IgE ELISA: T itration o f mouse sera  o f know n PCA reactiv ity . The
reag en t sera  used in  A was goat anti-mouse IgE (ICN) 1 in 100 dilution and 
donkey anti-goat IgG HRP (SAPU) 1 in  1000 dilution and in B sheep anti-mouse 
IgE HRP conjugate (The Binding Site) 1 in 100 dilution.
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(Hamilton etal., 1981, F inger and Wirsing von Koenig., 1985) to in terfere  with the IgE 
ELISA, by competition for the antigen coating on the plate. Therefore 48 h 
PC A-positive serum  was tested for IgE and IgG before and after absorption with 
form alin-killed whole cells of S. aureus.
In the IgG ELISA, the antibody titres were low in untreated serum and after 
the 1st and 2nd absorptions, w ere reduced 4 and 3-fold respectively (Fig, 12). 
Surprisingly, afte r the th ird  absorption, there was a massive apparent increase in 
detectable IgG. Conversely, the reciprocal IgE titre started high  in untreated serum 
and then  dropped 100-fold afte r the 1st absorption, and only increased in 2.5 and 
2-fold steps in  the 2nd and 3rd absorptions. In subsequent experiments, the sera were 
therefore no t absorbed with S. aureussmcs absorption seemed to have a detrim ental 
effect on both the IgE and IgG titration.
Titration o f mouse sera  o f know n PCA reactiv ity
Having explored some factors tha t m ight influence the perform ance of the 
conventional ELISA for IgE, a series of control sera were assayed. These were the 
standard PCA-positive mouse serum, before and after heating to 56° C, known 
PCA-negative sera  from Oa-immunized mice and normal mouse serum. Each series was 
tested with two reagen t sera, viz HRP-conjugated sheep anti-mouse IgE (The Binding 
Site) and goat anti-mouse IgE (ICN) used in conjunction with HRP-conjugated donkey 
anti-goat IgG (SAPU).
As shown in  Fig 13, the two reagent systems gave broadly similar results. 
With each, the standard PCA-positive mouse serum was the most active, although the 
dose response line only barely reached an absorbancy of 0.5 w ith 1 in 10 serum. This 
was considerably less active than  expected from previous experiments (Fig. 10, 11). 
The reason fo r the reduction in  activity was not uncovered but m ight have been due 
to use of a  d iffe ren t batch of reagen t or the detrim ental effect of storage and repeated 
freezing and thaw ing.
Despite the low initia l titre of the untreated PCA-positive serum, the 56° C 
treatm ent produced a sign ifican t reduction although less than expected from the PCA 
test. Normal serum  and PCA-negative sera were much less reactive.
M easurem ent o f IgE by sandwich ELISA
Because of the low IgE titres obtained with known PCA-positive sera in the 
conventional" ELISA it was decided to explore the possible beneficial effect of the 
sandwich" ELISA technique. This involved coating the plates with affin ity-purified
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14: Standard curve fo r  m easuring protein  con ten t in  a ff in ity  
p u rified  anti-Oa. By the method of Lowry et al., (1953) outlined in the 
m aterials and methods.
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Plate 2: Im m unodiffusion  pattern o f anti-Oa serum  before and a fter  
extraction  on a O a-sapharose colum n. The serum  v as  raised in  a rabbit v ith  Oa 
and FCA.
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Fig 15: IgE ELISA: E ffect o f the concen tration  o f a ff in ity -p u r if ie d  rabbit 
anti-O a as a coating a g en t in  th e sandw ich  
ELISA. The ELISA was done on IgE-positive serum, before (solid points) and 
a fte r heating  at 56° C (open points). The Oa for binding was used at a constant 
concentration of 100 ng/m l and the sheep anti-mouse IgE HRP at 1 in 100 
dilution. The concentration of AP anti-Oa in the in itia l coating stage is shown on 
the righ t.
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(AP) rabbit anti-Oa, instead of with Oa itself. However before describing these 
experim ents it was necessary to determine the concentration and purity  of the AP 
anti-Oa.
Characterization of a ffin ity-purified  anti-Oa
Starting w ith 25 ml of the anti-Oa serum w hich had been produced by immunizing 
rabbits w ith Oa in Freund s incomplete adjuvant, the anti-Oa antibodies (irrespective 
of im munoglobulin class) were removed by adsorption onto, and elution from an 
Oa-sepharose column. The eiuate was then concentrated to 2 ml by dialysis against 
Aquacide, to give a sample with a protein content of 1.75 mg/m l by the Lowry method 
estimated by extrapolation from  the standard curve (Fig 14). The yield of anti-Oa was 
estimated roughly  by immunodiffusion with the results shown in Plate 2.
Factors in flu en cin g  the ELISA
E ffe c t o f  co n cen tra tio n  o f  a ffin ity -p u r ifie d  anti-O a. Ten-fold dilutions of 
1.75 m g/m l AP anti-Oa were prepared in  coating buffer and incubated at 4° C 
overnight. In th is initial experim ent the Oa concentration was kept constant at 100 
Ug/ml and bound to the plate v ia  the AP antibody (Fig. 15). Throughout this sandwich 
ELISA technique all incubations were done at 4° C for 1 h apart from the 
substrate-incubation step w hich was done at 37° C for 30 min. Thus, the procedure 
differed from the conventional ELISA w here incubations were performed at 37° C and 
had been adapted from the method of Kenemy etal, (1985). Both unheated and heated 
anti-Oa sera, produced by the one-dose protocol, were tested in this system. 
Dramatically, the wells coated with 0.175 Ug/ml AP anti-Oa produced a satisfactory 
dose-response curve with an antibody titre of 600. Moreover, when heated test serum 
was used in the above system, the absorbance values of the lowest dilution of the test 
sera (1 in 10) with the 0.175 J i g / m l  AP anti-Oa coating concentration was very  low, 
giving an absorbance of < 0.3. It was therefore clear that the sandwich ELISA 
technique with AP anti-Oa as coating reagent would overcome the earlier difficulties 
of h igh  backgrounds.
With the h ig h e r concentrations (1.75 and 17.5 ug/m l) of AP anti-Oa, heating 
the IgE-positive serum caused a reduction in the dose-response line w hen compared 
with unheated serum (Fig. 15), but all the absorbances were > 0.5 and titres could not 
be calculated. Throughout the following experiments therefore, the coating 
concentration of AP rabbit anti-Oa was 0.175 Ug/ml.
E ffe c t o f  co n cen tra tio n  o f  Oa in  sandw ich la y e r . In the previous Fig. 15, it 
was shown tha t d ifferen t concentrations of AP rabbit anti-Oa had a marked effect on
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Fig 16: IgE ELISA: E ffect o f Oa con cen tration  in  the sandw ich layer  on 
th e m easurem ent o f IgE by sandw ich ELISA. The ELISA was done with 
standard anti-Oa IgE serum with the in itia l coating of the plate w ith AP anti-Oa 
at a fixed concentration of 0.175 Ug/ml. The concentration of Oa in the sandwich 
layer is shown on the righ t.
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Fig 17: IgGl ELISA: E ffect o f the d ilu tion  o f sheep  anti-m ouse IgGl HRP 
conjugate on th e m easurem ent o f IgGl. The dilutions of w hich are shown 
on the rig h t. A 2 h PCA-positive anti-Oa IgGl serum was used. The coating 
concentration of Oa was 100 pg/m l.
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anti-Oa IgE detection, with a constant dose of Oa (100 ug/m l) in the sandwich layer 
Subsequently, the AP anti-OA was kept constant at 0.175 Ug/ml and the Oa conc. was 
varied (Fig, 16). Taking the endpoint absorbance as 0.5, the 100 ug/m l Oa in the 
sandwich layer gave a titre of 1400 with the standard IgE serum. Whereas the 10 
Ug/ml and 1000 ug/m l Oa concentrations, although showing a similar trend, the 
absorbance readings at all the serum dilutions was < 0.5, which frustrated reading the 
endpoint. Routinely, therefore the concentration of Oa in the sandwich layer was 100 
Ug/ml with the initial AP anti-Oa coating being 0.175 ug/ml.
M easurem ent o f IgGl by con ven tion a l ELISA
The IgGl conten t of serum was measured because of its potential to in terfere  with 
both the PCA test and the ELISA. It was also studied for possible correlation with IgE 
content.
Titration o f conjugate
As before, in  the conventional ELISA, the conjugate had to be titrated to find a 
suitable dilution for the ELISA (Fig. 17). A range of dilutions from 1 in 100 to 1 in 
10,000 of the sheep anti-mouse IgGl-HRP conjugate were tried. A 2 h PCA-positive 
serum was used in the ELISA to evaluate the effect of the d ifferen t dilutions of 
conjugate. The 1 in 100 dilution at low dilutions of test serum produced absorbances >
2.0. The 1 in 1000 diln. gave a satisfactory response with a calculated IgE titre of
40.000. The titres obtained with 1 in 2500 and 1 in 10,000 dilutions of conjugate were 
7300 and 1000 respectively, a 7.5 and 55 fold decrease from that obtained with the 1 in 
1000 dilution of conjugate. In subsequent experiments, the sheep anti-mouse 
IgGl-HRP conjugate was used at a 1 in 1000 dilution.
Correlation of 48h PCA and ELISA for detection of IgE and IgGl
Having raised a large num ber of anti-Oa sera by various immunization protocols, and 
having tested them for IgE and IgGl by 2 different methods, it was then appropriate 
to compare the accumulated results, Table 20 sets out the PCA values for 26 sera, or 
pools of sera, together with the corresponding IgE ELISA data. One of the main 
features to em erge was tha t the log jq IgE ELISA titres tended to range from about 15 to
350-fold h ig h e r than the titres found in the PCA test for the same sera. Unexpectedly, 
this range of differences was only found in sera raised using the h igh  dose of Oa 
(200 ug). However, they did vary  with respect to adjuvant dose and day of bleeding. 
Conversely in the rem aining serum, the log j q PCA U/ml values for the test sera
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Table 20 : Comparison o f anti-Oa sera  by 48 h PCA. c o n v e n tio n a /fo r  IgGl
and sandw ich  ELISA for IgE. Details of the th ree methods can be found in the 
Materials and Methods.
Serum 
no. 1
loglO 
48 h PCA 
U/ml
loglO
I«E
litre
loglO
IgGl
titre
4f 0.9 n.t 4.7
3f 1.2 3.0 3.9
4e 1.2 n.t 3.9
5a 1.2 35 2.9
2e 1.3 n.t 3.7
la 1.3 2.7 2.6
3e 1.3 2.9 4.6
3g 1.3 3-8 3.5
4d 1.5 3.0 3.9
6b 1.5 2.7 3.8
3c 1.5 1.2 2.7
4b 1.6 2.6 2.8
2b 1.7 n.t 3.5
5c 1.7 2.5 2.7
3d 1.9 <1 2.9
lb 2.0 2 2.1
2a 2.0 n.t
2c 2.5 1.8
2d 2.5 <1 3
6a 30 b 3 3.3
3b 3.2 2.5 2.7
4c 32 2.0 3.6
3a 3.6 1.9 2.9
4a n.t n.t <1
4g n.t 3.3 2.7
5c n.t <1 4.9
* - for fu rth e r  particulars, see Appendix 7. Sera with serial num bers from l to 5 were 
individual mouse sera  obtained by protocol 2 and those with serial num ber o were 
pools of 25 obtained by protocol 3
b '  Standard defined as having lOOOU/ml, loglO value 3 in PCA and IgE ELISA
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Fig IS: C orrelation o f anti-Oa IgE. m easured by PCA and ELISA, with. IgGl 
m easured in  p ara lle l. The bars rep resen t the loglO IgGl titre  w here 1 cm is 
equivalent to 1 loglO, The line starts at a loglO IgGl titre  of 2 as the 1 in 100 
dilution was the lowest used in  the IgGl ELISA
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tended to range from about 2 to 550-fold h ig h e r than the loglO IgE titres for the same 
sera. In th is instance, the immunizing dose was mainly 20 jig Oa. the "low" dose. There 
did seem therefo re  to be a correlation between the 200 jig Oa immunizing dose and 
high  IgE titres in the ELISA while the PCA results remained low in comparison. The 
low 20 jig Oa im munizing dose sera produced high  PCA titres, w hen compared with 
log jq IgE titres in ELISA, w hich was invariably lower.
Before the data could be analysed statistically, a judgement on the norm ality 
of the data had to be made. For this purpose, the rank it test was applied. In appendix 
9, the ran k it plots of log10 PCA U/ml, lo g j0 IgE and IgGl titres can be seen. The ran k it
plot of the log|Q PCA U/ml showed a deviation from norm ality in  tha t the observed 
rank it line (solid) did not zig zag in a random fashion fairly  closely around the fitted 
theoretical line (dashed). From these ran k it plots, it was calculated tha t the logjQ PCA
U/ml and the logjQ IgGl titres were not normally distributed. The log^IgE  titres
however appeared not to depart from normality. Therefore the data as a whole were 
analysed by the Kendall ran k  correlation test, a non-param etric procedure th a t is 
applicable to populations w hich are not norm ality distributed. A graph of the 
negative correlation of lo g j0 PCA U/ml and log jq IgE titre can be seen in Fig. 18. 
Kendall statistics show tha t there was a h ighly  significant negative correlation with 
a p value of 0.006. In Fig 18, the log j0 IgGl data are also incorporated into the graph
(vertical lines) w here 1 cm is equivalent to 1 loglO. The lines start at a log^ q IgGl
titre of 2 as the 1 in 100 dilution was the lowest used in the IgGl ELISA. There did not 
seem to be any  real trend in  IgGl production at d ifferen t antigen and adjuvant 
immunizing concentrations, as most of the sera seemed to have sim ilar amounts of 
IgGl. Exceptionally, a and b on the graph in Fig. 18 , whose PCA and IgE ELISA results 
give equivalent titres also had low IgGl titres when compared with the o ther sera. 
Therefore there  may be a requirem ent in  these assay systems that the IgGl should be 
low, in  order to give a good comparison between PCA and IgE ELISA titres. A possible 
reason for the discrepancies between the PCA and ELISA titres could well be the 
in terference of IgGl antibodies in these systems.
IgE Responses to FHA, w ith  IgGl M easured in Parallel
With all the groundwork already investigated in the Oa system, it was easier to 
quantify IgE responses to the FHA of B. pertussis In the Oawork, a protocol for
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Table 21 : C haracterization o f 15 batches o f FHA. p u rified  by g e l-a f f in ity  
chrom atography. The protein content of each batch was measured by Lowry with 
BSA as standard .and the batches w ere variously examined for haem agglutination 
activity and /o r 200 kDa and o ther proteins by SDS-PAGE. The batches h ighlighted  in  
bold type w ere used fo r immunizations.
Batch Vol. 
culture
(L)
Vol.
(ml)
Protein
content
(Ug/ml)
HA
units
SDS-PAGE 
200 kDa approx. % 
contam.
Specific
activity
HAU/yg
Yield - 
HAU/ 
L
1 6 20 300 30S - J 1.03 1026
2 6 30 1000 19607 * 10 19.6 98035
3 6 20 600 9900 ♦ 10 16.5 33000
4 5 20 250 4805 n.t n.t 19.20 19.220
5 6 30 600 4805 + 10 8.0 24.025
6 5 15 100 615 10 6 15 1846
7 /■0 20 100 308 + 10 3 OS 1026
8 6 15 50 n.t n.t n .t n .t n.t
9 6 2S 900 n.t - 10 n.t n.t
10* 5 30 200 n.t 60 n t n .t
11 8 40 700 9900 + 10 14.14 49500
12 6 40 600 n.t + 5 n.t n .t
13 6 20 300 n .t *► 15 n.t n .t
14 6 24 300 n.t + 15 n.t n.t
15 6 20 200 n.t + 10 n.t n.t
n.t - not tested 
1 - discarded
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raising IgE antibodies and the PCA and sandwich ELISA were all studied for producing 
and m easuring IgE. However, the PCA had to be altered in the FHA system, as 
discussed below.
M easurem ent o f anti-FHA IgE by PCA 
C haracterization o f FHA
From a 6L culture supernate of B. pertussis strain  BP 337. FHA was purified by blue 
sepharose gel affin ity  chrom atography. The FHA fraction was eluted by h igh  salt and 
had a volume of 20 - 40 ml. Some of these batches (Table 21) were analysed for protein 
content by Lowry, haem agglutination and the presence of a  200 kDa protein  band on 
SDS-PAGE. The batches h igh ligh ted  in  bold were used for immunizations because they 
had h ig h  protein  values and good haem agglutination activity titres, and only 10% 
contam ination with o ther pro teins or degraded FHA. Batch 10 was discarded because 
of a v e ry  h igh  percentage contam ination as revealed by SDS-PAGE. The o ther batches 
were e ith e r used in challenge mixtures for PCA or as coating in  the ELISA.
Factors in f lu e n c in g  th e PCA test
A num ber of factors although already optimized in the Oa system, had to be checked 
and in  some cases altered in  the FHA system. These included the a) increasing  the 
sensitization in terval b) FHA challenge dose c) and the effect of four sites per mouse.
E ffe c t o f  in c re a s in g  th e  se n sitiza tio n  in terva l. In p relim inary  experim ents 
in the 48 h PCA with anti-FHA and FHA, there were problems of diffuse blueing on the 
undersurface of the skin w hich obscured the blue zone at injection sites. The 
diffuseness disappeared with dilution of the test serum, but so did the positive 48 h 
PCA responses, although in some anim als there was a slightly  darker reg ion  of 
blueing a t the site of injection. A possible reason for th is diffuseness could have been 
the in te rfe rin g  effect of h igh  levels of IgGl reacting throughout the vasculature 
after challenge. It was therefore decided to increase the sensitization in terval up to 7 
days, and to challenge groups of four mice at one-day in tervals during  th is period. A 
7-day in te rv a l was taken as the longest, since IgE has a half-life of 6 days.
As shown in Fig. 19, with sensitization in tervals between 1 and 5 days there 
was no detectable PCA response, in tha t the whole surface of the skin turned  blue. At 
day 6, the re  was azone of blueing w hich could be measured and. su rprising ly , on day 
7 this PCA zone diameter had increased to 12 mm with undiluted test serum. In 
subsequent experim ents , a  sensitization in terval of 7 days was adopted.
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Fig 19: The b e n e fic ia l e f fe c t  o f a 7-day in terv a l betvreen sen sitiza tion  
and ch a lle n g e  in  PCA tests v i t h  FHA. Mice were sensitized with anti-FHA 
serum  and groups of 4 mice were challenged i.v w ith FHA afte r d ifferent 
sensitization intervals. The points indicate the average zone diam eter and the 
SEM.
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Fig 20: E ffect o f  v a ry in g  the ch a llen g e  dose o f FHA in  th e 7-day PCA test.
Undiluted serum, raised by the three-in jection  protocol, and known to be 
IgE-positive was injected i.d into all mice; 7 days later, pairs of mice were 
challenged i.v w ith FHA and Evans Blue. The bars indicate the average zone 
diam eter (mm) and SEM with the num ber of replicates shown inside the bars.
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Plate 3: Layout o f th e PCA test w ith  4 s ite s  per m ouse. At positions A and D 
anti-FHA IgE rich  serum  was injected i.d. The anim als w ere challenged i.v with 300 tig 
FHA and Evans blue, 7 days a fte r sensitization. Positions C and B w ere injected with the 
same sera  heated to 56° C fo r l h ,
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E ffe c t o f  FHA c h e lle n g e  dose. The FHA challenge dose was altered in the 7-day 
PCA to see if  it would behave d ifferently  from the Oa system, w here the optimal 
concentration was 1 mg/mouse, In these experim ents pairs of mice w ere i.d injected, 
with a PCA-positive anti-FHA IgE serum and challenged 7 days la ter w ith FHA. A wide 
range of FHA challenge doses were used (Fig. 20). When 50 ug FHA was used, there  was 
no detectable IgE response in the 7-day PCA. The 250 jig &fld 1000 jig doses both gave 
sim ilar zone diameters, but the 500 ug challenge dose produced a sign ifian tly  h ig h e r 
average zone diameter than  the doses e ither side of it. In subsequent experim ents, the 
dose of FHA was set at 500 ug/mouse.
E ffe c t o f  4  s ite s  p e r  m ouse. In the Oa system, there was an abundant source of 
com mercially-available challenge antigen. However because of the leng thy  process 
involved in p reparing  purified FHA, there was a requirem ent for more sera  to be 
tested in  each challenged mouse. Therefore the PCA was modified to allow four sera  to 
be tested in  the one animal. A diagrammatic representation of the four injection sites 
is shown. Plate 3 shows sites A and D w here anti-FHA IgE-containing serum  was 
injected i.d and the same sera  heated to 56° C was injected at sites B and C. The mouse 
was challenged with 500 ug FHA and blueing indicative of IgE can be seen at positions 
A and D only. This was afte r the extended sensitization in terval of 7 days.
Anti-FHA IgE resp on ses a fter  one-dose im m unization
In the Oa system, the one-dose immunization protocol only gave positive 48 h PCA 
reactions from  individual h igh-responding  mice. With FHA at d ifferen t im m unizing 
doses and two strains of mice, the sera obtained were pooled and tested in the 48 h and 
7-day PCA. The 48 h PCA was reintroduced in th is experim ent because the IgGl 
content of the serum  was presumed to be low and therefore would not in te rfe re  in  the 
PCA, as had happened with the sera raised in the three-dose protocol. In fact, there  
was no detectable PCA reactiv ity  w ith these anti-FHA sera and with an FHA challenge 
given afte r a 48 h sensitization interval. Moreover, the generalised blueing th a t had 
been encountered earlie r was not a problem. Another strain  of mouse was 
therefore investigated, as Ham/ICR may have contained a mixture of h ig h  and low 
responding animals. Balb/c mice are known to be a reliable IgE-responding strain  
(Suko eta l, 1977).
In pools of anti-FHA sera raised in Ham/ICR mice, the re  was no PCA 
reactivity at e ith er 48 h or 7 days (Table 22). The controls w hich consisted of sera 
from antigen-alone injected mice did not elicit a IgE response at days 10, 21 and 28. On 
the o ther hand, there  w ere 4 positive 7-day PCA responses with pooled sera  raised in
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Table 22 : E ffect of a range o f im m unizing doses of FHA. when, mixed w ith  
a con stan t adjuvant dose o f PT (1 u g), on the developm ent o f an anti-FHA  
IgE resp on se  by the one-dose protocol in  both Ham/ICR and B alb /c m ice.
Sera were pooled from 5 individual mouse bloods and were tested undiluted in both 48 
h and 7-day PCA tests. The positive anti-FHA IgE responses are shown in bold type.
Imm unizing dose 
of FHA (u g )o n d ay  
zero
Adjuvant 
dose of PT
(lug )
10 
48 h
No. of PCA positive pooled sera  tested 
in  48 h and 7-day PCA test on bleed day:
21 28 
7-day 48 h 7-day 48 h 7-day
Ham/ICR
0.05 0/2 0/2 0/2 0/2 0/2 0/2
0.5 0/2 0/2 0/2 0/2 0/2 0/2
2.5 0/2 0/1 0/2 0/2 0/2 0/2
5 0/2 0/2 0/2 0/1 0/2 0/2
10 0/2 0/2 0/2 0/2 0/2 0/2
25 0/2 0/2 0/2 0/2 0/2 0/2
50 0/2 0/2 0/2 0/2 0/2 0/2
0.05 0/1 n.t 0/1 n .t 0/1 n.t
5 0/1 n.t 0/1 n.t 0/1 n.t
50 0/1 n.t 0/1 n.t 0/1 n.t
Balb/c
0.05 0/2 0/2 0/2 0/2 0/2 0/2
0.5 0/2 0/2 0/2 0/2 0/2 2/2
2.5 0/2 0/2 0/1 0/2 0/2 0/2
5 0/2 2/2 0/2 0/2 0/2 0/2
10 0/2 0/2 0/2 0/2 0/2 0/2
25 0/2 0/2 0/2 0/2 0/2 0/2
50 0/2 0/2 0/2 0/2 0/2 0/2
0.05 0/1 n.t 0/1 n.t 0/1 n.t
5 0/1 n.t 0/1 n.t 0/1 n .t
50 0/1 n.t 0/1 n.t 0/1 n.t
n .t - not tested
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Fig 21: A pplication  o f the 7-day PCA test to detect IgE antibodies to FHA 
in  m ice. Sera were raised by the three-in jection  protocol. A and B 
w ere replicate experim ents, w ith the im m unizing doses indicated on the 
abscissa. The bars indicate the average zone diameter and the SEM 
w ith the num ber of replicate observations inside the bars,
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Fig 22: E ffect o f  d iffe re n t im m unizing doses o f FHA on th e  developm ent 
o f anti-FHA IgE in  Ham/ICR and B alb/c mice. Sera vere  raised by the 
three-dose protocol and tested undiluted in the 7-day PCA test. The bars indicate 
the average zone diameters (mm) and SEM v ith  the number of replicates inside 
the bars.
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Balb/c, with a 0.5 Ug immunizing dose of FHA and a 28-day bleed, and with 5 Ug FHA 
immunizing dose and a 10-day bleed, both with 1 ug bioactive PT as adjuvant. Two 
pools, each of 5 mouse bloods were positive in the 7-day PCA performed on > 6 wk old 
Ham/ICR mice. These observations are outlined in bold in Table 22. Generally 
however the one-dose immunization protocol with FHA as antigen, PT as adjuvant and 
two different mouse strains, yielded very few PCA-positive responses, as judged by 
observations with pooled serum. Perhaps, with hindsight, if  the sera had been tested 
individually, any high reponders could have been detected.
Anti-FHA IgE resp on ses a fter  th ree-dose im m unization.
Before attempting to raise IgE-rich sera to FHA, prior studies were done in Ham/ICR 
mice with Oa as the model antigen. Strongly IgE-positive anti-Oa sera were obtained 
using the 3-dose protocol described in Materials and Methods. These anti-Oa sera were 
used as a pooled positive control at 1 in 20 dilution in the FHA PCA tests which  
required a 7-day interval for detection. The recipient mice in these tests received a 
mixed challenge of FHA and Oawith Evans blue.
In the 7-day PCA tests, the effect of different doses of a carbodiimide toxoid 
of PT/FHA was investigated as a stimulus for the production of IgE antibodies to FHA. 
As shown in Fig 21A, IgE was produced over a 100-fold range of imunizing doses of 
FHA/PT toxoid from 0.1 ug to 10 ug. The actual amount of FHA in this carbodiimide 
toxoid was one-half the dose inferred on the abscissa, as PT was present in equal 
amount in the toxoided mixture. There seemed to be no significant difference in 7-day 
PCA reactivity, with the different immunizing doses of FHA. In Fig 21B the entire 
experiment was independently replicated and the same trend as Fig 21A in the IgE 
response was found. Thus an anti-FHA IgE response was elicited over the entire range 
of FHA immunizing doses.
Because a PCA-positive reaction was produced so widely, subsequent 
experiments focussed on the effect of different immunization doses of FHA when 
mixed with a constant dose of PT, in the first injection, in the 3-dose protocol. Two 
mouse strains were used: Ham/ICR and Baib/c. In Fig 22, Ham/ICR produced a 
convincing IgE response, as detected by 7-day PCA, with immunizing doses of FHA 
ranging from 0.1 to 20 ug and with a peak at the 1 ug dose. There were no detectable 
responses at 0.01, 0 05 or 40 ug immunizing doses of FHA. This showed that the IgE 
response was limited to a particular immunizing dose range and that the animals 
would not respond to very low or high immunizing doses of FHA.
A different picture appeared with Balb/c mice (Fig. 22), in that an anti-FHA 
IgE response was observed only at the 10 and 20 ug immunizing doses. These
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Fig 23: IgE ELISA: E ffect o f the con cen tration  o f  a ff in ity -p u r if ie d  rabbit 
anti-FHA as a coating  a g en t on th e perform ance o f  th e  sa n d v ich  
ELISA. The ELISA vas done on IgE-positive serum, before (solid points) and 
after heating at 56° C for 1 h (open points). The FHA for binding vas used at a 
constant concentration of 100 jig/ml and the sheep anti-mouse IgE HRP 
conjugate at I in 100. The concentration of AP anti-FHA is shovn on the right.
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Plate 4: Im m unodiffusion  pattern  o f  anti-FHA serum  before and after  
ex traction  on a FH A-sepharose colum n.
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t U e  /vne±i^od o-j- AO. A p ^ i l e .
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experim ents h ighlighted  major differences in IgE-responsiveness between mouse 
strains. However, the FHA responses w ere d ifferen t from those produced in  the Oa 
system, in  th a t the la tter w ere restricted to the 0.1 and 1 ug doses.
Measurement o f anti-FHA IgE by saadvicb  ELISA 
Factors in flu en c in g  the ELISA
In itial studies using conventional ELISA to detect anti-FHA IgE w ere unsuccessful. 
Therefore, the sandwich ELISA technique was developed for the Oa system. For 
application of the  sandwich method to anti-FHA. an affin ity-purified  rabbit anti-FHA 
was required. This was done by affin ity  purification on an FHA-sepharose column. 
The anti-FHA was then  characterized by Lowry, immunodiffusion against FHA (Plate 
4) and SDS-PAGE. The AP anti-FHA coating and the FHA in the sandwich layer were 
both titrated to optimize the overall procedure.
E ffe c t o f  c o n cen tra tio n  o f  a ffin ity -p u r ifie d  ra b b it anti-F H A  in  th e
sa n d w ich  la y e r  The AP anti-FHA was prepared from 25 ml rabbit serum  raised 
a s  p e r  -tW e r r e b K o d e  • The resu ltan t fraction of 3
mi eluted from  the sepharose-FHA column and concentrated by dialysis against 
Aquacide, contained 2 m g/m l protein. This purified antibody was diluted in coating 
buffer, pH 9.6 to a  final concentration of 2, 20 and 200 ug /m l and used in  the 
sandwich ELISA as the in itia l coating layer (Fig. 23). The FHA in the sandwich layer 
was kept constant a t 100 ug/m l. With an endpoint absorbance of 0.5, the best coating 
concentration was 20 ug /m l (Fig. 23). The graph shows th a t a  satisfactory dose 
response line was obtained with unheated test serum  and th a t th is was reduced to a 
baseline level a fte r heating  the IgE-containing serum  at 56° C for 1 h. The 2 ug and 
200 ug coating concentration of AP anti-FHA showed no sign ifican t d ifference in dose 
reponse line produced with IgE-positive serum  and afte r heating at 56° C for 1 h  to 
destroy IgE. Subsequently, the AP anti-FHA coating concentration was used a t 20 
Ug/ml. as th is allowed the mouse anti- FHA serum  to give its h ighest titre  of 1360. 
w hich was reduced upon heating a t 56° C to a  titre of < 10.
E ffe c t o f  c o n cen tra tio n  o f  FHA in  th e  sandw ich  la y e r . With the FHA being 
scarce, tim e-consum ing and expensive to prepare, the 100 ug /m l concentration in  
the sandw ich layer was thought to be excessive. Therefore the FHA in  the sandwich 
layer was varied, so as to find the lowest concentration w hich would give an adequate 
dose-response line. In  Fig 24, th is was shown to be the 100 u g / ml FHA coating w hich
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Fig 24: IgE ELISA: Effect of vary in g  the FHA concentration in  the 
sandarich layer, v ith  a constant AP anti-FHA coating concentration  
(20 pLg/ml) in  the sandwich ELISA. An anti-FHA IgE positive serum  raised 
by the th ree-in jection  protocol v a s  used. Sheep anti-mouse IgE HRP conjugate 
v a s  used at 1 in  100 dilution.
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Fig 25: IgGl ELISA: E ffect o f FHA coating con cen tration  on the  
m easurem ent o f IgGl by co n v en tio n a l ELISA. The ELISA v a s  done w ith a 
known anti-FHA IgGl positive serum  w ith the sheep anti-mouse IgGl HRP at 
1 in 1000 dilution.
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allowed the mouse anti-FHA serum to yield a titre of 1300. The 10 ug/m l coating 
yielded a titre  of 700, and the 1 ug/m l a titre of 250. There was an approximate 
two-1 old difference between the titres of 100 Ug/ml FHA and 10 Ug/ml FHA. The dose 
response w ith 10 ug/m l was satisfactory for fu rth e r work. Therefore, to be 
economical w ith reagent, this dose was chosen. This allowed a large num ber of sera to 
be titrated in the sandwich ELISA w ithout using large amounts of a scarce reagent.
Measurement of IgGl by conventional ELISA 
Effect of FHA coating concentration
In the coAventional ELISA, th e re  was a requirem ent for the FHA to be titrated to find 
a suitable concentration for coating. The 100 ug/m l FHA coating concentration was 
most prom ising, but still unsatisfactory since over the mouse serum  dilutions w hich  
w ere used, the dose-response line did not in tercep t the 0.5 absorbance endpoint (Fig. 
2$). Conversely, the 1 ug/m l FHA coating was too weak even w ith the 1 in  10 dilution 
of IgGl-positive serum. However, the 10 ug/m l FHA gave a good reponse line in  th a t it 
in tersected the absorbance 0.5 and also allowed economical use of the FHA. This 
concentration was chosen for subsequent experiments.
Comparison of anti-FHA sera tested in PC A, sandwich and conventional 
ELISA.
Having raised anti-FHA sera, using a three-dose protocol and in  two d ifferen t mouse 
strains, it was im portant to detect and titrate the IgE and IgGl tha t m ight be present. 
Two methods w ere used: the 7-day PCA for detection of IgE; the sandwich ELISA for IgE 
titration, and the conventional ELISA for IgGl titration. Table 23, shows the results 
obtained in  each of these systems. In the 7-day PCA, a unitage or titre  could not be 
ascribed to the sera, as the PCA reactivity diminished to > 5mm after even a  1 in  5 
dilution. In  th is table however, the 7-day PCA and log10 IgE titre  w ere correlated, in
th a t w here  th e re  was a positive PCA reaction, IgE could usually be detected by ELISA 
and vice versa. Only in one case (serum G) was this correlation absent. Fig 26, shows 
the average zone diameters plotted against the logjQ IgE titres. The lines, coming
from  the points, respresent the IgGl titre of the particu lar serum. A point to note is 
th a t se ra  w hich were PCA-negative were ELISA-negative as regards IgE titre and did 
not elicit an IgGl response. Conversely, the h igh  IgE titre sera also had h ig h  IgGl 
responses. Thus there seemed to be a correlation between h igh  IgGl levels and h igh  
IgE levels in  serum. The average PCA zone diameter and log j q IgE titres showed an
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Table 23: Comparison o f anti-FHA pooled sera  by 7-day PCA. by 
con v en tio n a l ELISA for IgGl and by sandw ich ELISA for IgE. All sera 
consisted of pools of mouse bloods. Experiments 38 and 39 were pools of 10 and expts. 
7S and 79 were pools of 5.
Experiment 
no. and mouse 
strain  1
Serum
no.
7 day PCA 
(mm)
loglO
IgE
titre
loglO
IgGl
titre
38 3 11 36 6.8
Ham/ICR 1 10.75 34 4.3
2 9,5 2.7 5.3
39 3 12 3.6 4.8
Ham/ICR 2 11 3.5 4.9
1 10.75 3.2 3.9
78 D 13 3.7 4.7
Ham /ICR E 10 3.7 4.0
F 10 <1 3.9
A 0 <1 <1
B 0 <1 <1
C 0 <1 <1
G 0 3.7 5.0
79 F-2 11 <1 6.0
Balb/c E-2 10 33 4.0
A-2 0 <1 < 1
B-2 0 <1 <1
C-2 0 <1 <1
D-2 0 <1 < 1
G-2 0 <1 4.0
* - The sera w ere obtained by immunization protocol 3 with the mixtures listed in 
Appendix 7. The sera were tested undiluted in the 7-day PCA test.
I l l
Fig 26: C orrelation o f  anti-FHA IgE, m easured by PCA and ELISA, w ith  
IgGl m easured in  p a ra lle l. The bars rep resen t the loglO IgGl titre  w here 1 
cm is equivalent to 1 loglO. The line starts at a log 10 IgGl titre  of 2 as the 1 in  100 
dilution was the lowest used in the IgGl ELISA
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Table 24 : Characterization o f 9 batches o f PT p u rified  by g e l-a f f in ity  
chrom atography. The protein content of each batch was measured by the method 
of Lowry 1952) with BSA as standard, and the batches were variously examined
for h istam ine sensitization activity and /o r the 5 distinct bands characteristic  of PT or, 
o ther proteins, by SDS-PAGE. The batches h ighlighted in bold type w ere used for 
immunizations.
Batch Vol. Vol. Protein SDS-PAGE HSA
culture purified content PT* approx. % test
(L) PT (ml) (Ug/ml) subunits contamination
1 6 15 800 ♦ 5 ♦
2 6 20 1600 ♦ 5 *
3 6 10 400 + 5 n.t
4 r0 40 500 n.t n .t n .t
5 6 45 200 n.t n .t n .t
6 8 40 700 ♦ 15 ♦
7 s 50 600 ♦ 20 ♦
S 6 50 400 + 20 n.t
9 6 20 600 25 n.t
n . t -  no t tested
1 - The five bands characteristic of PT in  SDS-PAGE have molecular w eights of 9, 12, 
22, 23 and 28 kDa.
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almost sign ifican t positive correlation p= 0.057 using the Kendall correlation 
statistics. In conclusion, anti-FHA IgE responses seemed to occur only in association 
w ith h ig h  anti-FHA IgGl responses and there  is the suggestion of correlation 
between the two.
IgE R esp on ses  to  P e r tu s s i s  Toxin, w i t h  IgGl M e asu red  in  P a ra l l e l
M easurem ent o f mnti-PT IgE by PCA test
As before, w ith Oa and FHA, it was im portant to develop assays for detecting and 
m easuring the possible IgE responses to PT in sera of PT-immunized mice. These 
involved, as before, a 7-day PCA test and a sandwich ELISA for IgE, and conventional 
ELISA fo r IgGl. In the sandwich ELISA, instead of AP anti-PT antibody used at the 
coating stage, fetuin from foetal calf serum w hich is known to bind PT, v ia  sialic 
residues, was used as in itia l coating. In addition, the effect of d ifferen t toxoided 
preparations of PT w ere investigated for th e ir IgE-inducing abilities alone and w ith 
bioactive PT as adjuvant.
ChMTMCterizmtion o f  PT. All batches of PT were examined by the method of Lowry, 
(1951) fo r protein  content, and some batches were examined for the typical 5-band 
appearance of PT in  SDS-PAGE. In im portant batches, viz those highlighted  in  Table. 
24, tests for histam ine sensitization activity were done.
Nine batches of PT w ere purified in all. Batch num bers 2, 6 and 7 w ere used 
for im m unizations and, in particular, batch 2 was used for toxoiding with e ith er 
glutaraldehyde or carbodiimide. The yield was usually h igh  but yields for batches 4 
and 5 w ere low. This was thought to be due to the lowering of the blue sepharose 
binding capacity w ith repeated use. A new batch of blue sepharose was used in  the 
batches 6 to 9, and the yields increased markedly. The percentage contam ination with 
other protein  tended to be low (around 10%). However there seemed to be an increase 
with increasing  batch num ber, perhaps due to the FHA-minus strain  rev ertin g  on 
subculture. Thus the later batches started to show a fa in t line of FHA at 200 kDa. 
Histam ine-sensitizing activity (HSA) tests were carried out on the batches used in 
immunizations. The HSA test involved groups of 4 mice being injected with graded 
doses of PT from  0.11 ug to 3 Ug/mouse. The animals were challenged afte r 5 days w ith 
3 mg histam ine per mouse, the survivors scored 2-3 h later and the LD 50 estimated. In 
appendix 6, the approx. LD 50 of batches 1, 2, 6 and 7 were 0.1, 1.5, 0.5 and 0.5 
Ug/mouse respectively. When the PT was toxoided with glutaraldehyde and 
carbodiimide, the LD 50 was >3 w hen compared w ith the untoxoided PT w hich had a
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LD 50 of 1.5 ug/mouse. This m eant tha t the toxoiding of the PT had reduced its activity 
at least 2-fold and probably much more.
These toxoids were also tested in  the mouse w eight gain test (MWGT). w hich 
involved a large doses of toxoid being adm inistered i.p and the w eight gain recorded 
over a 6-day period and compared with a control group w hich received only the 
diluent, PBS. ]n appendix 6, shows tha t even w hen large doses of toxoids
w ere injected the mice gained w eight in  a sim ilar fashion to the controls, with the 
w eights consistently increasing  over the 6-day time in terval. From prelim inary  
experim ents in the Oa system (Table. 16), w hen bioactive PT at 5 Ug and 10 ug were 
given as adjuvant in immunzation a  large percentage of the mice (15% and 50%) died 
w ith in  the firs t few days. With the much h ig h e r doses of 25 Ug carbodiimide-PT per 
mouse and 50 ug giutaraldehyde-PT per mouse, there was no toxicity in  any of the 
anim als and they gained w eight progressively. Therefore, in conclusion, by toxoiding 
PT, the HSF activity was reduced more than two-fold and w hen large concentrations 
of toxoid w ere used in the MWGT there  was no detrim ental effect on the anim als as 
they gained w eight sim ilarly to controls.
Factors in f lu e n c in g  the PCA test
Most of the factors and problems encountered in  the PCA test had been resolved in  the 
Oa and FHA systems. In the PT system, it only rem ained for the effect of having  
bioactive PT in  the challenge dose and an illustration of four sites per mouse to be 
looked at in detail.
E ffe c t o f  P T  in  th e  ch a llen g e  dose. There is evidence (Fig. 3) in  the Oa section 
tha t PT may have a fast-acting inh ib ito ry  effect on histam ine release, resu lting  in  
s ign ifican t reduction in  the average PCA zone diameters. This effect was p rom inent at 
low (0.1 and 1.0 ug)  and h igh  (250 ug)  dose levels of PT, w hen injected along w ith Oa, 
in  the anti-Oa IgE 48 h PCA.
Using undiluted IgE-containing anti-PT serum  for skin sensitizing and a 
7-day sensitization in terval, mice were challenged with Evans blue mixed w ith 
bioactive PT in  doses vary ing  from  31.25 Ug to 1000 ug in  two fold steps (Fig. 27). The 
most s trong ly  positive PCA reactions ocurred w ith 500 ug and 1000 ug PT doses in  the 
challenge mixture. The anim als challenged with 125 Ug PT dose produced a PCA zone 
diameter of only 4 mm. a 3-fold decrease from tha t obtained w ith the 500 ug challenge 
dose of PT. When analysing these results, the possible inh ib ito ry  effect of PT has to be 
taken into account. If the 500 ug is the prefered challenge dose of PT in  the 7-day 
PCA. then  th is am ount of PT may also by having an inhib itory  effect on anti-PT IgE
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Fig 27: E ffect o f v a ry  in  g th e c h a llen g e  dose o f PT in  the 7-day PCA test
Sera raised by the three-dose protocol and known to be IgE-positive were 
injected into all mice: 7 days la ter . mice w ere challenged i.v w ith bioactive PT. 
The bars indicate the average zone diameter (mm) and the SEM with the num ber 
of replicates shown inside the bars.
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Plate 5: Layout o f tiie  PCA test w ith  4 s ite s  per m ouse. At positions B and C. 
anti-PT IgE rich  serum  was injected i.d. The anim als were challenged i.v with 500 ag 
PT and Evans blue, 7 days afte r sensitization. Positions A and D w ere injected with the 
same sera  heated to 56° C for lh .
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Table 25: E ffect o f a range o f im m unizing doses o f carbodiim ide and 
glutaraldehyde PT toxoids, w hen  mixed w ith  a constant s in g le  dose of 
b ioactive PT (1 pg), on the developm ent o f an anti-PT IgE resp on se  by 
th e one dose protocol in  both Ham/ICS and B alb/c m ice. Sera w ere pooled 
from 5 individual mouse bloods and w ere tested undiluted in  7-day PCA tests. The 
positive anti-PT IgE responses are shown in bold type.
Imm unization 
dose of PT 
toxoid on day 
zero
Adjuvant 
dose of PT
No. of PCA positive pooled sera 
on bleed day, tested in 7-day PCA, 
using e ither a carbodiimide or a 
glutaraldehyde PT toxoid for 
immunization
10 21 28
(1 Ug) Carb. Glut. Carb. Glut. Carb. Glut.
Ham/ICR
0.1 ♦ 0/1 0/1 0/1 0/1 0/1 0/1
1 0/1 0/1 0/1 1/1 0/1 0/1
5 + 1/1 0/1 0/1 0/1 0/1 0/1
10 0/1 0/1 0/1 0/1 0/1 0/1
20 + n.t 0/1 n.t 0/1 n .t n .t
50 -f n .t 0/1 n.t 0/1 n .t 0/1
0.1 - 0/1 n.t n .t 0/1 n .t n.t
10 - n .t 0/1 0/1 n.t n .t 0/1
Balb/c
0 1 ♦ 0/1 0/1 0/1 0/1 0/1 0/1
1 ■f 0/1 0/1 0/1 0/1 0/1 0/1
5 ■f 0/1 0/1 0/1 0/1 0/1 0/1
10 + n.t 0/1 n.t 0/1 n.t 0/1
20 ♦ 0/1 0/1 0/1 0/1 0/1 0/1
5 0/1 n.t n.t 0/1 n.t 0/1
n.t - no t tested
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detection in serum, indicated by the blueing reaction. Plate 5 illustrates the 7-day PCA 
test. An anti-PT IgE serum was injected i.d at positions B and C and the same serum  
heated to 56° C for 1 h at positions A and D, as indicated by the arrow s on the ske tch . 
The anim al was challenged with 500 ug PT i.v 7 days after sensitization. A positive 
7-day PCA response can be seen at positions C and B only, illustrating  tha t heating  at 
56° C destroys IgE and the PCA reactivity disappears.
Anti-PT IgE respon ses a fter  a one-dose im m unization w ith  carbodiim ide  
and glutaraldehyde toxoids.
A one-dose immunization protocol involving d ifferen t doses of two PT toxoids and a 
constant dose of bioactive PT was investigated for possible IgE responsiveness in  the 
7-day PCA. Two mouse strains were used : Ham/ICR and Balb/c. The bleed days were, as 
before, days 10, 21 and 28 days. Similarly to the FHA system, w hen the  sera  w ere pools 
of blood from  5 mice, the 7-day PCA yielded only 2 positive responses out of 64 sera  
tested (Table 25). Those protocols producing an IgE-positive serum  involved 5 Ug 
carbodiimide-PT and a 10-day bleed, and 1 ug glutaraldehyde-PT and a 21-day bleed. 
Each of the above sera was raised with injection mixtures th a t contained 1 ug 
bioactive PT. When PT toxoid alone was for immunization, the re  was no detectable IgE 
reponse w ith e ith e r of the toxoids, on any bleed day, no r w ith e ith e r the Ham/ICR or 
Balb/c stra ins of mice.
The only positive anti-PT IgE sera were raised in Ham/ICR mice, the Balb/c 
sera  w ere all negative. However there may be a requirem ent for the sera  raised in 
Balb/c to be tested in  Balb/c.
Anti-PT IgE resp on ses a fter  a three-dose im m unization
Initially , a mixed PT and FHA carbodiimide toxoid was used in  the 3-dose im munization 
procedure. However in subsequent experiments, only PT-alone toxoids (w ithout FHA) 
prepared by carbodiimide or glutaraldehyde treatm ent were tested for PCA reactivity .
C orbodiim ide to xo id  o f  FEA/PT. The effect of d ifferen t doses of a carbodiimde 
toxoid of PT and FHA was investigated for the production of IgE antibodies to PT and 
tested by 7-day PCA (Fig. 28). It will be seen tha t an IgE response was produced only at 
the lowest im m unizing dose of 0.1 ug The actual amount of PT in  the 0.1 ug dose of 
PT/FHA toxoid was 0.05 ug- as the PT and FHA in the toxoid w ere p resen t in  
approxim ately equal amounts (Christodoulides et &l, 1987). Therefore the IgE 
response to PT differs from tha t found to Oa and FHA, in tha t it was produced only at 
very  low im m unizing doses. Surprisingly, no detectable IgE response could be found 
afte r the 1 ug and 10 ug immunizing doses of the PT/FHA toxoid.
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Fig 28: A pplication  o f the 7-day PCA test to detect IgE antibod ies to PT in  
m ice a fter  FHA/PT carbodiim ide im m unization. Sera w ere raised by the 
three-dose protocol w ith the im m unizing doses indicated on the abscissa. The 
bars rep re sen t the average zone diameter and SEM of observations with 
undiluted serum. Figures inside the bars indicate the num ber of zones observed.
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Fig 29: E ffect o f d if fe r e n t im m unizin g doses o f  carbodiim ide toxoids of 
PT. w h en  m ixed w ith  a con stan t dose o f  b ioactive  PT (1 fig), on the 
developm ent o f  anti-PT IgE in  Ham/ICR and B alb /c  m ice. Sera were 
obtained by the three-dose protocol and tested undiluted in the 7-day PCA test. 
The bars indicate the average zone diameter (mm) and SEM with the number of 
replicates inside the bars.
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Fig 30: E ffect o f d if fe r e n t im m unizin g doses o f g lutaraldehyde toxoids of 
PT, w h en  m ixed w ith  a con stan t dose o f  bioactiYe PT (1 |ig ), on the 
developm ent o f  anti-PT  IgE in  Ham/ICR and B alb /c m ice. Sera were 
obtained by the three-dose protocol and tested undiluted in the 7-day PCA test. 
The bars indicate the average zone diameters (mm) and SEM with the number of 
replicates inside the bars.
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Carbodiim ide toxoid o f  PT  In the above system, only three different immunizing 
doses of PT/FHA toxoid were used. In Fig. 29, a range of immunizing doses were 
explored using a carbodiimde toxoid of PT alone, which did not contain any detectable 
FHA. Using the 7-day PCA, an anti-PT IgE response was elicited at only one dose of 
toxoid (0.05 Ug) Conversely, with sera raised in Balb/c mice, there was no detectable 
7-day PCA reactivity. The results in Ham/ICR were similar to those found in the initial 
experiment with PT/FHA toxoid. The PT toxoid in the mixture there was at a dose, only  
of 0.05 Ug. This showed that the channelling of anti-PT IgE occured only at one 
particular dose of the immunizing antigen and could not be detected in any of the 6 
other doses tested. The significance of this observation may be difficult to evaluate 
but may be a result of the diverse biological properties of PT and PT toxoids.
GlutM roldehyde toxoid  o f  PT  In previous work (Hayglass and Strejan, 1983), 
glutaraldehyde "toxoiding" of Oa was found to diminish IgE antibody production. 
Therefore PT was toxoided with glutaraldehyde to observe if it had a similar effect. 
This toxoiding was done by the method of Munoz etaJ., (1981) and the product was 
used for immunizing Balb/c and Ham/ICR mice, with bioactive PT (1 ug)  as adjuvant 
in the three-injection protocol. As with the carbodiimide results, Fig. 30 shows an 
anti-PT IgE response was produced only over a very narrow immunizing dose range. 
The glutaraldehyde PT differed from the carbodiimde PT in that the highest IgE 
responses were detected in sera raised in Balb/c mice with the 1 ug immunizing dose 
of toxoid. These sera gave average PCA zone diameter of 16 mm. Ham/ICR mice 
responded with an anti-PT IgE response at 0.1 and 1 ug immunizing doses of PT in the 
three-injection protocol. If anything, the glutaraldehyde treatment of PT seemed to 
be stimulating the IgE response when compared with the carbodiimide treatment, 
instead of suppressing the IgE response as reported in the Oa system. However, the 
carbodiimide toxoids produced the IgE response at 0.05 Ug immunizing toxoid dose, 
whereas the glutaraldehyde toxoid stimulated IgE both at 0.1 and 1 ug. The 
carbodiimide PT toxoid seemed to be more potent in that less was required to elicit an 
IgE response.
M easurem ent o f  IgE and IgGl by sandw ich ELISA
Previously, the sandwich ELISA had involved an affinity-purified antibody directed 
against the antigen in question, either Oa or FHA. In the anti-PT sandwich IgE and 
IgGl ELISA, the AP antibody was replaced by fetuin, a protein with a large number of 
sialic acid residues and which binds avidly to both PT and to plastic, Without initial 
coating of the plates with fetuin, the PT does not bind well. In the forthcoming
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Fig 31: E ffects o f a lter in g  th e fe tu in  coating  and PT binding  
co n cen tra tio n s in  the sandw ich ELISA fo r  anti-PT  IgE. The serum was 
known to be IgE-positive by 7-day PCA and the sheep anti-mouse IgE HRP 
conjugate was used at a constant dilution of 1 in 100.
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section, the effect of varying the PT and fetuin concentration in the IgE sandwich 
ELISA is reported.
E ffect o f concen tration  o f fe tu in  and PT in  the sandw ich la y er
Initially, microtitre plates were coated at pH 9.6 with different concentrations of 
fetuin (1 ug. 10 pig and 100 ug/ml). After an overnight exposure at 4° C, PT was added 
at concentrations ranging from 1 ug/ml to 100 ug/ml.
As shown in Fig.31. the coating concentration of fetuin seemed to have little 
effect on the anti-PT IgE ELISA, as the same pattern of responses was observed with 
all the concentrations of fetuin. However it should be noted that the dose-response 
line only intercepted the endpoint absorbance of 0.5 when the 100 ug/m l PT was used. 
With the 1 ug and 10 Ug/ml PT, and irrespective of the fetuin concentration, the 
absorbance values of the test sera were always below 0.5, at all dilutions. Therefore in 
this system, the PT had to be used at a concentration of 100 Ug/ml but since ail the 
fetuin concentrations gave similar results, the lowest fetuin concentration of 1 u g /m l  
was favoured.
In appendix 8, there is a calculation to determine whether solution of fetuin 
at 1 ug/m l could coat the surface of a microtitre well with a protein layer that was at 
least one-molecule thick. This was done by taking the surface area of the microtitre 
well and the molarity of fetuin at 1 ug/ml. and assuming that the diameter of the 
molecule would be similar to Oa, which has a similar molecular weight. The outcome 
was that 2x10 ^  molecules of fetuin would be required to coat the well one molecule 
thick. In 100 ul of 1 ug/m l fetuin, there would be approximately 1018 molecules, a 
3 00,000-fold excess. Therefore in 1 ug/m l fetuin, there should be a massive excess of 
molecules able to bind to the plastic and take part in the ELISA.
Comparison o f anti-PT sera  tested in  PCA. sandw ich and co n v en tio n a l  
ELISA.
Anti-PT IgE sera were raised in both Ham/ICR and Baib/c mice and against three 
different toxoids of PT using the three-injection protocol (Table. 26).
The sera were tested in the 7-day PCA test and in the sandwich ELISA. As in 
Figs. 28, 29, 30 an anti-PT IgE response was produced only over a very narrow 
immunizing dose range, and was independent of the toxoid or the mouse strain. 
However the fetuin PT ELISA was not as sensitive or specific as the AP sandwich 
ELISA for Oa and FHA, and therefore there were discrepancies between PCA and 
ELISA. In ail, five sera reacted positively in the 7-day PCA, but of those only 3 gave a 
definite titre in the IgE ELISA. Conversely to the FHA system. anti-PT IgE antibodies
125
Table 26: Comparison of anti-PT pooled sera  tested by 7-day PCA, by 
co n v en tio n a l ELISA for IgGl and by sandw ich ELISA for  IgE. All sera 
consisted of pools of mouse bloods. Experiment 43 was a pool of 10 and expts. 78 and 79 
were pools of 5
Experiment 
no. and mouse 
strain
Serum 
n o .1
7 day PCA 
(mm)
log 10 
IgE 
litre
loglO
IgGl
titre
43 1 12 3.4 34
Ham/ICR 2 0 <1 4.5
3 0 <1 4.8
78 K 11 <1 4.0
Ham /ICR L 11 <1 4.0
H 0 <1 1.9
1 0 <1 3.6
J 0 <1 2.8
M 0 <1 5.0
79 L-2 16.8 31 4.0
Baib/c H-2 0 <1 48
1-2 0 < 1 3-7
J-2 0 <1 4.0
K-2 0 <1 3.5
M-2 0 <1 50
N-2 0 <1 5.0
78 Ham/ICR R 10.5 2.2 3.3
1 - The sera were obtained by immunization protocol 3 v ith  the mixtures listed in 
Appendix 7. The sera were tested undiluted in the 7-day PCA test.
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Fig 32: C orrelation o f anti-PT IgE m easured by PCA and ELISA w ith  IgGl 
m easured in  p ara lle l. The bars represent the loglO IgGl titre where 1 cm is 
equivalent to 1 loglO. The line starts at a loglO IgGl titre of 2 as the 1 in 100 
dilution was the lowest used in the IgGl ELISA
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Table 27: Comparison o f sera from intranasaily  infected  mice tested in  
the conventional and sandwich ELISA. All pooled sera v e re  tested for IgE by 
sandwich and IgGl by conventional ELISA.
Bleed loglO loglO
day IgE IgGl
(afte r infection) titre titre
PT FHA PT FHA
5 <1 <1 <1 <1
12 <1 <1 1.5 <1
14 < 1 <1 1.2 <1
20 <1 <1 <1 < 1
32 < 1 1.5 < 1 <1
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Fig 33: Lung scores from Hun/ICR mice infected  i.n  with. B. p ertu ssis^  
1S323- The lungs w ere scored by the num ber of lobes w hich  w ere infected. The 
open points indicate the infected group and the solid points indicate the control 
anim als th a t only received casamino acids. The points show the average lung 
scores and the SEM along w ith the num ber of mice.
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w ere only produced w hen the IgGl content of the serum was low (Fig. 32). The 
non-responding serum in the PCA and ELISA all showed very  h igh  IgGl titres. Using 
the Kendall correlation test, and com paring the IgE detected by PCA and by ELISA, 
there  was a definite trend but no sign ifican t correlation in tha t IgE to PT was only 
produced over a narrow  im munizing dose range and tha t h igh  levels of IgGl may 
play an im portant role in  suppression of anti-PT IgE.
Comparison of sera from intranasally  infected mice tested in  the 
conventional ELISA for IgGl and in the sandwich ELISA for IgE.
Mice w ere infected i n  with B.pertussis strain  BP 1S323. T heir w eight afte r infection 
was recorded, and groups of 2 to 5 mice were sacrificed at approxim ately 5-day 
in tervals  for serum  and for lung examination for signs of infection. Table 27, gives 
an indication of the low im m unogenicity of FHA and PT as regards IgGl and IgE 
production under these conditions. There were s ligh t detectable IgGl responses at 
days 12 and 14, but the lo g j0 IgGl titres to PT reached only 1.48 and 1.18 respectively.
A small anti-FHA IgE response was detected at day 32 by ELISA. At all the o ther bleed 
days, n e ith e r IgE nor IgGl responses to FHA or PT could be detected. The lung 
pathology scores of the anim als showed tha t sign ifican t infection had taken place 
(Fig. 33). The infected group had widespread lung  infection (4 lobes) at 12 days after 
the i.n challenge. The severity of the disease decreased th e reafte r but was still 
apparen t at day 32. All the controls, who received only casamino acids, but w ere kept 
in  the same cages as the infected animals, were all clear of any  lung infection. 
Perhaps the secretory IgA and IgM response m ight be more prom inen t during  the 
sho rt duration of the experim ent and IgG and IgE m ight be more p revalen t in  the 
convalescent stage.
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D I S C U S S I O N
DISCUSSION
This investigation has shown that in mice, IgE antibodies to at least two of the major 
v iru lence factors of B. pertussis, nam ely FHA and PT can be induced under appropriate 
conditions of antigen and adjuvant dose, time of bleeding and mouse stra in  The 
significance of IgE production in B. pertussisinfection and after pertussis vaccination 
will be discussed.
Detection of IgE by PCA
Although the 48 h PCA test for IgE had been in existence for 30 years (Ovary, 1958), at 
the s ta rt of this investigation it proved inadequate for detecting IgE responses to FHA 
and PT of B. pertussis Thus the detection of anti-FHA and anti-PT IgE was crucially  
dependent on extending the sensitization period from 48 h to 7 days. In fact, early  in 
th is work with Oa as the model antigen, it was necessary to explore various aspects of 
the conduct of the PCA test in order to apply it to IgE quantitation.
Mouse strain
It is im portant, in the PCA test, to find a recip ien t animal species and strain  w hich will 
react well w hen injected with serum raised in ano ther individual. The species of 
choice for PCA is stated to be the guinea pig (Ovary and Warner. 1972) but the PCA test 
has also been done in the rabbit, the ra t and the mouse (Ovary, 1976). According to 
Ovary (1964), less antibody was required to produce a positive reaction in the guinea 
pig than  th a t required  for the same reaction in the mouse.
In the p resen t work, for reasons of convenience and availability, female 
Ham/ICR albino mice (6-8 weeks old) were used for the PCA test. Generally females 
w ere p refe rred  because males tend to figh t and cause scarring  of the dorsal skin with 
consequent non-specific blueing. Justus and Saelinger. (1976) examined th ree  
d ifferen t mouse strains CFW, ICR and C57B1/6J. They found tha t ICR mice w ere most 
sensitive to histam ine, w hereas C57B1/6J were least sensitive. CFW proved to be the best 
PCA recip ien ts of test sera, w hen the sera had been raised in the CFW mouse strain . 
This seems to contradict Ovary etal., (1975) who had previously shown tha t CFW mice 
w ere inadequate fo r mouse IgE titration. As well as differences between strains, the re  
may be marked variability  in  the PCA-reactivity of individual anim als w ith in  a stra in  
(Ovary, 1986) Therefore it may be necessary for sera to be tested in  more than  one 
recip ien t. All sera in the presen t study were therefore tested more than  once, to 
overcome the problem of between-animal variability.
Route o f in jection
Ham/ICR mice w ere clipped, as chemical depilation was known to irrita te  the skin and 
lead to non-specific reactions (Ovary, 1976). The clipping was done on the dorsal sides
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of the back before the intra-derm al injection of test sera. The midline of the back 
contains slightly  fewer mast cells than the dorsal sides of the back. Injections were 
therefore not done on the midline of the back because of the reported low reactiv ity  in 
this area  (Watanabe & Ovary, 1977). Anti-Oa IgE sera were usually serially  diluted in 
2-fold steps and injected i.d into 2 sites on the dorsal sides of d ifferen t mice. Four 
injection sites (Levine and Vaz, 1970) and up to a maximum of 6 sites (Watanabe, 1976) 
have been reported. With 6 sites per mouse, the size of the anim al and the size of the 
response make this difficult, as each injection site should be at least 1 cm or more from  
the others. In the FHA and PT PCA tests, the antigen was costly to p repare and was 
needed in  large amounts for PCA challenge. Therefore the num ber of injection sites 
on each anim al was increased to 4. One of these sites was assigned to a standard anti-Oa 
IgE serum  w hich was used as a positive control in  the PCA test. The animals, afte r the 
sensitization in terval, were challenged i.v with a mixture of Evans blue and Oa and 
e ith e r FHA or PT depending on the test serum. The Oa reacted with the anti-Oa IgE 
positive serum  w hich produced a blueing reaction in the mouse. This m eant there  was 
the expectation of a positive blueing reaction in all the anim als w ith w hich  to 
compare the test sera and also to check the PCA-reactivity of the individual rec ip ien t 
mouse. In the literature, there  seems to be no m ention of this particu lar method of 
PCA, although other types of control mice are common. These involve positive sera 
being injected into one animal and the PCA reaction compared w ith test sera  injected 
into o ther anim als of the same batch (Justus and Saelinger, 1976; Ito etaJ., 1988). The 
advantage of the method developed in the present study is tha t the individual rec ip ien t 
mouse is checked for reactivity, as also is the success of the i.v challenge injection.
Sensitization period
The sensitization period (SP) in  the mouse PCA, between i.d injection of test serum  and 
i.v challenge with antigen is reported to be optimal at 2 h for IgGl and at 48-72 h  for 
IgE (Ovary. 1958.1976). However in  my work. I found that for IgE, the SP for detection 
of IgE could usefully be extended to 7 days.
In the Oa system, with anti-Oa serum, a 48 h SP produced distinct PCA reactions 
w ith well defined spots of blueing on the undersurface of the skin. M oreover these 
reactions w ere confirmed as being due to IgE by showing abolition of the reaction 
w ith 56° C heated serum. However w hen anti-FHA sera with FHA challenge, and 
anti-PT sera  w ith PT challenge, w ere tested in  the PCA, the 48 h  SP gave a diffuse 
blueing on the whole undersurface of the skin with only a slightly  darker region at 
the site of injection. When these sera were diluted, the diffuse blueing disappeared but 
so also did any positive PCA reactivity. Clausen el' al. (1969) also noted th is diffuse 
blueing in the skin with a 72 h SP and Oa as the challenge antigen. A possible 
explanation is tha t IgGl antibodies, responsible for the 2 h PCA in mice, may still be
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in te rfe rin g  in the 48h PCA (L ehrer eta]., 1975, 1976; Clausen etal., 1968. 1969), The 
actual mechanism of in terference is unclear but may be a result of an tigen-specific 
IgGl in the serum. IgGl binds to mast cells for a few hours, but may rem ain in the skin 
for 24 to 48 h (Ovary, 1982), presumably w hen present in h igh  concentrations. When 
the challenge antigen is injected, it may in teract with IgGl in the circulation and 
perhaps also fixed to mast cells th roughout the body causing an overall 
h istam ine-releasing effect and therefore the diffuse blueing. Lehrer, (1977) reported 
tha t in some instances IgE was not detected, due to a masking effect of IgGl. In studies 
with IgE myeloma protein, mouse IgE and IgGl had d ifferen t receptor sites on mast 
cells. Therefore the masking effect of IgGl is not a resu lt of competing for the same 
receptor sites. In contrast, Binaghi and Badoux, (1976) observed tha t in  rats, both IgE 
and IgGa antibodies acted in an additive way in the resu ltan t PCA w hen IgE antibody 
was injected at the same site 24 h before IgGa, and challenged with an tigen  2 h later. 
Apart from IgGl involvem ent in the 48 h PCA, Watanabe et al, (1983) also suggested 
tha t pre-existing IgE molecules on the mast cells in the skin in te rfe re  in the PCA.
As was stated previously, IgGl can rem ain in the skin for 24 to 48 h (Ovary, 1982) 
and th is may have had a detrim ental effect on observing a positive 48 h PCA reaction. 
In the p resen t study, the SP was increased from between 2 to 7 days in the hope tha t 
such in te rfe rin g  antibody would diffuse out of the skin. In fact, the effect of 
increasing  the SP allowed a positive reaction to be scored at 6 days, w hich increased 
slightly  afte r 7 days. Thus the diffuse blueing ceased to be a problem. This is 
in terpreted  as the in te rfe rin g  antibodies diffusing away, afte r the long SP, leaving 
only the IgE tigh tly  bound to mast cells. Mota (1964) had previously shown tha t anti-Oa 
IgE could still be detected in the skin at 31 days, but activity peaked at 72 h. Hirano et 
al.. (1983) reported that the half-life of i.d injected m urine IgE antibody was 6 days. In 
my work, by extending the in terval of the PCA test to 7 days , there  was a marked 
beneficial effect on the detection of IgE and a resolution of the problem of diffuse 
blueing.
Dose o f A ntigen
The dose of challenge antigen in the PCA test was also a crucial factor for 
consideration, as it determines the am ount of IgE-specific antibody detectable in  the 
test sera. High levels of specific antibody requ ire  less antigen to elicit a 48 h 
PCA-positive reaction. In the 48 h  PCA test for anti-Oa IgE, and the 7-day PCA tests for 
anti-FHA and anti-PT, the optimal concentration of challenge dose was found to be 1 
mg, 0.5 mg and 0.5 mg/mouse respectively. Ovary etal., (1983) also observed tha t the 
best dose of antigen was around 0.5 mg/mouse in most PCA systems. Specifically, 
Watanabe eta l, (1983) observed tha t 0.5 mg of Ascaris extracts was enough to elicit an 
an ti-Ascaris IgE response in the ra t PCA. The am ount given i.v is also affected by the
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Table 28: The e ffec t of molecular w eight of antigen in the PCA test
Antigen Molecular Minimal amount of challenge an tigen
w eight (kDa) for PCA. with Ab nitrogen (lie) *
1 0.025
Ribonuclease 13 0.05 0.63
Egg albumin 45 0 31 10
Bovine serum 70 063 31
albumin
Haemocyanin 650 14.0 100
Data from Ovary, 1958,1976
*Ab N (ug) is am ount injected i.d and challenge antigen is the am ount of challenged 
i.v in  the PCA test for IgE
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m olecular size of the antigen. The la rger the molecular w eight of the antigen, the 
more was required for a PCA response even with large amounts of specific antibody 
(Table 28). On this basis, haem ocyanin with a molecular w eight of 650 kDa would be 
required  at a dose of 14 ug per mouse to elicit a positive PCA response with a large (1 
Ug) dose of specific antibody, w hereas Oa would be required  at only 0.31 Ug to elicit the 
same response with 1 ug anti-Oa. In our study, the Oa (45 kDa) challenge was found to 
be optimal at 1 mg, but the PT (100 kDa) and FHA (200 kDa) challenge doses were 
optimal at 500 ug although the amount of specific antibody used w ere not standardized. 
In the Oa system the optimal dose was found by in jecting  a 1 in 20 dilution of anti-Oa 
IgE positive serum  into mice and challenging them with d ifferen t concentrations of 
Oa. In the FHA and PT system, undiluted sera were used. This may relate to the optimal 
concentration differences between Oa and FHA and PT because the anti-Oa sera  was 
diluted and so there  would be a requirem ent for more Oa in the challenge. Undiluted 
sera  w ere used in the FHA and PT system because with the 7-day sensitization period, a 
positive reaction could not be elicited w hen the sera w ere diluted. However, w ithout 
know ing the am ount of specific antibody in the test serum this hypothesis is d ifficult 
to prove.
E ffect o f h ea tin g
Previously it has been reported tha t w hen serum is heated to 56° C for 30 min, the 48 h 
PCA reactiv ity  is abolished (M otaand Piexoto, 1966; Clausen etal., 1969, 1970). On th is 
basis th a t this treatm ent destroys IgE, it has been used to provide IgE-negative controls 
in the 48 h PCA. However, in the presen t work, a particu larly  h igh  titre anti-Oa IgE 
serum, heated to 56° C for 30 min, did not lose all of its 48 h PCA activity. In fact, 
approxim ately 10% of the initial activity was still detectable. The heating  in terva l was 
therefo re  increased to 1 h, w hich caused apparently  complete lose of 48 h PCA 
reactiv ity
The actual mechanism involved in  this inactivation has been studied by 
D orrington and Bennich, (1973) v h o  found tha t after a 30 min heating, the in tac t IgE 
showed changes in both the aromatic side chains and peptide bond spectral regions. 
They also noticed that these effects w ere partially  reversed upon cooling to 25° C. The 
irreversib le  transition of IgE was localised in  the Fc region, viz. the site tha t in teracts 
w ith mast cells, but the Fab rem ained in tact as the heated molecules still reacted w ith 
specific antigen.
In our study, the heating procedure was always perform ed on undiluted serum  as 
d iluting serum  in a solution of h igh  solute concentration has a preventative effect on 
therm o lability (Binaghi and Demeulemester, 1983). They observed tha t 50-100% of the 
48 h PCA activity of ra t and mouse an tisera is recovered afte r heating to 56° C for 1.5 to
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5 h. in solutions of 1M MgSO^ or 2M glucose respectively. This protection is thought to
be a resu lt of steric hindrance, between molecules of IgE in solutions containing high 
concentrations of ions or hexose molecules.
The failure to inactivate completely our high titre IgE serum  by heating to 56° C 
for 30 min was not due to high ionic protection of the IgE molecule, since the serum  
was heated undiluted. It is more likely to have been due to the in itial h igh  potency of 
the serum. Our results suggested that there was 90% inactivation afte r 30 min; 
therefore after 1 h, the inactivation would be expected to reach 99%
E ffect o f PT in  the On ch a llen g e
PT has a vast a rray  of biological activities. It was im portant the re fo re  to 
ascertain  any possible effects of in jecting  large doses of PT, as p art of the challenge 
dose, in  the 48 h PCA with the Oa system before exploring PCA tests w ith PT in the 
challenge injection and anti-PT used for sensitization. An inh ib ito ry  effect of PT, 
incorporated in  the Oa challenge was noted with anti-Oa serum  in  the 48 h PCA test. 
Very low (0.1 and 1 ug) and h igh  (125 and 250 ug) concentrations of PT, w hen mixed 
with 1 mg Oa, caused a significant reduction in the recorded PCA zone diameters. This 
effect took place w ithin the norm al 30 min observation period and if caused by PT, is a 
very  fast acting biological activity of PT. Munoz and Anacker, (1959) had previously 
found tha t bioactive PT had no effect on PCA induced with anti-Oa and Oa. More 
recently , Nakamura and Michio, (1983) observed tha t w hen small concentrations 
(0 1-3 Ug) of PT w ere administered 3 days before Ascaris an tigen  challenge, the 
resu ltan t PCA was suppressed. They did not explore in jecting  PT in the actual 
challenge dose, but did find that by in jecting  small doses of PT, just before the an tigen  
challenge, had no effect on the resu ltan t 48 h PCA zone diameters w hen compared to 
controls w hich had been injected w ith Ascaris alone.
Our results are contrary  to the above, in tha t as little as 0.1 ug PT had a 
sign ifican t inh ib ito ry  effect on the 48 h PCA, w hen injected with the Oa challenge. 
The actual m echanism  causing this suppression is still unknow n, as PT usually 
requ ires a longer lag time, of the order of hours, for its biological activities to be 
m anifest (Katada and Ui. 1980) This is due to the time required  for the binding of the B 
subunit to ta rge t cell surface and for the A component of PT to traverse the plasma 
m em brane of cells and to ADP-ribosylate key molecules w ith in  the cell w hich, in  tu rn , 
a lter the cells responses to various exogenous stimuli. Although, Karlsson eta l, (1985) 
reported tha t PT blocked noradrenaline-induced pigm ent aggregation in fish 
m elanophores. This effect had a maximal effect in 10 minutes.
In the 7-day PCA test with anti-PT and PT, an IgE response was detected but the 
possible inhib itory  effects of the 500 ug PT in the challenge dose was not investigated.
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In view of the findings with Oa, a suppression of the PCA is most likely This could 
have been investigated with toxoids of PT as challenge, mixed with d ifferen t amounts 
of bioactive PT. Therefore the PCA test may not be the most senstive test for detecting 
IgE against PT antigen. In the following section, an in  r/frv test, the enzyme linked 
im m unosorbent assay (ELISA) will be discussed as an alternative to the PCA test for 
detection and quantitation of IgE.
D etection o f IgE and IgGl by ELISA
Although in  vitro tests for detection of IgE have been available since 1967, with the 
in itia l discovery of the radioallergosorbent test by Wide e / ,2/,(1967), the firs t repo rt of 
an IgE ELISA was by Zeiss etal, (1977)
A main aim of our study was to detect IgE antibodies to components of B. pertussis 
using e ith er the PCA test or the in  vitro test ELISA. However, before study of B. 
pertussis antigens, extensive p reparato ry  work was done w ith Oa as the model 
an tigen . In parallel IgGl, w hich will be discussed first, was detected w ith a 
conventional ELISA but this ELISA was not sensitive or specific enough for IgE. w hich 
eventually  was assayed successfully by sandwich ELISA. IgGl antibody is thought to 
play a role in  IgE regulation and as a masking antibody in both PCA and ELISA 
detection systems.
D etection o f IgGl by con ven tion a l ELISA
The ELISA was devised by Engvall and Perlm ann, (1972) as a simple and sensitive 
method for quantify ing antibodies in  serum. The firs t antigen used in  th is system was 
dinitrophenyl-ovalbum in (DNP-Oa). In our work, Oa was considered as a suitable model 
an tigen  in  the conventional IgGl ELISA. However there was no inform ation on the 
m easurem ent of IgGl responses to Oa in  mice by th is method.
The firs t step in  the conventional ELISA involved coating m icrotitre plates with
the protein  antigen. The type of plate used can be a crucial lim iting factor in  very
sensitive systems, such as for IgE. Kenemy etal., (1986) reported that, in  an allergen
IgE ELISA, the type of plate was critical and tha t irradiated plates generally  gave best
results. In  our studies, the Nunc F maxisorp plate was used routinely, afte r testing a
varie ty  of o ther plates. In fact, they all acted sim ilarly in the conventional IgGl ELISAand
w ith Oa. However, Kenny (1983) observed tha t adsorption of BSA varied with the
type of plate, and tha t certain  plates were ineffective for m easuring anti-BSA IgG 
antibodies. The differences in BSA adsorption between plates may be a resu lt of 
detachm ent of the coating protein during incubation and w ashing. Proteins bind by 
hydrophobic in teractions with the plastic, and overcoating can lead to a  reduction in 
binding of the protein because a monolayer of antigen cannot be m aintained and 
antigen  molecules already absorbed can become detached during  the test, and hence
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give reduced sensitivity and reproducibility (McLaren etal., 1981)
It is im portant that d ifferen t coating concentrations are explored in the ELISA so 
as to find the one most suitable. In our system, the optimal Oa and FHA coating 
concentration, for detection of IgGl, was 100 ug/m l. Kenny e ta l, (1983) also found 
tha t rabbit anti-Oa IgG bound optimally to Oa w hen the Oa coating concentration was 
100 ug/m l, w hereas BSA coating was optimal at 0.1 ug/’ml. These concentrations were 
also dependent on the type of plate. McLaren e ta l , (1981) have reviewed the literatu re  
and found tha t generally  the best coating concentrations in the ELISA were in  the 
range of 1 ug to 10 ug/m l, although they stated tha t h igher concentrations have been 
used. Bidwell et al, (1976) advised that in all systems, the best antigen concentration 
should be established in prelim inary  experiments.
D etection o f IgE by con ven tion a l ELISA
In the p resn t work, the conventional ELISA was firs t investigated as a method to 
quantitate IgE levels in  serum. Initially, a major problem was h igh  background levels 
w ith norm al serum and with control wells w hich had not had any test serum  added. 
These problems w ere thought to be partly  due to incomplete blocking of unreacted 
sites on the plastic of the m icrotitre plates. A num ber of d ifferen t blocking agents 
w ere therefo re  tested in the system including foetal calf serum, horse serum, skimmed 
milk and gelatin. Although BSA at 2% (w /v) gave the best results. Other investigators, 
using d ifferen t antigen/antibody systems have used BSA as the blocking agent in  the 
IgE ELISA (Hamilton etal., 1981; Gaveriaux etal., 1986; Hirano etal.. 1988) but the effect 
of d ifferen t blocking agents was not reported. If a blocking agent is not incorporated 
into the ELISA, sites on the plates can rem ain uncoated, w hich allows non-specific 
serum  proteins or even conjugate to bind and affect assay sensitivity and specificity 
Other antibody classes have also been reported to in terfere  w ith the IgE ELISA, 
by competing for the antigen coating on the plate (Zeiss etal.. 1977; Kenemy etal., 
1985; Lee et al, 1988). IgG is usually the predom inant im munoglobulin in serum  
w hereas IgE is found in m inute quantities, w hich can be increased by helm in th  
infection (Capron etal, 1975; Dessein etal., 1981) or immunization (Clausen etal.. 1969, 
1970). T herefore o ther classes of specific antibody in an IgE ELISA can be a major 
problem. Protein A of S. aureus binds to the Fc region of IgG and has been used to 
deplete IgG from serum. Conversely, however our experim ents showed th a t instead of 
decreasing IgG, upon the fina l absorption, the IgG titre apparently  was dram atically 
increased. This could possibly have been due to the com mercially-available protein A 
becoming detached from the S. aureus, and rem aining soluble in serum, w ith IgG 
bound to it and thereby increasing the IgG titre detected in the ELISA instead of 
decreasing it. Protein A adsorption should only have affected the IgG titre  but it also 
caused a decrease in the IgE titres. Perhaps, the IgE molecules were being masked by
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Table 29 :Problejas encountered by various investigators v ith  ELISA
D etrim ental effect on Source of problem References
Sensitivity
Choice of plastic for plates Kenemy etal., (1986)
Coating antigen concentration
<£ndL £> okiskvi
Kenny (1983)
Lov titre conjugates McLaren etal., (1981)
Insufficien t blocking Hamilton eta l, (1981)
Specificity '
Quality of antigen Wong and Skelton, (1988)
In te rfe rin g  antibodies F inger and W irsing von Koenig (1985)
Choice of plastic Kenemy etal., (1986)
Incubation period Engvall and Perlm ann, (1972)
Quality of conjugate McLaren etal., (1981)
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the increase in IgG in the system. This method of IgG reduction was abandoned in our 
experim ents although it has been shown to have a beneficial effect in some types of 
ELISA (Finger and Wirsing von Konig, 1985) However, ano ther 
com mercially-available form of Protein A was used in this study. Hamilton etal., (1981) 
found it d ifficult to detect IgE to Brugla malayi antigens. They extracted IgG from 
immune serum  and found this procedure did not affect detection of IgE by RIA, but it 
did enhance the IgE ELISA. Thus IgG may in terfere  with the IgE ELISA. In a sense, the 
effect of IgG in the ELISA may be sim ilar to tha t in the diffuse blueing problems 
encountered in the PCA, thought to be due to IgGl.
The conventional ELISA was tried with 48 h anti-Oa serum  w hich was 
PCA-positive, and therefore should have contained anti-Oa IgE. The serum was assayed 
before and afte r heating for 30 min at 56° C. Earlier, the secondary antibody goat 
anti-m ouse IgE and the sheep anti-mouse IgE-HRP conjugate had been titrated. All the 
absorbance readings at A492 nm were very  low. These antibodies may have 
deteriorated on storage w hich may be a possible reason for the titres being lower than  
expected. Kenemy e ta l, (1986) also observed very  low absorbance readings in  the 
conventional ELISA for IgE. They gave no explanation for this effect but did suggest 
th a t the coating stage was critical. They also explored a sandwich ELISA in parallel and 
found it to be much more senstive.
Thus the conventional ELISA for IgE was abandoned because of h ig h  background 
levels and massive day to day variablity, w hich reduced its sensitivity and specificity 
Some of the factors causing these problems are h ighlighted  in  Table 29. The 
conventional IgGl ELISA, however, was found to be sensitive, specific and did not 
su ffer from  h igh  background levels w hich were found to be a problem in the  IgE 
ELISA.
D etection o f  IgE by m odified ELISA
Underestimation, or masking, of antigen-specific IgE and w hich is caused by specific 
antibody of o ther immunoglobulin classes has been documented in  RAST (Zeiss et al 
,1981) and in  the ELISA (Reid etal., 1985; Vassella etal., 1990).
To overcome this problem, Kenemy etal., (1985) devised an IgE ELISA w hich 
involved an in itia l coating with an affin ity-purified  (AP) rabbit antibody directed 
against mite or grass pollen. They found that the AP antibodies bound antigen  to the 
plate and greatly  increased the assay sensitivity w ithout increasing  background 
absorbances. Our study showed tha t by binding Oa and FHA to the plate with AP rabbit 
anti-Oa and anti-FHA respectively, specific IgE antibodies in the test serum  could be 
readily quantified. The 56° C control and the norm al serum controls w ere always at 
baseline levels. An absorbance at A492nm of 0.5 was taken as the endpoint and used to 
calculate the serum titre. This method of quantitation has been used previously
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(Bidwell etal., 1976, Granstrom etal., 1982)
The concentration of AP antibody was titrated to find the most appropriate 
dilution for IgE detection. In both Oa and FHA IgE ELISA, the concentration of AP 
antibody was critical and the assay only worked w hen the coating was w ith in  certain  
ranges. As little as 0.175 Ug/ml of AP anti-Oa and 20 ug/m l of AP anti-FHA were optimal 
for coating, in conjunction with 100 ug/m l Oa and 10 ug/m l FHA for the sandwich 
layer. Kenemy eta l, (1985) found tha t 10 ug/m l of mite antigen was optimal in the 
sandwich layer for binding monoclonal anti-P l or poly-specific rabbit anti-m ite at 1 
in 1000 dilution. However, they did not give the actual concentration of the 
monoclonal or AP polyspecific antibodies. These authors used a very  high  
concentration of anti-IgE conjugate (1 in 30 dilution) w hereas a 1 in  100 dilution of 
the sheep anti-mouse IgE-HRP was sufficien t in our ELISA. They also noted tha t the 
addition of large amounts of antigen did not affect the assay, although I found th a t the 
concentration of both AP antibody and antigen were crucial.
In the PT IgE and IgGl ELISA, fetu in  was used to bind the PT to the m icrotitre 
plates. Fetuin was used in place of the AP antibodies, and successfully bound the PT 
w ith h igh  affin ity  (Wong and Skelton, 1988). The coating concentration of fetuin was 
not critical in tha t as 1 ug/m l and 100 ug/m l gave sim ilar results, but only w hen the 
PT concentration was 100 ug/m l. In Appendix 8, there is a calculation for the a rea  of a 
m icrotitre plate and the num ber of fetuin molecules required to coat it. Even with the 
1 ug /m l fetuin solution, there was roughly a 300,000-fold excess of molecules for 
coating the plastic with a complete layer of protein one-molecule thick. Therefore 
w ith the 10 and 100 ug/m l fetuin concentrations, there was a vast excess.
PT is known to bind to fetuin v ia sialic acid residues on the glycoprotein. There is 
not a requ irem ent in the fetuin ELISA for h igh ly  purified PT, as the fetuin binds PT 
specifically. Burstyn eta l, (1983) perform ed an IgG ELISA with purified PT, w hich did 
not involve an initial fetuin coating stage, but reported tha t to do an ELISA with 
purified PT routinely  for diagnosis of pertussis would be d ifficult and expensive. The 
fetuin ELISA does not suffer from these problems as a partially  purified PT can be 
used. Wong and Skelton, (1988) coated plates with 25 Ug/ml fetuin and requ ired  only 
2.5 -  5 ug /m l of PT in the sandwich layer for an IgG, IgA and IgM ELISA. In our study, 
we needed less fetuin (1 ug/m l) but more PT (100 ug/m l) in both the IgGl and IgE 
ELISA. Our work differed in some respects from tha t of Wong and Skelton, (1988). They 
used a d iffe ren t strain  (NIH) of B. pertussis w hich may have given better yields of PT 
in the partially  purified preparations. They also modified the cyclodextrin medium to 
p rev en t extraction of unwanted cellular antigens, w hich may mean tha t th e ir  PT was 
p u re r  than  ours and therefore less was required in the coating stage of the ELISA.
With d ifferen t sera, when we compared PCA and ELISA there  was a positive 
correlation between reactivity in the PCA and h igh  titres in the modified ELISA for Oa
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and FHA. However, the fetuin ELISA for PT, occasionally yielded positive results in the 
PCA but not in the ELISA and also vice versa.
In conclusion, the conventional ELISA suffered form a varie ty  of problems 
including h igh  backgrounds, low specificity and senstitivity and massive day to day 
variability . However the conventional IgGl ELISA worked well and did not su ffer from  
the problems encountered in the IgE ELISA. IgGl was measured because of the 
possibility of an in terfering , or contributory effect in the 48 h PCA. Moreover, the 
problems of the conventional ELISA were overcome with the sandwich ELISA w hich 
involved an initial coating stage with AP-rabbit antibody. This AP-antibody was 
employed because it bound the Oa, to the plates, and gave the an tigen  'flexibility", 
perhaps showing epitopes specific for the IgE antibodies, w hich may have been 
hidden in  the conventional ELISA, w here antigen was bound directly to the plate. 
Heating the test sera caused a massive reduction in the subsequent IgE sandwich ELISA 
titres. Heating is known to dram atically affect the Fc region of the antibody. T herefore 
w hen conjugate was added it could not bind to the epsilon chain, and the resu ltan t 
absorbances rem ained low.
In summary, the fetuin-PT ELISA was applied to measure IgE and IgGl, as fetuin 
p referen tia lly  binds PT to the plate. This particu lar ELISA was not as sensitive or 
specific as the AP-modified ELISA used for Oa and FHA, but did show some positive 
correlation w ith the corresponding PCA results. The AP-ELISA was the best in  vitro 
system, for m easuring IgE antibodies, to Oa and FHA. There w ere no problem s in  
m easuring IgGl by conventional ELISA.
Production o f IgE
In order to elicit an IgE response, a num ber of factors have to be taken into account 
including strain  of animal, tim ing of injections, dose of antigen and adjuvant and the 
effect of boosting. A large and varied num ber of protein an tigens can induce IgE 
antibodies in a range of mammalian species (Jarre tt etal., 1974, 1980; Mota etal., 1974; 
L ehrer etal., 1977).
Factors tha t favour IgE production include the use of m inute but repeated doses 
of an tigen , admixture of the firs t dose of antigen with Ai(0H)3, the use of pertussis 
vaccine and, in particular, PT as adjuvants (Levine and Vaz, 1970; Clausen e t al., 
1969,1970). In the p resn t study, a three-in jection protocol was best for raising  IgE. but 
the in itia l one-dose experim ents with Oa as the model an tigen  allowed optimization of
the adjuvant PT dose.
In p relim inary  experiments, it was found tha t boosting anim als on day 14 w ith 
an tigen  alone, after in itial immunization with Ag and PT on day zero and bleeding on
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day 21 did not give a good IgE response against Oa in Ham/ICR mice A more succesful 
protocol involved bleeding at day 21, w ithout boosting. However, boosting is thought to 
provoke an increased secondary IgE immune response. Ishizaka and Okudaira. (1972) 
reported that with Oa as the antigen and AKOH)^ as the adjuvant, boosting increased
two-fold the IgE response as detected by PCA. In the ir experim ent, adjuvant was 
adm inistered as p art of the boosting mixture w hereas in our experim ents the an tigen  
alone was used for boosting. However, the effect of boosting w ithout adjuvant has also 
been studied. Ja rre tt etu i, (1981) noticed tha t boosting enhanced the IgE response in 
rats. L ehrer e t el, (1973) examined the variability  of d ifferen t mouse stra ins in 
producing IgE afte r prim ary stimulation with Oa and HSF (PT). They found tha t with 
100 ug Oa and 10 ug HSF, there was a marked increase in the PCA titre w hen anim als 
were boosted with as little as 10 ug Oa. These responses were strain-dependent, w hich 
probably relates to the genetic make-up, environm ental conditions and sex and age of 
the animals. CBA/J mice were the best IgE-responding strain . The in itia l treatm ent of 
anim als with an tigen  and HSF resulted in the production of memory cells since 
subsequent immunization with Oa evoked a secondary reaginic antibody response. 
L ehrer e t el,, (1976) also speculated tha t factors sim ilar to PT, w hich acts as an 
adjuvant, could be produced by o ther microorganisms to modulate the immune 
response of individuals to common allergens.
Relating to allergy, Ishida et el, (1989) repeatedly challenged guinea pigs with 
Oa and B. pertussis intranasally, then  subsequently challenged w ith Oa . This produced 
cyanosis and breath ing  difficulties. They also showed that the re  were increased 
num bers of eosinophils in the epithelium  and airway wall areas. However, they did not 
quantify  or test for IgE, w hich would have been in teresting, to determ ine w h eth er the 
above factors related to an increase in IgE production.
Our own single-boosting experim ent may not have increased the IgE response 
because, for example, of the non-optim ality in the dose of antigen and adjuvant o r the 
tim ing of the boost. The boosting experim ent was found to be unsuitable fo r IgE 
production, therefore a  one-dose immunization was tried with bleeding at 10, 21 and 28 
days. Two levels of antigen, a low (20 ug) and a h igh  (200 ug) dose were used, and the 
PT adjuvant doses were varied to find a suitable value for IgE production. Individual 
sera  w ere tested, since pooling had the potential effect of diluting the IgE-positive 
sera. The best adjuvant dose was found to be 1 ug PT, with the lower dose of Oa (20 ug)  
giving the best responses on day 21. The large dose of Oa (200 ug)  produced an erra tic  
IgE response over the three bleed days but there was a peak of activity on day 28 with
the 1 ug PT adjuvant dose.
Other w orkers have explored the effect of a one-dose system, and usually the re  
was a p rim ary  increase in IgE antibodies at days 10 to 14, as illustrated by L ehrer et el.,
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(1975, 1976), w hen Al(OH)^ was used as adjuvant. This also caused an increase in IgGl,
w hich appeared after the IgE response. They also noted that the IgE response to Oa 
w ith 1 ug HSF (i.e PT), showed an initial peak at day 10, and there  was a plateau of 
activity between days 20 and 40. This seemed to be independent of an tigen  
concentration although the adjuvant doses administered were h ig h  (10 ug and 40 ug), 
enough to kill an animal. This suggests tha t th e ir p reparation was not just HSF but 
contained a large amount of contam inating factors. However Suko e ta l, (1977) found 
th a t the IgE antibody response to Salmonella - DNP with B.pertussis vaccine as 
adjuvant was h ighest at 21-30 days w ith no in itia l increase at 10 days.
Thus IgE responses are dependent on antigen and adjuvant dose, anim al and 
strain , boosting and even the route of injection. Gerbrandy and Bienenstock, (1976) 
reported tha t in tra trachael and in traperitoneal immunization routes were most 
effective for the production of IgE.
One of the main aims of this investigation was to see if  it was possibly to produce 
an IgE antibody response against components of B. pertussis itse lf. The one-dose 
im munization protocol with FHA and PT toxoid as antigens, showed no detectable IgE. 
T herefore a multiple boosting experim ent w hich had been devised by Levine and Vaz, 
(1970) was tried in an attempt to induce persisten t and boosterable reag in  form ation in 
mice, sim ilar to tha t in allergic humans. In the three-in jection  scheme, the adjuvant 
dose of PT (given only on day zero) was kept constant at 1 ug , as it was found to be the 
most suitable in the one-dose immunization system. The 3-dose schedule involved 
antigen  and adjuvant being injected i.p on Day 0, then the animals boosted on days 28 
and 56 with antigen alone and bled on day 63- Initially, the dose range of an tigen  was 
kept w ith in  the range (0.1 - 10 ug) The benefit to the IgE response of m inute amounts 
of Oa (0.1 ug)  (Vaz et al.. 1971; Schwartz and Levine, 1973; Ja rre tt and Stewart, 1974; 
Bazin, 1976) was confirmed. The resulting  high  IgE titre serum was used as a positive 
control serum  in  all experim ents w ith FHA and PT. Pooling the serum  did not dilute out 
the IgE reactiv ity  in the PCA, as had been seen in  the one-dose experim ent. Therefore 
a large pool of serum  from 10 mice was prepared.
Our immunization protocol differed from that of Levine and Vaz, (1970), because 
PT was used as adjuvant instead of AHOH^, but we also produced h igh  titre IgE sera
w ith Oa as antigen at doses of 0.1 ug and 1 ug. They found tha t mouse stra in  was 
im portant as anim als could be divided into low and h igh  responders. We also found 
sim ilar results w ith in  the Ham/ICR mouse strain  w here some anim als behaved as low 
and others as h igh  responders.
An anti-FHA IgE response was elicited after the th ree-in jection  protocol w ith all 
3 doses (0.1, 1 and 10 ug) of antigen. F urther experim ents confirm ed th is and IgE was 
also produced at the 20 ug antigen dose level. In a large num ber of studies by o ther
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workers, usually, only one immunization dose has been used. For example, Sydbom and 
Karlsson,( 1979) immunized rats with one dose (20 jig) of Oa, Suko et a l,(1977) 
immunized Balb/c mice with 2 xlO10 DNP-Salmonella and Imada e ta l,(1977) 1 jig O a, 
all using PT as adjuvant. None reported the effect of vary ing  the an tigen  dose on the 
IgE response In our study the dose effects seemed to fall into 2 distinct categories. The 
anti-Oa and anti-PT IgE responses were elicited over a narrow  dose range, w hereas 
anti-FHA IgE was produced over a wide dose range. This may relate to the channeling  
system for IgE production in mice, and may be genetically determined, because with 
both glutaraldehyde and carbodiimide toxoids of PT, Balb/c mice react d ifferen tly  to 
Ham/ICR. The form er strain  behaved as non-responders when immunized with the 
carbodiimide PT toxoid. They did not produce an IgE response at any of the dose levels 
tested. Ham/ICR mice responded to the 0.05 Ug dose of the toxoid. This corresponded 
precisely to the previous experim ent, w here a  mixed toxoid of FHA and PT (ratio 1:1) 
only elicited an IgE rsponse at 1 ug viz 0.05 Ug FHA and PT. The effect of 
glutaraldehyde toxoiding was studied, because glutaraldehyde polymers of Oa were 
found to suppress anti-Oa IgE responses (Hayglass and Strejan, 1983) This time the 
Balb/c mice responded with an anti-PT IgE response at the 1 ug PT toxoid im m unizing 
dose. Ham/ICR mice only reacted at doses of 0.1 ug and 1 ug glutaraldehyde toxoid and 
no t at 0.05 Ug level as in the carbodiimide experiment. Glutaraldehyde treatm ent 
apparen tly  therefore destroyed some of the im m unogenicity of PT toxoid, ie. more 
glutaraldehyde toxoid was required to elicit an IgE response. This disagrees w ith the 
findings of Hayglass and Strejan,(1983) who reported tha t an anti-Oa response showed 
a 8-fold reduction in PCA titre after 14 days w hen groups of mice were injected i.p on 
day 0 with 80 ug Oa-polymer (glutaraldehyde) w hen compared w ith those anim als 
injected with 80 ug Oa (untreated). In contrast Attallah et al, (1975) found th a t low 
m olecular w eight ragweed allergen  became im munogenic in rats afte r glutaraldehyde 
polym erisation. These differences may relate to the toxoiding process, particu larly  to 
the spectrum  of molecules produced and th e ir interaction with the anim al's immune 
system. Some molecular clustering may suppress while o thers may induce IgE 
production. With the Balb/c mouse, carbodiimide toxoiding may have altered the PT 
protein  s tructu re so much tha t the antibodies produced could not reac t w ith native PT.
Throughout the PT toxoid immunizations, an anti-PT IgE response was only 
produced w ithin  a very  narrow  immunizing dose range. This may relate to an tigen  
processing of PT toxoid molecules and how they are recognised by T-cells, as IgE 
production is T-cell dependent for protein antigens. Takatsu and Ishizaka, (1976) 
reported th a t anti-Oa IgE antibody formation was depressed if Oa or urea-denatured Oa 
was injected i.v during the course of the experiment. Using spleen cell transfer, 
evidence was obtained tha t this treatm ent suppressed the expansion of IgE-B memory 
cells, and w hen T-suppressor cells from the spleen were transferred  to norm al mice,
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Table 30: Summary o f the IgE and IgGl resp on ses in  m ice. The sera w ere all 
produced by the three-dose immunization protocol and tested as pools of five sera in 
the PT and FHA systems and as a pool of 25 in  the Oa system. The an tigen  dose range  is 
shown. Throughout, bioactive PT (1 ug) was used as adjuvant
Antigen Molecular 
w eight (kDa)
Antigen dose ( jig) 
range producing IgE
Levels of
IgE IgGl
Oa 45 0.1 -1.0 High High
PT 100 0.05 -1.0 High Low
FHA 200 0.1-20 High High
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the p rim ary  antibody response to Oa was suppressed.
The antibody responses we detected could be explained by antigen size and IgGl 
production. A summary of our results can be seen in Table 30. IgE production may be 
dependent partly  on the molecular w eight of the antigen. In particular, a relatively 
low molecular w eight protein an tigen  such as Oa, with PT as adjuvant, may trig g e r the 
im mune response to produce h igh  levels of both IgE and IgGl class antibodies. 
Sim ilarly with a h igh  molecular w eight antigen such as 200 kDa FHA, there was a 
rela tionship  between h igh  IgE and h ig h  IgGl litres after the three-dose immunization 
schedule. It has been proposed tha t IgG production can tu rn  off the synthesis of IgE in 
rats (Tada et al., 1972). L ehrer etu i, (1973, 1976) did not support this conclusion since 
mice immunized with h igh  doses of Oa and a crude extract of HSF (ie. PT) produced 
h ig h  titres of both IgE and IgGl antibodies. O kudairaand Ishizaka, (1973) sim ilarly did 
not observe a suppression of IgE synthesis by IgG in  the mouse.
In  our work, an anti-Oa IgE and IgGl response was produced over a 10-fold 
an tigen  dose range (0.1 - 1.0 ug). W hereas anti-FHA IgE and IgGl was produced over a 
m uch wider (400-fold) antigen dose range (0.05 - 20 ug). L ehrer e tu i, (1975), reported 
th a t large doses of Oa were required to elicit both an IgE and IgG response afte r 
p rim ary  immunization. However Bazin (1976) stated tha t large prim ary  doses w ere 
inh ib ito ry  to the production of secondary reaginic responses. Our system of 
im munization and range of antigen dose relate more to those allergy  systems w here 
repeated small doses of the allergen  stimulated the IgE response in man.
An anti-FHA IgG response in children has also been detected afte r pertussis 
vaccination (Baraff e tu i, 1983) and also afte r B pertussis infection (Granstrom e tu i. 
1981, 1988). To date, however, there  have been no reports on anti-FHA IgE responses 
a fte r disease or immunization in e ith e r animals or man, although IgE responses to 
whole cells of B. pertussis have been found. Using the RAST assay, Haus e tu i, (1988) 
showed th e re  was an IgE response to whole-cells of B. pertussis a fte r DTP vaccination. 
They speculated that, because of the h ig h  risk  of allergy in certain  individuals, the 
adm inistration of vaccine should be delayed. In 1989, Wirsing von Koenig and F inger 
devised an ELISA against whole cells of B. pertussis and tested convalescent sera  for 
IgE. They detected IgE antibodies in  only 3% of individuals and concluded tha t IgE did 
not have any  effect on the course or outcome of the disease. The particu lar 
com ponents of B. pertussis responsible for the response were not identified.
In  our study, the PT toxoids acted in a completely d iffe ren t m anner to the Oa and 
FHA, since IgE could only be detected w hen IgGl levels were low (w hen compared with 
IgE-negative sera  w here IgGl levels were h igh). Hedenskog e tu i, (1989), using the 
RAST, detected an anti-PT IgE response during whooping cough and also a fte r both AC 
and WC vaccination. During pertussis infection and after immunization, 65% and 35% 
respectively of individuals tested exhibited an anti-PT IgE response. There was no
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inform ation given on the corresponding IgG response. Anti-FHA and anti-PT IgG 
responses have been detected after DTP vaccination (Baraff et al, 1983). acellular 
vaccination (Storsaeter eta l, 1990) and infection (Wisnes eta l, 1985) in  man. In our 
work, in tranasaily  infected mice were bled at intervals, for 35 days, but no anti-FHA or 
anti-PT IgGl response was detected. Sato and Sato, (1984) found tha t a s ign ifican t 
antibody response was not found in mouse sera until five weeks a fte r i.n infection.
C onclusions and p ersp ectives
IgE antibodies can be produced in  mice against two of the B. pertussis antigens 
nam ely FHA and PT, w hich are major components of the new acellu lar vaccines. The 
IgE was successfully detected and quantified in two systems: the PCA and the ELISA. 
There was a  requ irem ent for the conventional tests to be modified for detection of 
anti-Oa, FHA and PT IgE. The usual 2-day sensitization period in the PCA test was 
adequate for titra ting  anti-Oa IgE but had to be extended to 7-days for detection of 
anti-FHA and anti-PT IgE. Future work could involve extending the PCA sensitization 
in terva l beyond 7 days to see if the test sensitivity could be improved. The IgE ELISA 
involved an initial coating stage with an affin ity-purified  antibody directed against 
the an tigen . This increased the sensitivity of the IgE ELISA. It would be in teresting  to 
investigate the effect of this modified ELISA on the sensitivity of the IgGl ELISA.
In the p resen t study, in the th ree antigen systems i.e w ith Oa, FHA and PT, an IgE 
response was produced using the 3-dose immunization schedule of Levine and Vaz, 
(1970). However, w ith each antigen, a d ifferen t im munizing dose was needed. Oa and 
PT produced an anti-Oa and anti-PT IgE response over a narrow  im m unizing dose 
ran g e  and FHA produced an anti-FHA IgE response over a wide range of im munizing 
doses. IgE and IgGl production also seemed to be related. With Oa and FHA as antigen, 
IgE and IgGl were produced to h igh  levels after immunization. W hereas w ith PT toxoid 
as an tigen , a h igh  IgE response was produced in conjunction with a low IgGl response. 
It would be in teresting  to see if  o ther protein antigens could be slotted into one of the 
above groups with relation to IgE production, with h igh  and low m olecular w eight 
an tigens eliciting both a  h igh  IgE and IgGl response but interm ediate m olecular 
w eight an tigens such as PT toxoids p referen tially  producing IgE.
In infected mice we found that the IgE or IgGl response could not be detected up 
to 35 days afte r infection, even though the lung scores reduced rapidly afte r 10 days. 
If th is experiment had been extended, IgE m ight have be detected in those mice with a 
more persisten t infection.
Future work could involve m easuring the levels of all the o ther im m unoglobulin 
classes, a fte r immunization and infection, to get an overall p icture of the immune 
response concom itant with IgE production. It would also be im portan t to investigate 
the types of T-cell populations involved in this IgE antibody response.
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The disease, whooping cough is a localised resp iratory  infection m anifesting in 
the characteristic  paroxysmal cough. In certain individuals the in itia l inflamm ation 
of the bronchi, larynx and nasopharyngeal cavity may extend to deeper structures 
and resu lt in diffuse bronchopneum onia. There may be num erous small areas of 
atelectasis, causing obstruction of the lower airways with mucus plugs, and increased 
fibrous tissue about the bronchi due to leukocytic in filtration .
What role does IgE play in the pathogenesis of whooping cough? In Schistosoma 
man so a  i  infections, IgE seems to have a beneficial effect for the host by reducing the 
worm burden (Ogilvie 1966; Capron e ta l, 1980; Damonneville e ta l, 1986). In a 
few instances, mostly seasonal rh in itis, it has been possible to detect a s ign ifican t 
correlation between the quantity of specific IgE and the in tensity  of the patien t 
symptoms (Lichtenstein e ta l, 1973). Such correlations provide ind irect evidence tha t 
the IgE antibody also plays a role in the pathogenesis of atopic resp ira to ry  diseases 
and suggests tha t quantitation of IgE-specific antibodies may be useful in  the 
assessm ent of IgE-mediated resp iratory  symptoms. V elliver et ai., (1980) h inted  at a 
correlation between IgE production and increased pathogenesis of acute illness, 
caused by resp iratory  syncytial virus, w hich may explain the re c u rre n t episodes of 
w heezing afte r infection.
Most microbial agents and environm ental macromolecules gain access to the 
hum an host v ia the mucosa of the in testinal and resp iratory  tracts. Adjuvants are 
know n to stimulate the immune responses to antigens adm inistered w ith them. The 
basis behind allergy and sensitization involves exposure to an antigen, IgE-specific 
antibodies being produced and, upon subsequent challenge w ith the same or related 
an tigen , the release of pharmacologically-activated mediators from  specific IgE coated 
mast cells and basophils.
In in fan ts  su ffering  from whooping cough, and afte r vaccination, an IgE 
response has been detected against whole-cells of B. pertussis and particu la rly  against 
PT, but the re  is no evidence th a t specific IgE is e ither beneficial or detrim ental to the 
outcome of the disease. One tentative suggestion by Bjorksten and Ahlstedt, (1984) was 
th a t exposure to B pertussis bacteria or o ther adjuvants, could possibly induce IgE to 
unrelated  an tigens in allergic patients.
IgE is known to bind with high  affin ity  to mast cells and basophils w hich are 
distributed th roughout the body In pertussis, IgE may therefore be involved in 
specific degranulation at the sites of infection i.e. the lung, causing the release of a 
num ber of pharmacological agents into the respiratory  mucosa.. Sedgwick and Holt, 
(1985) repeatedly exposed rats to Oa and found that the parathym ic and posterior 
mediastinal nodes drain ing  the lower lung were the major sites of specific IgE and IgG 
production. The positive effects of mast cell degranulation at th is a rea  would be a) 
chemotaxis of immune cells such as leukocytes into the site of sensitization, w hich
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may help in clearance of viable B. pertussis and b) histam ine release, v h ic h  could 
cause bronchospasm and help in the "paroxysmal coughing up" of the organism  from 
its site of infection. On the o ther hand, the IgE response may be detrim ental to the host 
by causing hypersensitiv ity  reactions, resulting from an over stimulation of mast 
cells and release of large amounts of vasoactive amines, v h ic h  locally may aid in 
removal but v h ic h , more generally , m ight damage the mucosa. This damage may, in 
tu rn , lead to some of the complications found in the clinical course of the disease.
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A P P E N D I C E S
A ppend ix  1 - C u ltu re  M edia  and  B ac te r ia l  D iluen ts
Cas&mino acids (CA) solution
To p repare 1 L of CA solution, the following ingredients were dissolved in 950 ml 
distilled water and adjusted to pH 7.1 with approximately 10 ml of 2.5N NaOH The 
volume was made up to 1 L and the solution autoclaved at 121* C for 15 min.
8
Casein hydrolysate (Gibco) 10.0
M gC ^. 6H2O 0.1
CaCl2 0.016
NaCl 5.0
Casamino a c id s-g ly cero l
Glycerol (10% v /v )  was added to CA solution and the mixture autoclaved as above. 
Bordet Gengou agar
BG agar base was norm ally prepared in  500 ml aliquots in 1 L bottles by firs t 
dissolving two portions, each of 18 g, of BG agar base (Oxoid) in  500 ml of distilled 
w ater contain ing 20 ml of glycerol. The bottles w ere placed in  a steam er at 100° C for 
30 min and the dissolved agar sterilized by autoclaving at 121° C for 15 min. After 
sterilization, the agar base was allowed to cool to 56° C in a w ater bath and 100 ml 
defibrinated horse blood at R.T was added to each 500 ml BG base. The blood was 
carefu lly  mixed into the agar by ro tating the bottle. Approximately 25 ml of the 
completed medium was poured into 10 cm diameter petri dishes in a lam inar flow 
cabinet. Air bubbles on the agar surface were removed by flam ing.
Bordet Gengou agar w ith  kanam ycin
For BG-kanamycin plates , a 10 ml stock solution of 10 m g/m l kanam ycin in w ater was 
prepared and sterilized by passage th rough a  0.45 um pore size, 25 mm diameter 
Acrodisc sy ringe filter (Gelman Sciences). The filtrate was dispensed directly (2.5 ml 
per 500 ml) into the melted and cooled BG agar before addition of the blood. The final 
concentration of kanam ycin in  the agar was 50 ug/m l.
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Sta iner Scholte liquid  medium
g
L- glutamate (monosodium salt; BDH) 10.72
L-proline (Sigma) 0.24
NaCl 2.50
KH2P04 0.50
KC1 0.20
MgCl2.6H20 0.10
CaCl2 0.02
Tris 6.10
Casein hydroiysate 0.50
Supplem ent
L- cysteine mono HC1 0.04
FeS04 0.01
Ascorbic acid 0.02
Niacin 0.004
Glutathione 0.15
All ingredients except those listed in  the supplem ent w ere dissolved in  900 mi of 
distilled water. The pH of the solution was adjusted to pH 7.4 with 2.5N HC1, and made 
up to a total volume of 990 ml, then  autoclaved at 121° C for 15 min and allowed to cool. 
The supplem ent was dissolved in  10 ml of distilled w ater and sterilized by passage 
th rough  a 0.45 Um pore size, 25 mm diameter Acrodisc syringe filte r (Gelman 
Sciences). The supplem ent (10 ml) was added to 990 ml of the autoclaved medium.
Cyclodextrin m odified Sta iner Scholte liqu id  medium
The only modification to the above to obtain cyclodextrin modified S tainer Scholte 
medium involved 1.0 g of MeBCD being added to the above ingred ien ts before 
autoclaving.
A p p en d ix  2 -  FHA and  PT E xtrac tion .
Tris-HCl b u ffer
0.1M Tris (50 ml) and 0.1M HC1 (26.8 ml) w ere mixed and a total volume of 200 ml was 
made up with distilled water. The pH of the resu ltan t solution was 8.0. For 0.05M
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Tris-HCl, 1M NaCl, pH 8.0, 11.7 g of NaCl was dissolved in the 0 1M Tris and 0.1M HC1 
and the total volume, once the NaCl was dissolved was made up to a total of 200 ml with 
distilled water. 0.1M Tris-HCl, pH 8,0 was prepared as above except 50 ml of 0.2M Tris 
and 26.8 ml of 0.2M HC1 were added together and made up to 200 ml with distilled water.
ImM p h en y l m ethyl su lp h o n y l fluoride!PM SF)
To p repare 1 mM PMSF, 1.74 mg of PMSF (Sigma) was dissolved in 1ml of 0.1M 
iso-propanol and made up to a total volume of 10 ml with distilled water. For each litre 
of culture, 1 ml of 1 mM PMSF was added. The final concentration was luM /m l PMSF.
P h y sio lo g ica l sa lin e
NaCl (9 g) was dissolved to a total volume of 1 L with distilled water. The pH of the 
resu ltan t solution was 7 0.
A ppend ix  3 - Enzym e L in k ed  Im m u n o s o rb e n t  A ssay
Coating b u ffer
g
NaoCO  ^ 1.59
NaHCOj 2.92
Both reagents were dissolved in 1 L of distilled w ater and kept at 4° C. The pH of the 
solution was approxim ately 9 6.
V a sh /In cu b a tio n  b u ffer
g
NaCl 8.0
KH2P04 0.2
Na^HPO^ 1.15
KC1 0.2
All the ingredien ts were dissolved in 1 L of distilled water. Tween 20 (0.5 ml) was then  
added to a final concentration of 0.05%. The pH of the solution was 7.4.
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C itrate-phosphate
Solution A: 0.1M citric acid (21.01 g/1 of distilled water)
Solution B: 0.2M Na2HP04 (35 6 g/1 of distilled water)
To p repare a 0.15M solution of citrate-phosphate pH 5 0, 49 ml of solution A and 51ml 
of solution B were added together just before use.
Substrate
A stock solution of O -phenylenediam ine (34 m g/m i in citrate phosphate) was 
prepared and 200 \xi was added to 100 ml of citrate phosphate along w ith 20 lil of ^ ( K
A p p e n d i i  4 -  SDS P o ly a c ry la m id e  Gel E le c tro p h o re s is  
A crylam ide
g
Acrylamide 30.0
Bis acrylam ide 0.8
The ingredients were dissolved and made up to 100 mi in distilled water. The solution 
was filtered through a  18.5 cm diameter Whatman 1 filte r and store at 4° C in the dark.
Tris HC1 pH S.S
ml
2 M Tris 50
1MHC1 16.2
The solutions were added together w ith 0.4 g of sodium dodecyl sulphate (SDS) and 
made up to a  total volume of 100 ml with distilled water. The buffer was aliquoted into 
20 ml amounts and stored at -20° C.
Tris HC1 pH 6.8
ml
lM T ris  50
1 M HC1 45
The solutions w ere added together w ith 0.4 g of SDS and made up to a total volume of 
100 ml w ith distilled water. The buffer was aliquoted into 20 ml am ounts and stored at 
-20° C.
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Tris G lycine pH 8.3 (lOx)
g
Glycine (Chromatography grade) 144.13
Tris 30.28
The above were dissolved in 900 ml of distilled water. The pH was adjusted with 2.5N 
HC1. The volume was made up to 1 L w ith distilled water and stored at 4° C. The solution 
was diluted 1 in 10 in distilled w ater p rio r to use.
Ammonium persu lphate
A 1% w /v  stock solution of ammonium persulphate (0.01 g/1 of distilled w ater) was 
prepared  just p rio r to use.
Solubilizing buffer
ml
Tris HC1 pH 6.8 2
SDS 32
B-m ercaptoethanol 1.6
Glycerol 32
Bromophenol 0.32
Distilled w ater 5 68
All ingredien ts were added together and keptatR.T.
Coo m assie blue stain
Coomassie blue R250 1.25 g
50% v /v  m ethanol 454 ml
Glacial acetic acid 46 ml
The coomassie blue was dissolved in m ethanol and acetic acid. The stain was filtered 
th rough  a  18.5 cm Whatman paper filte r Number 1.
Destain so lu tion
ml
M ethanol 50
Glacial acetic acid 75
Distilled w ater 875
The solutions were mixed in the order th a t the appear above.
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L over gel
ml
L over gel buffer 10
Distilled w ater 13.4
Acrylamide solution 16.6
Ammonium persulphate 0.2
TEMED 0.02
The solutions were added w ithout aeration and used immediately.
Upper g e l
mi
U pper gel buffer 2.5
Distilled w ater 6.0
Acrylamide solution 1.5
Ammonium persulphate 0.03
TEMED 0.02
The solutions were added carefully  to avoid aeration and used immediately.
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Appendix 5 : Histam ine sen sit iz in g  a ctiv ity  o f PT used in  im m unizations  
and for  toxoiding. Groups of 4 mice were injected i.p with various concentrations 
of PT or carbodiimide and giutaraldehyde toxoids of PT. After 5 days, the mice were 
challenged with 3 mg of histam ine and the survivors scored after 2 h.
Toxin batch Dose of PT No. of surv ivors/ no. of mice Approx.
and trea tm ent or toxoid (ug/m l) challenged. LD50/mouse (ug)
PT
1 0
1
033
0.11
0/4
0/4
1/4
3/4 0.1
3
1
0.33 
0 11
2/4
3/4
3/4
4/4
1.5
3
1
0.33
0.11
0/4
2/4
3/4
4/4
0.5
3
1
0.33
0.11
1/4
2/4
4/4
4/4
05
Glut. PToxoid 
2 3
0.3
0.1
0.01
4/4
4/4
4/4
4/4
>3
Carb PToxoid
3
0.3
0.1
001
4/4
4/4
4/4
4/4
>3
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Appendix 6 : E ffect o f c h a lle n g in g  Ham/ICR mice v ith  k n o v n  con cen tration s  
o f carbodiim ide and giutaraldehyde toxoids in  the mouse w e ig h t  
gain  test.
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Appendix 7 : Plan of immunization mixtures used for raising anti-Oa sera
for testing in PCA and ELISA for IgE and IgGl.
Serum No. Imm unizing dose 
OA(ug) PT (ng)
Bleed day
la 200 250 10
lb 200 250 10
2a 20 2500 21
2b 20 250 21
2c 20 250 21
2d 20 250 21
2e 200 2500 21
3a 20 1000 21
3b 20 1000 21
3c 20 100 21
3d 20 100 21
3e 200 100 21
3f 200 10 21
3g 200 1 21
4a 20 1000 2S
4b 200 1000 28
4c 200 1000 28
4d 200 100 28
4e 20 10 28
4f 200 10 28
4g 200 1 28
5a 200 200 21
5b 20 200 21
5c 20 200 21
6a 0.1 1000 63*
6b 1 1000 63*
6c 10 1000 63*
* - The sera  were obtained by Protocol 3 and were pools from 25 mice. The others were 
obtained by Protocol 2 and consisted of individual mouse sera.
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Appendix 7 : Plan of immunization mixtures used for raising anti-FHA
sera for testing in PCA and ELISA for IgE and IgGl.
Experim ent 
num ber and 
sera  code
Immunizing dose ofFHA( ug) with a constant 
dose of PT (1 ug) in Ham/ICR and Balb/c mice
Ham/ICR Balb/c
38 1 0.1
2 1
3 10
39 1 0.1
2 1
3 10
78 A 0.01
B 0.05
C 0.1
D 1
E 10
F 20
G 40
79 A-2 0.01
B-2 0.05
C-2 0.1
D-2 1
E-2 10
F-2 20
G-2 40
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Appendix 7 : PIaa o f immunization mixtures used for ra isin g  anti-PT sera
for testing in PCA and ELISA for IgE and IgGl.
Experiment Im m unizing dose of toxoid (ug) w ith a constant
num ber and dose of PT (1 ug) in  Ham/ICR and Balb/c mice
sera  code
Ham/ICR Balb/c
Carb. FHA/PT Carb. PT Glut. PT Carb. FHA/PT Carb. PT Glut.PT
43 1 0.1
2 1
3 10
73 H 0.001
I 0.01
J 0.05
K 0.01
L 1
M 10
79 H-2 0.001
1-2 0.01
J -2 0.05
K-2 0.01
L-2 1
M-2 10
N-2 20
73 R 0.05
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Appendix 8 : The ability of fetu in  at a concentration of 1 lig /m l to coat a
m icrotitire plate v e i l  surface one molecule thick.
Surface area of m icrotitre v e il
Radius - 3 mm
Height - 4 nun (containing 100 yl of fetuin)
Surface area = 2IIrh  ♦ H r2 
= 103 mm*
= 103 x 1012 nm 2
Molecular w eight of fetu in  = 48,700 take as 50,000 (assume it is a globular protein 
sim ilar to Oa w hich has a molecular radius of 24A, w hich is the same as 2.4nm)
Molarity of fetuin so In
50000 g/1 - 1M 
I yg /m l - 0.00002M or 20 yM
No. of molecules in lu g /m l fetuin is equivalent to
20 yM x Avogadros number(6.022 x 1023)
= 1.2 x 1019 molecules/ml 
= 1.2 x 1015 molecules/100 yl
If the hypophetical radius of fetuin is the same as Oa 24A or 2.4nm take the diameter 
as twice tha t num ber to account for the c ircu lar natu re of the molecule and the 
binding properties to the plate. The diameter is 5 nm. The dim ensions of the square 
are 25 nm
To find the num ber of molecules required  to coat the well one molecule layer th ick  .
Surface area of well = 103 x 10-^  nm = 4.12 x 1012 molecules
Radius of one molecule 25 nm
t OTherefore 4.12 x 10 ** molecules of fetuin is required  to coat the well one molecule 
thick. In a 100 yl solution of 1 yg/m l fetuin there  is 1.2 x 1015 molecules, a 300,000 fold 
excess.
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Appendix 9 Ran t i t  plots o f the loglO PC A U/m l and the loglO litres
o f IgE and IgGl resp ective ly , in  the Oa im m unization  
system .
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